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Abstract
Background: Living kidney donor transplantation is the ideal treatment for many
patients with kidney failure. However, the living donor evaluation process has been
criticized by patients and healthcare providers as inefficient. In the present research, we
evaluated the inefficiency of the living donor evaluation process.
Methods: We conducted a scoping review of the literature and obtained data from large
administrative datasets (1256 living donors) and medical chart review (849 prospectively
recruited living donors across 12 transplant centres plus retrospective analysis of 1065
living donor candidates from a single centre).
Results: The median time to complete the entire evaluation was 9-11 months for donors
and 4.3 months for candidates who were declined or withdrew from the evaluation. Up to
35% of recipients who could potentially have received a pre-emptive transplant (avoided
dialysis entirely) started dialysis before transplantation, costing the healthcare system
$8.1M for dialysis alone. Shortening the evaluation time by only 10% translated to an
annual cost savings of at least $1.3M in Ontario due to averted dialysis costs and up to 38
intended recipients each year could have received a transplant they otherwise did not
receive (17% increase in living donor transplantation). The cost to the healthcare system
was $3,641 for the donor evaluation, $11,695 for the donor surgery (including
perioperative costs), and $933 for the first year post-donation. There are many reasons
that may contribute to a longer living donor evaluation. Donation through kidney paired
donation prolonged the time until donation by 6 months. The evaluation time was
doubled if the intended recipient started dialysis part-way through the donors’ evaluation.
Finally, every month delay in the recipient referral extended the time until donation by
0.4-0.9 months and increased the likelihood that the recipient would start dialysis before
transplant. Between-centre differences were observed for evaluation times and donation
costs.
Conclusions: The living donor evaluation is time-consuming, resulting in potentially
avoidable unintended adverse consequences to donor candidates, their intended recipient,
i

and the healthcares system. Potential strategies to improve the efficiency of this process
include eliminating unnecessary or redundant tests, evaluating multiple donor candidates
simultaneously, performing 1-day evaluations, and promoting earlier recipient referrals.

Keywords
Living kidney donation; efficiency; evaluation; pre-emptive transplant; costs; living
donor evaluation; transplantation; kidney
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Chapter 1

1

Background

The kidneys are mainly responsible for eliminating wastes and excess fluids through
urine production. For a healthy adult, the kidneys filter more than 90 milliliters of blood
every minute per 1.73 m2 (normalized for body surface area), a feat that declines
naturally with age.1 Chronic kidney disease (CKD) is defined as a sustained filtration rate
of less than 60mL/min/1.73 m2, resulting in ionic imbalances that can lead to mineral
bone disorders and cardiovascular complications that will ultimately result in kidney
failure (e.g. a filtration rate <5 mL/min/1.73 m2) and death if left untreated.2–5 Filtering
the blood through dialysis is currently the best technological means of mimicking the
native kidney, but is associated with a variety of complications (morbidity and mortality
is high) and is time and resource intensive for both patients and providers.6–8 For some
patients, their kidney disease can be managed and disease progression can be effectively
slowed through medication (e.g. phosphate binders), dietary restrictions (e.g. limiting
fluid intake; low-protein diet), lifestyle changes (e.g. smoking cessation), or early
detection (e.g. through screening of high-risk patients).9–11 For others, the progression to
kidney failure is sudden and unpredictable, requiring rapid initiation of dialysis.12
Adequately preparing patients for dialysis takes months of planning related to sustaining
dialysis access and choosing the right modality for the patient that includes location (e.g.
at home or in the clinic), type (e.g., hemodialysis or peritoneal dialysis), and the
frequency and timing of dialysis sessions. Compared with dialysis, kidney transplantation
is associated with increased longevity, improved quality of life, and results in substantial
cost savings to the healthcare system beginning as early as 1 year after
transplantation.5,13–16 Among kidney transplants performed in the United States between
1996 and 2005, grafts remained viable for a median of 10-27 years depending on the type
of donor.17 Thus, kidney transplantation offers patients with end-stage kidney disease the
best chance for dialysis-free survival. Despite this, the number of transplantable kidneys
available from deceased donors does not meet the need, and there is opportunity to
reduce this gap through living donor kidney transplantation.
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1.1 Some statistics on kidney disease and transplantation*
The incidence of kidney failure in Ontario has risen steadily from 180 to 219 per million
population between 2006 and 2015 (Figure 1).18 As the risk factors for CKD continue to
rise (particularly obesity, hypertension, and diabetes), the burden of CKD and kidney
failure among Canadians is also expected to rise; the most common causes of CKD are
diabetes (38%), renal vascular disease (14%), and glomerulonephritis (11%).18,19
230
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170
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2007
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2011
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2015

Figure 1: Incident end-stage kidney disease patients by province/territory, Canada
(excluding Quebec), 2006 to 2015. Source: Canadian Organ Replacement Register, 2016,
Canadian Institute for Health Information; Statistics Canada.

Despite the benefits of transplantation, dialysis is typically the first treatment given: 76%
of patients with kidney failure received hemodialysis and 21% received peritoneal
dialysis over the last decade (Figure 2).18 In 2015, 41% (15,037/36,251) of Canadians
living with end-stage kidney disease were living with a functioning transplant, which is
only a modest rise from the 39% observed in 2006.18

*

All statistics derived from the Canadian Organ Replacement Register (CORR) exclude Quebec because
of significant underreporting from 2011-2015
2
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Figure 2: Incident end-stage kidney disease patients by initial treatment, Canada
(excluding Quebec), 2006 to 2015 (percentage of total). Source: Canadian Organ
Replacement Register, 2016, Canadian Institute for Health Information; Statistics Canada.

Most kidney transplants across Canada are made possible by deceased donors (60%)
(Figure 3).18 The rate of living kidney donation has stagnated or even declined since 2006
and remains well below the rate of deceased donation.20–23 This trend was observed
across Canadian provinces, and by 2015 the proportion of all kidney transplants that were
enabled by a living donor was 41% in Manitoba, 40% in British Columbia, 37% in
Alberta, 37% in Ontario, and 26% in Nova Scotia.18 On an international stage, Canada
ranked below the United States and Norway on the number of living donor transplants
per million population, but had a higher proportion of transplants from living donors.22
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Figure 3: Number and proportion of kidney transplants enabled by living and
deceased donors. Source: Canadian Organ Replacement Register, 2016, Canadian Institute for
Health Information; Statistics Canada.

1.2 Living donor kidney transplantation
Living donation is preferred over deceased donation because it can be planned (i.e.,
scheduled), wait-time is reduced, and organ ischemic time† is reduced, leading to better
recipient outcomes.5,24,25 Between 2013 and 2015, the median time spent on dialysis until
transplant was 4.0 years from a deceased donor and 1.6 years from a living donor (Figure
4).18 Considering the potential for pre-emptive transplantation (transplant occurring
before dialysis onset), this falls to 0.84 years for living donation (deceased donation
remained at 4.0 years).18
Pre-emptive transplantation is recognized by many healthcare professionals as the ideal
treatment for patients with kidney failure.26 Pre-emptive transplantation avoids
complications related to dialysis (e.g. infection of dialysis catheters) and promotes better
survival as the time on dialysis is minimized.7,27–30 Despite this, pre-emptive transplants

†

The time spent without oxygen, usually due to removal of the organ from the body’s blood supply (e.g.
ligation of an artery, physical removal)
4

only occurred in 3% of Canadians, a proportion that has remained stable from 2006
through 2015 (Figure 2).18 Pre-emptive transplants are mostly made possible by living
donors due to deceased donor allocation systems that distribute organs and tissues by
need (e.g. by time spent on the wait-list, and this generally only accrues after dialysis
initiation).31
6
5
Median time 4
on dialysis
3
before
transplant
2
(years)
1
0

Deceased donor

Living donor

Figure 4: Median time on dialysis before transplant (years), excluding pre-emptive
transplantation. Source: Canadian Organ Replacement Register, 2016, Canadian Institute for
Health Information; Statistics Canada.

1.2.1 Barriers to living kidney donation
Several barriers to living kidney donation have been identified, including difficulties in
identifying potential donors (“The Ask”), financial barriers associated with donation, a
lack of knowledge of the long-term medical and psychological risks to donors, a lack of
patient and provider education, socioeconomic and demographic factors leading to
disparities in access to living donor transplantation (i.e., cultural, geographical, financial
barriers), a lack of social support, and a lack of general knowledge about living kidney
donation.32–44 While these areas of research tackle critical barriers that may improve
living kidney donation rates or the number of living donor candidate evaluations
performed, the healthcare system seems to be presenting an additional barrier that has
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received relatively little attention and is the focus of this research: the living kidney donor
evaluation process is too long, difficult to complete, and is inefficient.45

1.2.2 Efficiency of the living donor candidate evaluation process
Prior donors and recipients have strongly advised that it is necessary to “be your own
advocate”, shedding light on the frustration and difficulty of navigating the healthcare
system and completing the living donor evaluation process.46,47 Several donors view the
evaluation as the worst phase of the donation experience.47,48 Recommendations from a
recent international consensus conference cite the efficiency of the evaluation as a highpriority area for research.49,50 These sentiments were further promulgated in the 2017
Kidney Disease: Improving Global Outcomes (KDIGO) Guideline on the Evaluation and
Care of Living Kidney Donors and the United Kingdom’s guidelines on Living Donor
Kidney Transplantation.51,52 Despite these recent advances, recommendations to improve
the efficiency of the evaluation are not supported by evidence and are predominantly
based on the ideas of key opinion leaders.49 More work is needed to understand the
current state of the evaluation process, the gaps in care created by an inefficient
evaluation, and tractable solutions to improve the evaluation process.

1.2.3 Thesis breakdown
In Chapter 2, I briefly describe the main components that are required to complete a
thorough living donor evaluation. Chapter 3 is a targeted discussion on various
components of the evaluation where efficiency improvements have been recommended.
Chapter 4 follows with a scoping review of the literature to understand the knowledge
gaps and summarize the research conducted on the efficiency of the living donor workup.
Chapter 5 describes the specific aims of the thesis. Chapter 6-10 follow with original
work to satisfy these aims. Finally, Chapter 11 provides an overall discussion of the work
and discusses its context for future developments.
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Chapter 2

2

Evaluation and Selection of the Living Kidney Donor
Candidate‡

The purpose of this chapter is to describe the main components of the living donor
evaluation. Although an efficient evaluation is not the subject matter, this chapter is a
useful source of reference for the remainder of the thesis.

2.1 Introduction
The practice of living donor kidney transplantation is based on the principle that the
benefits to the recipient outweigh the minimal risks to the carefully evaluated and
selected living donor. Living kidney donors should undergo a rigorous evaluation and
selection process to ensure that the short- and long-term risks to the donor are minimized.
In addition to this, the benefits and risks to the intended recipient are also considered.
From the recipient perspective, an aim is to select donors who will provide adequate graft
function while minimizing the transmission of any donor-derived diseases, such as
infections or malignancy. To mitigate potential conflict of interest, it is recommended
that the evaluations of the donor candidate and the intended recipient be performed by
separate, independent healthcare teams.1–5
Multiple guidelines assist clinicians in the complex process of donor evaluation and
selection. A systematic review of these clinical practice guidelines found that while many
recommendations were consistent, important variations exist and many appeared to lack
methodological rigor.6 The 2017 Kidney Disease: Improving Global Outcomes (KDIGO)
‘Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors’
provides a comprehensive set of best practice recommendations based on a systematic

‡

A version of this chapter has been accepted for publication as a subsection of a book chapter. Steven
Habbous was responsible for completing this subsection of the book chapter: Lam NN, Habbous S, Garg
AX, LentineKL. “Considerations in Living Kidney Donation”. Transplantation.
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evidence review, de novo evidence generation, and expert opinion when evidence was
lacking.1 When possible, the guideline recommends that transplant programs establish
numeric thresholds for short- and long-term post-donation risks above which the program
will not accept the candidate for donation. It also demonstrates how tools can be
developed to help estimate a donor candidate’s risk of long-term complications such as
end-stage kidney disease based on their individualized set of pre-donation demographic
and health characteristics.
A central goal of the KDIGO guideline is to promote “consistent, transparent and
defensible decision-making” based on comparisons of individualized, quantitative
estimates of donor risks “to a transplant program’s acceptable risk threshold”.1 Risk
threshold is defined as the upper limit of acceptable risk established by a program for
donor candidate selection. Under this framework, when a candidate’s estimated risk is
above the acceptable threshold, the transplant program is justified in declining the
candidate and can ground its decision in a quantitative framework. When a donor
candidate’s estimated risk is below the acceptable risk threshold, the transplant program
should accept a donor candidate, and it should be the candidate’s decision whether to
proceed with living kidney donation after being informed of the risks. Once established,
acceptable risk thresholds should be applied consistently and transparently for all donor
candidates evaluated at a program. The KDIGO framework was informed by a systematic
evidence review.7 The KDIGO group also developed a tool to quantify a donor
candidate’s risk of post-donation complications such as end-stage kidney disease. This
tool projects the 15-year and lifetime risk of renal failure based on level of predonation
glomerular filtration rate (GFR) and other baseline demographic and health factors.8 For
practical applications, the resulting risk models were incorporated into an online risk
prediction tool (http://www.transplantmodels.com/esrdrisk. The tool serves as an
example, and can be improved with future research efforts for various types of living
kidney donors worldwide.
The evaluation process should include a comprehensive history, physical exam,
laboratory and radiological investigations, and specialist consultations. Aspects of the
process may vary by region and transplant center, including the order and timing of the
13

components and what is considered required or additional testing. Depending on local
resources and policies, transplant programs may also choose to evaluate multiple donors
for an intended recipient either simultaneously or sequentially. The 2017 KDIGO living
kidney donor guideline recommends that all donor candidates should be evaluated using
the same criteria, regardless of who the intended recipient is.1

2.2 Kidney function
The purpose of evaluating GFR in kidney donor candidates is to detect kidney disease
and to project long-term outcomes for the candidate and their recipient should they
proceed with donation. Recommended methods for evaluating GFR in donor candidates
are based on the 2012 KDIGO CKD guideline.9,10 Considering practicality, test
availability, and costs, the 2017 KDIGO living donor guideline recommends initial
estimated GFR (eGFR) based on serum creatinine (eGFRcr) and confirmation using one
or more of the following measurements according to their availability: measured GFR
(mGFR) from clearance of exogenous radio-labeled filtration markers, measured
creatinine clearance (mCrCl) based on collecting a timed (24-hour) urine specimen,
eGFR based on serum creatinine and cystatin (eGFRcr-cys), or repeated eGFRcr; the
latter being the least preferred approach.1,9,10 Although mGFR or mCrCl is required for
donor evaluation in the United States according to Organ Procurement and
Transplantation Network (OPTN) policy, a timed urine collection for albumin excretion
rate (AER) is not required (i.e., measurement of urine protein or albumin may be
performed on a random “spot” urine sample). In countries where clearances are required
for assessment of GFR, an efficient strategy may be to omit timed urine collections and
rely on mGFR using clearance of an exogenous filtration marker and a random urine
albumin-to-creatinine ratio (ACR). In countries where clearance measures are not
required for assessment of GFR, transplant programs could obtain eGFRcr, eGFRcr-cys,
and urine ACR prior to a candidate donors’ visit to the center.11
The 2017 KDIGO living kidney donor guideline recommends a GFR ≥90 mL/min/1.73
m2 as an acceptable level of kidney function for donation, while donor candidates with
GFR <60 mL/min/1.73 m2 should not donate. The decision to approve donor candidates
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with GFR 60-89 mL/min/1.73 m2 should be individualized based on demographic and
health profiles.

2.3 Albuminuria
Elevated protein in the urine (proteinuria) may suggest the presence or risk of developing
kidney disease due to increased permeability of the glomeruli to protein, and/or an
inability of the renal tubules to reabsorb protein. Until acceptable standardization
methods are available for quantifying deficiencies in tubular reabsorption, urine albumin
remains the most reliable indicator of kidney disease, standardized to urinary creatinine
as the ACR. The 2017 KDIGO living kidney donor guideline recommends initial
evaluation using ACR in a random urine specimen with confirmation by AER (from a
timed urine specimen) or otherwise a second random urinary ACR. Donor candidates
with an AER >100 mg/d (or ACR >30 mg/mmol) should not donate. Such candidates
have microalbuminuria and are at an elevated risk of developing chronic kidney disease
in their lifetime.12 Candidates with an AER <30 mg/d (or ACR <3 or below the
detectable limit of the assay) may be acceptable for donation, while the decision to
approve donor candidates with AER 30 to 100 mg/d should be individualized based on
demographic and health profiles in relation to the transplant program’s acceptable risk
threshold.

2.4 Hematuria
The persistent presence of blood in the urine (hematuria) is another indicator for the
presence or risk of developing kidney disease. Presence of hematuria is established by
visualizing 2-5 red blood cells per high-powered field on microscopic evaluation.
“Persistence” is established if hematuria is observed in more than 50% of urine samples
obtained from 2-3 separate occasions. When hematuria is persistent, further investigation
is warranted which many include a urine culture for bacterial or fungal infection (this
may be treated without affecting candidacy), a 24-hour urine kidney stone panel, a
cystoscopy, imaging to rule out a urinary tract malignancy, and a kidney biopsy to rule
out underlying kidney disease (thin basement membrane disease may not be a
contraindication to donation).13,14
15

2.5 Kidney stones
A renal calculus in the donor’s remaining kidney may affect kidney function if it results
in ureteral obstruction. Reassuringly, living kidney donors do not appear to have an
increased risk of kidney stones requiring treatment with surgical intervention compared
to healthy, matched non-donor controls (median follow-up of 8 years).15 Evaluation of
kidney stones in living kidney donor candidates includes a history from the candidate,
laboratory investigations, including persistent microscopic hematuria, and renal imaging
such as computed tomography. If suspected, further investigations may be performed,
including parathyroid hormone measurements and 24-hour urine collections for
metabolic testing. A history of previous stones does not necessarily rule out donation,
particularly small, unilateral, non-recurrent stones.1 There is also the option to remove
small kidney stones at the time of procurement prior to transplantation.16

2.6 Hyperuricemia, gout, and metabolic bone disease
Compared to non-donor controls, living kidney donors have an increased risk of gout
(3.4% versus 2.0% in non-donor controls, a median 8 years after donation).17 This may be
due to the reduced ability of a single kidney to excrete excess uric acid, a precursor to
gout. Although a comprehensive gout assessment is not usually conducted for all
candidates, pre-donation serum urate is frequently ordered alongside other biochemical
indicators of metabolic kidney disease, including inorganic phosphate, calcium, and
parathyroid hormone. Living kidney donor nephrectomy may lower the concentration of
1,25-dihydroxyvitamin D and phosphate and raise the concentration of parathyroid
hormone, with no appreciable effect on the concentration of calcium. Whether these
changes in bone mineral metabolism alter skeletal fracture risk in living kidney donors is
an open question. To date, a single study of over 2,000 living kidney donors (median age
43 years) matched to a segment of the general population selected for good health has
found that after a median follow-up of 6.6 years (maximum 17.7 years), the rate of
fragility (osteoporotic) fractures is no higher in donors compared to non-donors.18
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2.7 Blood pressure
Sustained elevated blood pressure is a common cause of kidney disease, and conversely,
kidney disease may accelerate the development of high blood pressure. Candidates with
hypertension are eligible for donation only if their blood pressure can be controlled with
anti-hypertensive medications and that they are without end-organ damage related to their
hypertension.1 The systolic and/or diastolic blood pressure thresholds and the nature of
the anti-hypertensive medications used (e.g. number of agents, class of drugs, and dosage
used) to disqualify a candidate may vary across programs and according to other
candidate characteristics. Blood pressure measurements should be performed on at least
two separate occasions by trained personnel. An ambulatory (e.g. 24-hour) blood pressure
monitor may be used if hypertension is suspected. Donor candidates with hypertension
that can be controlled to less than 140/90 mmHg using 1 or 2 antihypertensive agents,
and who do not have evidence of target organ damage, may be acceptable for donation.
The decision to approve donation in persons with hypertension should be individualized
based demographic and health profiles in relation to the transplant program’s acceptance
risk threshold.

2.8 Metabolic and lifestyle risk factors
Obesity is a strong risk factor for diabetes, cardiovascular disease, and kidney disease.
Living donor nephrectomy is more difficult for patients with excess visceral fat,
increasing the risk of perioperative complications including infection, blood loss, and
delayed wound healing.19 Various body mass index (BMI) cut-points have been reported
in the literature as absolute or relative contraindications to donation. Elevated serum
glucose or glucose intolerance are also strong risk factors for diabetes. Apart from
personal and family history assessments of diabetes (childhood, adult-onset, gestational),
glycosylated hemoglobin and serum and urinary glucose are typically measured early in
the assessment of all candidates. Fasting glucose and glucose tolerance tests are
recommended for high-risk candidates (e.g. high random glucose, positive family
history). According to the 2017 KDIGO living kidney donor guideline, donor candidates
with type 1 diabetes mellitus should not donate. The decision to approve donor
candidates with prediabetes or type 2 diabetes should be individualized based on
17

demographic and health profiles in relation to the transplant program’s acceptance
threshold. Donor candidates with prediabetes and type 2 diabetes should be counseled
that their condition may progress over time and may lead to end-organ complications.1
Less evidence is available to comment on the influence of predonation lipids (e.g.
cholesterol, triglycerides, and high-density and low-density lipoproteins) and smoking on
donor candidacy, although notably, smoking was a strong risk factor for kidney failure in
healthy persons.8 While candidates should be educated and encouraged to modify their
dietary and smoking habits, eligibility based on these factors may vary across programs.
Smoking should be considered as part of comprehensive risk assessment.

2.9 Screening for transmissible infections
To minimize the risk of viral transmission from the donor to the recipient, the evaluation
should include assessment of prior history of infections, recent travel history, and
virology screens early in the evaluation and again within the 2-4 weeks of donation to
minimize the window of infection.20,21 The 2017 KDIGO living kidney donor guideline
recommends screening for human immunodeficiency virus, hepatitis B and C, EpsteinBarr virus, cytomegalovirus, syphilis, urinary tract infection, and other potential
infections based on geography and environmental exposures.1 If a donor candidate is
found to have a potentially transmissible infection, then the donor candidate, the intended
recipient and transplant team should weigh the risks and benefits of proceeding with
donation, and develop a management plan if the decision is to proceed with donation.

2.10 Cancer screening
All candidates should be up-to-date with local cancer screening guidelines according to
age, sex, and family history. Donors with active cancer are generally not eligible to
donate. Donors with a prior history of successfully treated cancer with a high risk of
reoccurrence may be excluded from donation because anti-neoplastic agents may be
nephrotoxic, and because transmission of cancer from the donor to the recipient can have
serious consequences to the immunocompromised recipient.22 Candidates with a prior
history of cancer with a low risk of reoccurrence may be considered on a case-by-case
basis. In some cases, candidates with small renal tumors (high-grade Bosniak renal cysts
18

(III or higher) or small (T1a) renal cell carcinoma curable by nephrectomy) may be
acceptable for donation, and the donor and recipient provide consent for the cancer to be
resected at the time of donor nephrectomy.23,24

2.11 Genetic kidney diseases
If the donor candidate is biologically related to the intended recipient, the cause of the
recipients’ kidney disease should be well understood before accepting the candidate.
Candidates with a genetic kidney disease generally are not eligible to become donors. If a
candidate has a family history of a genetic kidney disease, the candidate may be eligible
to donate if the risk of developing kidney disease after donation is acceptably low and the
risks are discussed with the candidate. Genetic diseases that may be assessed during the
donor candidate evaluation include autosomal dominant polycystic kidney disease,
APOL1-related kidney disease, atypical hemolytic uremic syndrome, Alport syndrome,
Fabry disease, familial focal segmental glomerulosclerosis, and autosomal dominant
tubulointerstitial kidney disease.
If a donor candidate is of sub-Saharan African ancestry, testing for APOL1 risk alleles
may be offered.25,26 The presence of two APOL1 risk alleles increases the lifetime chance
of developing kidney failure even in the absence of donation. The effects of kidney
donation on this risk are unknown, but are a topic of active research.

2.12 Pregnancy
While donation does not preclude future pregnancy and child-bearing, patients are not
evaluated or do not donate while they are pregnant. A history of hypertensive disorders
related to pregnancy (e.g. preeclampsia, gestational hypertension) increase the risk of
developing kidney failure later in life, and the severity, timing, and frequency of these
conditions should be considered before determining the potential donor’s candidacy.

2.13 Psychosocial assessment
The 2017 KDIGO living kidney donor guideline recommends that a psychosocial
assessment be conducted for all donors (regardless of relationship with the intended
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recipient), in the absence of the intended recipient (to reliably assess voluntariness), and
by a professional independent from the care of the intended recipient. A thorough
psychosocial assessment should minimize the incidence of poor psychosocial outcomes
postdonation by careful selection or treatment (e.g. counseling).51 Quality of life is
generally positive postdonation, but there have been instances of regret, depression, and
financial hardships.52,53

2.14 Conclusion
This chapter summarized the main components of the living donor assessment, as well as
quantitative and qualitative issues related to donor eligibility. With this background,
concerns of efficiency can be discussed while completing a thorough evaluation.
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Chapter 3

3

Optimizing efficiency in the evaluation of living donor
candidates: Best practices and implications§

3.1 Introduction
Compared with chronic dialysis, kidney transplantation is associated with increased
survival, improved quality of life, and reduced costs to the healthcare system.1–5 Living
donor transplant is preferred over deceased donor transplant because the surgery can be
scheduled when the recipient is in optimal health, without the wait for a deceased donor
kidney to become available, potentially avoiding the need to start dialysis (pre-emptive
transplantation), with a better graft survival than deceased donor kidney
transplantation.6,7 Despite these benefits to the recipient, in most regions the rate of living
kidney donation has been stagnant over the last decade and remains well below the rate
of deceased donation.8–12 Thus, there is interest in safely increasing the number of living
donor kidney transplants.
There are many recognized barriers to living kidney donation. One barrier that has
received little attention, and is the focus of this review, is inefficiencies in the living
kidney donor evaluation process.13 A study in Ireland reported that the donor evaluation
process can exceed 2 years, leading to donor fatigue and eventual dropout.14 A multicenter Canadian and Australian study reported a median evaluation time (from evaluation
start until donation) of 10.3 months (Chapter 6).15 Notably, most donors feel that even 6
months is too long for this process.16 The United Kingdom has set a target to complete
the donor evaluation in under 5 months, but in current practice this target may not be

§

A version of this chapter has been published: Habbous S, Garg, AX, Lam, NN. “Optimizing efficiency in
the evaluation of living donor candidates: Best practices and implications”. Curr Transplant Rep.
2018;5(1):55-63.
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achievable in many programs.17 Although donor candidate withdrawal rates can reach
30% in some centers, it is difficult to quantify how many of these withdrawals are
attributable to a prolonged evaluation process.18,19 An international consensus conference
highlighted the efficiency of the evaluation as a research priority.20,21 The 2017 Kidney
Disease: Improving Global Outcomes (KDIGO) Guideline on the Evaluation and Care of
Living Kidney Donors recommends that transplant programs conduct efficient donor
evaluations, meeting the needs of donor candidates, intended recipients, and the
transplant program.22 However, due to a lack of supporting evidence, this
recommendation is ungraded.22 In this review, we examine reasons why the living kidney
donor evaluation may be inefficient, and make recommendations to optimize this process.

3.2 The Donor Candidate Evaluation
A thorough evaluation will result in donor selection that will optimize the medical and
psychosocial outcomes of the donor candidate and their intended recipient. Minimizing
donor risk is one of the main objectives of the living donor candidate evaluation and is
the reason why donors and recipients often have different healthcare teams responsible
for their care.23,24
A schematic of an overview of the evaluation process is shown in Figure 5. Typically, the
donor candidate must contact the transplant program by phone, internet, or in person to
express their interest in donation and initiate the evaluation process. Then, donor
candidates complete a standard medical-social questionnaire and initial compatibility
testing with an intended recipient (e.g. blood group). Following this, there is a more
comprehensive set of laboratory and diagnostic investigations (Table 1). Candidates also
meet with members of the transplant team in consultation, including nephrologists,
surgeons, and psychosocial experts (e.g. social workers, psychologists). Candidates who
meet the transplant center’s eligibility criteria and make an informed decision to proceed
will then be scheduled for nephrectomy.
For each of these steps, we offer recommendations that may lead to improved efficiencies
with respect to reducing costs and/or the time to completion, drawing on the literature
where possible (Figure 5). To improve economic efficiency, the process should perform
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the minimal number of tests needed, use the least costly alternative, and avoid redundant
or repeat testing. The living donor evaluation process is typically graded, organized to
progress from less invasive and less costly tests to more invasive and costly tests, as
needed.25,26 To improve technical efficiency, the process should attempt to maximize the
number of successful donations with respect to the number of donor candidates who start
the evaluation process. The process should also attempt to maximize the number of
completed evaluations with respect to the number of donor candidates who start the
evaluation (regardless of donation).

Figure 5: General flow of the living donor evaluation process with potential
efficiency improvements
a

Could also provide a living donor toolkit, with frequently asked questions, testimonials from previous
donors, and details about the donation process
b Automated data quality checks to ensure it is filled out completely
c Care is needed to avoid evaluating the donor candidate too far ahead in case the recipient is never
referred
d
Encourage multiple candidates to initiate the process
e Can also have online tests to ensure the donor candidate understands the information provided to them

3.2.1 First contact
The donor candidate must self-refer to a living donor program. At first contact, the living
donor coordinator can answer any initial questions the candidate may have and can
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identify any absolute contraindications (e.g. type 1 diabetes mellitus) or issues that must
be resolved before the evaluation can proceed (e.g. very high body mass index,
uncontrolled hypertension). One strategy to improve the efficiency of the first contact
stage is to provide information on absolute contraindications on a trusted website to
reduce contacts from ineligible donor candidates and the associated workload on living
donor coordinators.27,28 Also, renal program staff working with patients with kidney
failure and their families can provide basic education on absolute contraindications when
discussing living kidney donation.
Table 1: Tests related to the living donor evaluation
Test

Indication

Paina

Time to
complete

Time to results
(approximately
)

Location of test

Initial screening
First contact
Medical-social questionnaire

all
all

0
0

various
various

immediately
7 days

digital
digital or paper

Compatibility testing
ABO blood typing
HLA typing
Biological crossmatching

all
all
all

1
1
1

5 min
5 min
5 min

1 day
1 day
5 days

local lab
hospital
hospital

Blood
Blood chemistry
Virology
Oral glucose tolerance test

all
all
if indicated

1
1
1.5

5min
5min
2 hours

1 day
1 day
2 days

local lab
local lab
local lab

all
programspecificb

1
2

5 min
24 hours

1 days
1 day

local lab
local lab

if indicated
all
all
if indicated
all
all
if indicated
if indicated
if indicated
if indicated

2
1
1
1
1
2
2
2
3
3

24 hours
5 min
10 min
1 hour
45 min
1 hour
1.5 hours
4.5 hours
15 min
6 hours

1 day
1 day
1 day
7 days
2 days
2 days
2 days
2 days
1 day
1-3 weeks

home
local lab
local lab
hospital
local lab
hospital
hospital
hospital
hospital
hospital

Urine
Random urine test
24-hour urine test

Imaging/other
24-hour blood pressure monitor
Electrocardiogram
Chest x-ray
Echocardiogram
Renal ultrasound
Renal imaging (CT or MR)
Nuclear renogram for split GFR
Nuclear GFR
Cystoscopy
Biopsy
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Cancer screening
Consults
Nephrology consult
Surgical consult
Social worker consult
Cardiology consult

if indicated

1-2

?

?

hospital or clinic

all
all
programspecificb
if indicated

1
1
2

1 hour
45 min
1.5 hours

1 to 5 days
1 to 5 days
5-6 days

1

1 hour

7 days

hospital
hospital
hospital or phone (at
least one in person)
hospital

GFR – glomerular filtration rate; CT – computed tomography; MR – magnetic resonance; HLA – human leukocyte
antigen
a
a subjective measure of invasiveness or pain based on our opinion (1 – least; 3 – most)
b
all or if indicated, depending on the program’s standard procedure

At this stage, there is also an opportunity to prioritize donor work-up when multiple
donor candidates come forward for the same recipient. The donor candidate that is
assessed first should be the one who is most likely to donate (i.e., has fewer
comorbidities, has a closer relationship to the intended recipient, is biologically
compatible). Most living donor programs perform sequential evaluations (i.e. work up
one donor at a time). Although this is a cost-saving strategy with regard to donor
evaluation costs, if the primary candidate does not donate, then the potential recipient
will have consumed more healthcare resources related to their disease while waiting
longer for the next donor to be approved. Currently, there is no evidence that sequential
donor evaluations are more cost-effective than simultaneous donor evaluations.

3.2.2 Medical-social Questionnaire
A questionnaire is the most effective way to obtain information on the donor candidate’s
medical and psychosocial history, family history, and social habits (e.g. behaviour
associated with transmissible infections, substance use). Results from the questionnaire
can identify risk factors to both the donor and the recipient and inform the content of the
evaluation or the order of tests. For example, some donors may require additional tests or
consultations, while others may require a psychosocial assessment earlier than usually
offered by the program.
The medical-social questionnaire can be done at the time of first contact or can be
completed and received by the donor program after the first contact. At some donor
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programs, a coordinator completes this questionnaire over the phone or in person with the
donor candidate. While such a process can be time-consuming and resource intensive, it
has the advantage of allowing coordinators to answer any initial questions the donor
candidate may have, as well as gather further information on their medical history, if
positive. Other programs provide this questionnaire on their website to be downloaded or
completed online by the candidate; however, online submission may create a backlog of
completed questionnaires that cannot be reviewed by healthcare staff in a reasonable
amount of time. The length of the questionnaire varies across programs. For example,
individual programs in Canada can modify a standardized questionnaire that includes at
least 50 questions.29 In contrast, a quality improvement initiative in Ireland developed a
short (one-page) questionnaire with yes/no responses for ease of administration.14
However, it is unclear whether the length of this questionnaire influences the time to
complete the evaluation.

3.2.3 Compatibility Testing
Donor and recipient ABO blood typing, human leukocyte antigen typing, and crossmatch testing are required to minimize the risk that the donor kidney will be rejected by
the intended recipient.30–32 If multiple donor candidates come forward for the same
recipient, then it may be prudent to prioritize candidates who are more immunologically
compatible.
For biologically incompatible pairs, alternatives include kidney paired donation
(incompatible donor-recipient pairs exchange with each other) or performing
incompatible transplants with desensitization protocols (a treatment option that removes
antibodies from the recipient and aggressively suppresses the immune system).33,34 Due
to the costs and medical risks associated with desensitization, kidney paired donation is
often the preferred option. However, kidney paired donation poses other challenges that
may impact the efficiency of living donation, such as finding and organizing multiple
exchanges with hard-to-match transplant candidates.35–38 Matching cycles are conducted
intermittently (e.g. every 3-4 months), which may prolong the time until donation can
occur and impose a barrier for some donor candidates.39 A recent study of 849 living
kidney donors reported that the paired donation program prolonged the total time until
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donation by 6.6 months (Chapter 6).15 Furthermore, many donor candidates are unable or
unwilling to travel to donate due to financial or time constraints or lack of family support.
To address this barrier, one strategy is to transport the donor’s kidney to the recipient’s
transplant hospital, recognizing that this may increase the cold ischemia time.40,41
Medically suitable but biologically incompatible donors should be counseled early about
the advantages and disadvantages of paired donation programs and be given the option to
stop their evaluation early if they are not willing or able to proceed.

3.2.4 Laboratory and Radiologic Testing
For convenience, most initial blood and urine tests can be performed at local laboratories,
rather than at the transplant center. These tests are typically performed before the donor
candidate visits the transplant center for the first time, and the results can guide the
remainder of the evaluation.42 For example, if a donor candidate has persistent
microscopic hematuria on multiple urinalyses, further work-up would be recommended
to rule out infection, renal calculi, malignancy, and renal pathology. To rule out bladder
malignancy, consultation with a urologist for consideration of cystoscopy is routine;
however, for low-risk patients (i.e., <35 years of age), this step may be unnecessary given
its low yield.43 Moreover, cardiac evaluations (e.g., cardiology consultations,
echocardiograms, nuclear stress tests) may not be necessary for donor candidates who
have good exercise tolerance, yet guidelines are vague on this topic.43
A 24-hour urine collection is used to measure the donor candidate’s creatinine clearance
(an indicator of kidney function); however, results may be inaccurate in the setting of
over- or under-collection.44 Currently, there is no consensus on how many 24-hour urine
tests should be performed (range 0-2 tests considered as part of the standard work-up).15
Although there is no evidence that eliminating this test from the evaluation process
results in more timely completion, it may reduce the burden on donor candidates.15
Due to its relatively low cost and high availability, renal ultrasound may provide the first
image of the kidney in some regions. Renal ultrasound can identify cysts, kidney stones,
and other anomalous findings in adjacent anatomy that require further investigation (i.e.,
liver, ovaries).45–47 Advanced renal imaging, such as computed tomography (CT) or
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magnetic resonance (MR) angiography, is a critical part of the living donor evaluation
and may be reserved for a later phase of the evaluation because of its higher costs and
wait times in some regions. CT or MR angiography provides higher resolution than renal
ultrasound, enabling more accurate mapping of the renal vasculature, which is necessary
to plan the donation surgery.48,49 Nuclear renogram has been recommended to measure
the split kidney function to determine which kidney should be donated, if indicated by
differential kidney dimensions identified earlier in the evaluation. Due to the graded
nature of the evaluation, advanced (and costly) imaging modalities are usually performed
later. When donor candidates do not proceed to this stage of the evaluation (i.e., declined
or withdrew), these tests would not be needed and fewer resources would be used to
complete the evaluation. Even in the setting of a 1-day evaluation, the CT scan may be
scheduled later in the day and subject to cancellation following review of earlier test
results by the consulting nephrologist or surgeon.14
Other efforts to improve the efficiency of the living donor evaluation process have
focused on eliminating the need for some tests, such as an assessment of split function
with nuclear renogram. Some investigators have suggested using CT volumetry to
estimate split kidney function instead of nuclear renogram.50,51 Others have devised an
algorithm to omit the measured glomerular filtration rate (GFR) test to assess the total
kidney function: donor candidates whose estimated kidney function (based on serum
creatinine and/or cystatin C) is sufficiently high or sufficiently low that the measured
GFR will not change the decision on the candidate’s eligibility may proceed or be
declined without the need for measured GFR.52,53

3.2.5 Consults
All programs require donor candidates to receive consultation with a nephrologist and a
surgeon, with less agreement on routine consultation with a psychosocial specialist.54
Some programs have systems in place to permit all initial testing and imaging as well as
consultations to be scheduled for the same visit. This is intended to reduce the travel
burden for donor candidates, particularly for those who live far from the transplant
center, but may also permit a one-day donor evaluation as a routine process for all donor
candidates.14,15 Despite this, the time between these three consultations is on average 3
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months across Canada and Australia.14 Another strategy to improve the efficiency of the
consultations may be to delay the surgical consult in patients without a significant history
of abdominal surgery, who have a healthy weight, and no abnormalities on initial testing.
In this way, the surgeon would only see patients who are more likely to proceed with
nephrectomy.

3.2.6 Donor Nephrectomy
CT angiography is generally regarded as one of the late-phase tests in the evaluation, and
may further delay the evaluation as there may be a significant waiting time to book a CT
angiogram in some regions. One potential solution is to negotiate dedicated time with
radiology, and so the living donor program can expect a given number of spots for living
donor assessments each week. The average time from CT until donation was reported to
be 4.8 months across Canadian and Australian centers, ranging from 3-8 months.15 If
these delays are attributable to difficulties scheduling the operating room (OR), then
efforts should be made to book the OR as early as possible, considering the needs of the
donor candidate, the recipient, and the OR staff. Donor candidates often express times of
the year when they can (or prefer to) donate so the recovery process will not greatly
interfere with their work, dependent care, or other responsibilities. In situations where
this leaves ample time for an evaluation, booking the OR should not be a factor delaying
the time until donation. Conversely, if an expedited work-up is necessary, then the living
donor program should work with the surgeons and the OR staff to book the ORs once the
donor and recipient are likely to be approved (rather than waiting until the actual
approval date). Alternatively, the living donor program could negotiate having a standing
time in the OR schedule to accommodate the expected number of donations each year.

3.2.7 Other Aspects of the Evaluation
3.2.7.1

When does the living donor evaluation actually start?

Most programs do not start the living donor evaluation until the recipient has at least been
referred to the transplant program. Some programs may additionally require that the
recipient is approved for transplant. This latter strategy is a cost-conscious one, avoiding
donor evaluations for those whose recipients will not be eligible for transplant. However,
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this may delay the time until transplant, which will be particularly costly for recipients
who are on dialysis. Although the optimal strategy to initiate the living donor work-up is
unknown, the funding model and payer perspective are important considerations, as cost
savings in one domain (fewer living donor evaluations) may not be reconciled by cost
savings in another (less time on dialysis). In either case, earlier recipient referrals are
expected to translate into earlier transplants.

3.2.7.2

Navigators as part of the evaluation

Donors are healthier than the general population, and may therefore be unfamiliar with
healthcare systems. The use of prior recipients as navigators has been shown to be
effective at increasing the number of steps completed as part of the evaluation for
recipient candidates.55 In Ontario, a pilot Transplant Ambassador Program is being
launched: by connecting potential donor and recipient candidates with prior donors and
recipients, candidates will be better positioned to make decisions about donation or
transplantation and will be better informed about navigating the evaluation process. The
Transplant Ambassador Program is expected to increase the number of living donor
candidates contacting programs and the number of evaluation tests completed, but will
also be positioned to assess the impact of donor ambassadors on the timeliness of
donation.56

3.2.7.3

Cost to the living donor

The out-of-pocket costs to the donor to participate in and complete the evaluation have
been recognized as a substantial barriers to living kidney donation.57–59 Although
reimbursement for at least some of these costs helps some donor candidates, others are
still disadvantaged because reimbursement may occur some time after the evaluation is
complete, be limited to only to those who complete an evaluation, or include only a
portion of costs incurred (e.g., costs of travel and lodging, but not lost wages).59–63 A prepaid credit card for valid expenses or validated hospital parking may remove this barrier
and allow candidates to complete the evaluation in a timely manner. Telemedicine is also
a valid option for some consultations or educational sessions, particularly for donors who
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live far from the transplant center. However, the effectiveness of such strategies has not
yet been demonstrated.

3.2.7.4

Evaluating center is not the same as the center where
donation is intended

The donor candidate is typically assessed at their home program, and if approved, their
chart is sent to the intended donor recovery program for review. Differences in programspecific evaluation and selection criteria may result in inefficiencies, particularly when
the home program may not perform tests routinely done by the recovery center. This may
lead to additional or redundant testing after the candidate has already been approved by
the home center. To ameliorate this, for donor candidates enrolled in the Canadian kidney
paired donation program, a minimum set of required tests has been established by
consensus.29 However, for donor candidates who are not in the kidney paired donation
program, this remains a potential source of inefficiency, and a uniform set of criteria for
donor selection and evaluation should be adopted, regardless of donation strategy (direct
donation, simple exchanges, national paired donation programs).

3.3 The intersection of efficiency and quality
Numerous quality indicators are reported by governmental health authorities each year
that may be used to provide benchmarks or serve as indicators of quality, equity, or
effectiveness. Common metrics include the number of deaths after an intended recipient
has been approved for transplant but has not yet received one, the time spent on the waitlist, the number of patients on dialysis, the number of living and deceased donor kidney
transplants performed, and the burden of disease on the healthcare budget.64 A prolonged
living donor evaluation will adversely affect most of these outcomes, but there are
additional indicators that are important, yet not reported (Figure 6). If the intended
recipient could receive a pre-emptive transplant, then this may avoid complications of
kidney failure, reduce costs, and increase quality-adjusted life expectancy.65–69 A new
study at five centers in Ontario, Canada found that one-third of living donor transplant
recipients initiated dialysis prior to receiving their living kidney donor transplant, despite
their donor’s evaluation being well underway (Chapter 8).66 A faster donor evaluation
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may increase the number of pre-emptive transplants.14,70 In a similar vein, if the intended
recipient dies while the living donor is being evaluated, this can also have long-term
implications on the psychosocial health of the donor candidate. Finally, since most
programs do not remove transplant candidates from the deceased donor wait-list because
they have a living donor, deceased donor kidney transplantation is a competing treatment
option that prevents another recipient from receiving that deceased donor organ, if the
deceased donor organ is accepted in favor of living donation.7 These outcomes are also
not routinely reported.

Figure 6 Potential implications of an inefficient living donor evaluation process.
Once the living donor begins the evaluation and the intended recipient is approved
for transplant, a prolonged evaluation may result in adverse consequences for the
intended recipient, including dialysis initiation, transplantation from a deceased
donor instead, or ineligibility resulting from death or illness.

3.4 Recommendations for future research
It is clear that an inefficient living donor evaluation can have substantive unintended
consequences that have not yet been consistently measured and reported to date. The
rather nebulous definition of “efficiency” complicates measurement using any single
metric and likely requires multiple complementary indices.15 However, we propose a
working definition: an efficient evaluation is one that is completed in as little time as
possible, results in optimal outcomes, and meets the expectations of patients and
healthcare providers.
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Quality indicators are needed for quality improvement projects.14,71 Such indicators
should be defined clearly and measured to enable comparisons between and within
transplant programs. They should be measured retrospectively to provide an
environmental scan and allow benchmarking, and also prospectively to facilitate
monitoring in continuous audit-feedback loops. We recommend a few quality indicators,
such as the total time until donation, among others15,70, but a systematic approach is
needed to generate a more complete list and define measures operationally (i.e., these
metrics may require uniform definition of the evaluation start date, or a minimum time
sufficient to complete an average donor’s evaluation). We recommend that all
stakeholders (patients, healthcare providers, insurers, and policy-makers) be involved in
this process and remain engaged to identify, design, and implement solutions to improve
the efficiency of the donor evaluation process. A more efficient living donor evaluation is
expected to improve the living donor experience, increase the rate of living donor kidney
transplants, improve recipient health, and reduce healthcare expenditures.
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Chapter 4

4

The efficiency of evaluating candidates for living kidney
donation: a scoping review**

4.1 Introduction
An efficient living donor candidate evaluation is completed in as little time as possible
and meets the needs of the donor candidate, the intended recipient, and the healthcare
system. An inefficient evaluation process can result in missed opportunities for
preemptive transplants if the intended recipient’s kidney disease progresses.1,2 If an
intended recipient is approved for transplant but the evaluation of their living donor is
delayed because of an inefficient healthcare process, this may cause anxiety and
frustration for the recipient and the donor.3 Finally, there may also be missed
opportunities for living donor transplants if the intended recipient receives a deceased
donor kidney transplant while their donor is being actively evaluated.4
A need to improve the efficiency of the living kidney donor candidate evaluation is
featured in reports from patient advocacy groups, a recent consensus conference in the
United States (U.S.), the 2017 Kidney Disease Improving Global Outcomes (KDIGO)
international practice guideline, and a report from the National Health Services in the
United Kingdom (U.K.) targeting an 18-week evaluation, where possible.5–8 However,
while advocating for efficiency, these reports do not provide any recommendations on
how efficiency can be achieved.

**

A version of this chapter has been accepted for publication: Habbous S, Woo J, Lam NN, Lentine KL,
Cooper M, Garg, AX. “The efficiency of evaluating candidates for living kidney donation: a scoping
review”. Transplantation Direct. 2018:4(10):e394.
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A review that summarizes existing information on the efficiency of the donor candidate
evaluation can provide a necessary foundation for quality improvement.9 As a
multidimensional construct (including the time to complete the evaluation, patient
outcomes, and resource use), an efficient evaluation process may not easily be
summarized in a single systematic review of a focused question. Instead, we undertook a
scoping review to map the available literature to themes related to an efficient living
kidney donor candidate evaluation. We also reviewed the websites of living donor
programs from four countries to describe the information provided to candidates about
the nature and length of the evaluation process.

4.2 Methods
4.2.1 Literature review:
We followed the recommendations of the Joanna Briggs Institute for conducting and
reporting scoping reviews.10 On September 12, 2017, one author (S.H.) searched
bibliographic databases using the search terms “living AND kidney AND donor AND
(assessment OR evaluation OR practice OR screening OR selection OR efficient OR
efficiency)” [Medline (n=2,801 citations via PubMed), PsychInfo (n=58), EMBASE
(n=2,899 via OVID), and ABI Inform Collection (n=5)]. Search terms were chosen based
on terms associated with known articles of interest. Articles were restricted to human
studies published in English from 2000 onwards. Conference abstracts were excluded.
Studies were not restricted by age or country. Google searches and reference lists of
relevant articles were screened and manually added if appropriate, regardless of
publication date. The title, abstract, or full-text of an article was used to sort the literature
into themes related to the efficiency of living kidney donor evaluations. We then
summarized the findings within each theme, focusing on how they could be used to guide
future efficiency improvements. Articles only considering how accepting donors with
certain characteristics influenced their postdonation outcomes were excluded.
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4.2.2 Living donor program websites:
From May to August 2017, we searched the websites of living donor programs in
Canada, U.S., U.K., and Australia for information related to an efficient evaluation
process.

4.2.3 Statistical methods
Meta analysis was performed using the metaprop package in STATA v13.0 using a
random-effects model. Confidence intervals were calculated using exact methods.

4.3 Results
A total of 4,706 articles were available for screening after duplicates were deleted. After
applying the exclusion criteria, 273 articles were available for mapping (Figure 7). Five
relevant themes emerged through the mapping process: 1) surveys of living donor
program practices (eight studies); 2) renal imaging for the living donor assessment (159
studies); 3) kidney function assessment (56 studies); 4) the flow of living donor
candidates through the evaluation process (38 studies); and 5) the living donor experience
with the evaluation process (12 studies).

43

Figure 7: Summary of literature search, study inclusion and mapping for scoping
review.

4.3.1 Studies surveying living donor programs
Eight surveys of multiple transplant programs were conducted in the U.S.11–14, U.K.15,16,
France17, and Europe18 (Table 2). These surveys revealed some similarities in the
evaluation and selection of living donor candidates, but also some notable differences in
donor eligibility criteria and tests performed to evaluate a candidate.12,19,20 Evaluating the
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efficiency of the living donor evaluation process was not an objective of any of the
surveys.
Table 2: Survey of living donor programs

Reference

Country

Number of centres responding

Bia 199512
USA
173/231 (75%)
16
Lumsdaine 1999
UK
29/31 (94%)
18
Gabolde 2001
France
36/46 (78%)
13
Mandelbrot 2007
USA
132/205 (64%)
or Rodrigue 200714
Lennerling 201219
Europe
113 programs over 40 countries
15
Brar 2012
USA
72/181 (40%)
Arunachalam
UK
44/74 (59%) includes transplant and
201317
non-transplant centres
Table: Studies surveying living donor programs

4.3.1.1

Average number
of living donor
transplants per
centre each year
13
4.7
1.6
39
median <50
median ~80
69

Number of donors evaluated simultaneously

Several donor candidates may come forward at the same time for the same recipient. This
may increase to dozens of candidates when recipients share their need for a living donor
on social media, which is often public.21 One survey from the U.K. reported that 50% of
centres evaluate one donor candidate at a time, while 20% evaluate 2 or more
simultaneously (although it was not reported what the policy is among the remaining
30%).16 Detail on the relative rigor of the evaluations was not reported (e.g. one
candidate evaluated quicker; full versus partial evaluation for one or all candidates).
Further research is needed on the optimal use of resources in evaluating multiple donor
candidates simultaneously versus sequentially.

4.3.1.2

Removal from the deceased donor wait-list

Some intended recipients are on a waitlist for a deceased donor kidney while the
evaluation of their living donor candidate is underway. In such cases, a prolonged living
donor evaluation may result in a deceased donor transplant and the loss of a kidney from
a potential living donor at that time. A recent survey of 44 transplant centres from the
U.K. reported that recipients are removed from the deceased donor waitlist when the
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living donor kidney transplant date is scheduled (16 centres), when the candidate is
approved for donation (eight centres), when the final crossmatch is complete (five
centres), or on the actual day of the living donor transplant (one centre).16 The U.S.,
Organ Procurement and Transplantation Network policy now requires potential recipients
of all organ types (living or deceased) to be registered on the waiting list prior to their
transplant, although listing status may be inactive to prevent offers of a deceased donor
(policy 3 in reference).22

4.3.1.3

Receipt of a formal psychosocial evaluation

Survey responses suggest a formal psychosocial evaluation is required for all donor
candidates by 74% of programs in the U.S. (survey from 2007), 60% in Europe (survey
from 2001), and 53% in France (survey from 2013).13,17,18 Whether these assessments
were conducted by a psychiatrist, psychologist, or social worker varied. Programs that do
not routinely conduct a formal psychosocial evaluation may do so if underlying problems
were identified or suspected during the evaluation, or if the donor was unrelated to the
intended recipient. The 2017 KDIGO guideline recommends that all candidates receive
an in-person psychosocial evaluation (an ungraded recommendation due to insufficient
evidence).7 As of 2013, a psychosocial evaluation is required during the assessment of
donors (rather than candidates) in the U.S., which can be conducted by any of the 3
aforementioned professionals (policy 14 in reference).22 We are unaware of whether these
policies impacted the efficiency of the living donor work-up.

4.3.1.4

Time for smoking cessation or abstinence

The requirements related to smoking have become less stringent over time. Most centres
do not routinely exclude active smokers (36% of French centres exclude only heavy
smokers; only 2% of U.S. centres require documentation of cessation), but instead urge
donors to stop (or reduce) smoking for some period of time before donation.13,17

4.3.1.5

Time to complete evaluation

The time to complete the donor evaluation was mentioned briefly in two surveys from the
U.K. Twenty programs did not have a targeted time period, but 3-6 months was seen as
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an appropriate window by nine programs (although the start and end dates of the
evaluation were not defined).15,16

4.3.1.6

Other differences

Living donor programs also varied on donor eligibility criteria. These issues relate to the
age of an acceptable candidate, acceptable limits for hypertension, and other components
of the evaluation. As these issues relate to the safety of the evaluation rather than
efficiency, we describe these differences briefly in Appendix A.

4.3.2 Renal imaging studies
A total of 159 studies reported on renal imaging modalities in the candidate evaluation.
Most of these studies considered the accuracy of computed tomography (CT) and
magnetic resonance (MR) angiography to define the renal vasculature compared with the
actual vascular findings observed during surgery (CT was more common than MR).16,23
Correctly charting the vascular network and characterizing any abnormalities as benign
(i.e., cysts, lesions, small excisable tumors or stones) is a critical function of CT or MR
imaging in the living donor evaluation and is necessary to ensure donor and recipient
safety.24 Regarding efficiency, CT or MR imaging is generally performed later in the
evaluation because these tests are costly and expose donor candidates to mild risks
related to contrast media or ionizing radiation.12,16,25,26 In some centres there may be a
waiting time to receive such testing.
If a clinically important size discrepancy between the left and right kidney is observed
(i.e., >1 cm or >10% difference from prior imaging), then a nuclear renogram may be
performed to assess the relative function of each kidney, called the “split renal function”
(if significantly different then the donor may be left with the higher-functioning kidney).
All living donors complete a CT or MR scan as part of the evaluation (Figure 8A).
Because of the expected relationship between kidney size and function (larger kidney =
more nephrons = higher function), 18 studies assessed whether the relative kidney
volume determined by CT can be used as a surrogate for relative function as determined
by nuclear renography (Figure 8B). Most authors concluded that CT volumetry could
replace split renal function measurement, eliminating this test from the evaluation process
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for some candidates. Given such consistent reporting, a systematic review and metaanalysis was conducted separately (including these studies and more), which reported a
moderate correlation between split renal volume by CT scan and split renal volume by
nuclear renogram (Pearson’s r=0.74, beta=0.76 by linear regression).27 For predicting a
clinically significant size difference between the two kidneys, CT had a specificity of
88% and negative predictive value of 86% (sensitivity 35%; positive predictive value
40%).27

Figure 8 Improving the efficiency of the evaluation: The use of split renal volume
measured by computed tomography to replace split renal function measurement by
nuclear renogram. A) The current renal imaging protocol at many transplant
centres, where the computed tomography (CT) scan and nuclear renogram are both
performed for donor candidates. Both exams may be conducted on the same day,
but this is not necessary. B) The proposed renal imaging protocol, where the nuclear
renogram is replaced by CT scan for some donor candidates.
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4.3.3 Studies measuring predonation kidney function
Acceptable living donor candidates must have sufficient predonation kidney function to
minimize the risks associated with living with one kidney. Glomerular filtration rate
(GFR) measured using a radionuclide (mGFR) is the current gold standard, but is a
resource-intensive test, is not always readily available, exposes donor candidates to
potentially harmful radioisotopes, and may be subject to systematic bias and
measurement error.28 Because of this, GFR is estimated (eGFR) early in the evaluation
using serum creatinine (a biomarker that can be measured from a simple blood test).7,29,30
Confirmation using another test can be performed later, including a second eGFR from
creatinine with/without cystatin-c, measured creatinine clearance, or mGFR.7,31
Fifty-six studies focused on measuring or estimating GFR in kidney donor candidates.
Most studies compared the accuracy of various equations to estimate kidney function or
predict postdonation kidney function. In contrast, two studies were identified that directly
addressed the role of GFR in an efficient living donor evaluation.32,33 In the presence of
imprecision and biases among existing methods, Huang et al.32 developed an algorithm to
determine whether mGFR could be unnecessary for some candidates based on high
predictive value of eGFR, age, sex, and race for measuring kidney function. The rationale
behind this algorithm is presented in Figure 9. The authors recommend that the second
eGFR (the first confirmatory test, or “post-test probability 2” in Figure 9) be performed
using both serum creatinine and cystatin-c. However, two validation studies used a
second eGFR based only on serum creatinine since cystatin-c is not routinely
available.33,34 Huang et al. estimated that at least 53% of donors in the U.S. from 20092015 would not have required a mGFR based on an eGFR high enough to assure a mGFR
≥90 ml/min/1.73 m2. In one validation study, 27% of mGFR could have been avoided,
but a post-test probability cut-point >98% (rather than 95% in the original study) was
required to achieve 100% sensitivity.33 In a second validation study, 14% of mGFR could
have been avoided, but a post-test probability cut-point >99.98% was required to achieve
100% sensitivity.34 More work is needed to advance this prediction tool to clinical
practice.
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Figure 9: Algorithm to remove measured glomerular filtration rate (GFR) by
radionuclide for some donor candidates. Threshold is an arbitrary cut-point
generated by the data to permit 100% sensitivity. Algorithm described by Huang et
al.32 mGFR – measured GFR; eGFR – estimated glomerular filtration rate using
serum creatinine (eGFRCr) or serum creatinine and cystatin c (eGFRCr-Cys). GFR –
glomerular filtration rate; eGFR – estimated GFR; mGFR – measured GFR; Cr –
serum creatinine; Cys – cystatin C; eGFRCr – eGFR estimated using serum
creatinine only; eGFRCr-Cys – eGFR estimated using both serum creatinine and
cystatin C

4.3.4 Studies describing the flow of living donors through the
evaluation process
A total of 38 studies reported on the number of donor candidates evaluated by their
programs.2,3,35–73 We summarized these results, tabulating the proportion who donated,
the number of potential donors lost because the intended recipient either received a
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transplant from a deceased donor or died or became too ill to receive a transplant, and the
time required to evaluate candidates.
The proportion of living donor candidates who ultimately donated ranged from 8% to
86%, averaging 37% across studies (Figure 10). Although the definition of the numerator
and denominator varied, no difference was observed when we excluded any study.

Figure 10: Forest plot with proportion of donor candidates who donated. Studies
were pooled using a random effects model. There was significant variability (I2 =
99.5%, p<0.0001). ES – effect size (a proportion); CI – confidence interval.
Twenty-four (63%) studies reported a loss of intended recipients due to illness or death
(range 1-7%) or receipt of a deceased donor kidney (1-21%) (Table 3). Although these
recipients had a potential living donor, none of these studies evaluated whether a living
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donor transplant was feasible (i.e., the donor candidate may have come forward only a
few weeks before, which was not enough time to complete a thorough evaluation). It is
possible that up to 21% of potential recipients could have received a living donor
transplant if the evaluation was quicker. This is, however, an upper theoretical limit and
the true loss of potential living donor transplants remains unknown without more data. A
recent study projected that a more efficient living donor evaluation process (i.e., donor
evaluation completed three months sooner) may result in a 20% increase in the total
number of living donor kidney transplants performed, translating to substantial healthcare
system cost savings through avoided dialysis.4 These findings are supported by a recent
quality improvement project that reduced the time to complete the living donor
assessment using a one-day donor assessment model.2
Table 3: Summary of studies reporting on the loss of potential donor candidates due
to recipient illness or death or competition from deceased donor transplantation
Reference

Transplant centre

Saunders
200035

Leicester General Hospital,
Leicester UK

Schweitzer
200438
Calder 200440

University of Heidelberg
Hospital, Germany
St. George’s Hospital, UK
University of Cape Town
and Groote Shuur
Hospital, South Africa
Thomas Jefferson
University Hospital, PA

McCurdie
200541
Kayler 200542

Time period

Loss of potential donor candidates
due to recipient
due to deceased donor
illness or death
transplant

1994-1998

1 no longer eligible after
surgeon consult (recipient
cancer), but no indication of
recipient death or loss
before surgeon consult

1997-2002

NR

1997-2001

2 (1%) (death only)

3 (7%) (in subset of 45
candidates)
13 (7%)

Jan 2000-Mar
2003

4 (3%)

25 (21%)

Jan 2000-April
2003

NR

64 (6%) (estimated)

25 (9%)

Tuohy 200644

Beth Israel Deaconess
Medical Center, NY, USA

2000-2003

12 donors were approved but recipient too sick or died or
received a transplant (unsure of donor source); for donors who
did not initiate medical work-up (definition of this is unclear,
n=120), 18 recipients died/too sick and 84 already transplanted
(unsure of donor source)

Akoh 200846

South West Transplant
Centre, UK

Jan 2003-Feb
2008

7 (2%) (death only)

34 (9%)

Larsen 200948

Rigshospitalet, Denmark

Jan 2002-Dec
2006

NR

Reese 200949

Hospital of the University
of Pennsylvania

Dec 2006 – March
2008

NR (recipient unfit for
transplant in 5 (4%), but no
indication of deaths or loss
due to illness)

52

NR

20 (17%) (but unclear if all had a
live donor)

Roodnat
200950

Erasmus Medical Center,
University Hospital
Rotterdam

Lin 201051

National Taiwan University
Hospital, Taiwan

Lapasia 201053

Stanford, CA

*Sanner 201155
Norman 201156
Moore 201257
Weng 201259
Gozdowska
201362
Romagnoli
201363
Connaughton
201666
Alsulaiman
201667

59 (6%) recipient reasons
including death, malignancy,
cardiovascular disease
(grouped)
5 (2%) [illness only, no
indication of death]

Jan 2000-Dec
2007
Jan 2005-Dec
2008
Oct 2007-March
2009

15 (1%)
5 (2%)

28 (6%) (deaths)

not clear

Jan 2004-July
2008

6/135 recipients

N/A (recipients only)

Jan 1995-June
2006
Jan 2004-July 1
2009

14-20% of those excluded
donors (death only)
35 (11%) (combined death,
illness or incompatible)

Jan 2000-Dec
2005

56 (5%)

36 (3%)

Poland

2007-2011

NR (assume zero deaths)

17 (14%)

Catholic University, Rome,
Italy

Jan 2005-March
2012
Jan 2000-Mar
2014
Jan 2004-Jun
2008

5 (6%)

6 (8%)

33 (3%)

75 (8%)

Karolinska University
Hospital, Stockholm
Sweden
University of Michigan
Transplant Center
Vanderbilt University
Medical Center, TN, USA
Saint Barnabas Medical
Center in Livingston, N.J.,
USA

Ireland

23-28% of those excluded
NR

Christchurch Hospital, New
17 (10%) combined
Zealand
Kenyatta National Hospital,
4/84 (5%) deaths (records
0 (no cadaveric donation in
Muturi 201769
2010-2014
Kenya
available for only 84)
Kenya)
Al-Rabadi
King Hussein Medical
Jan 2008-June
42 (7%)
NR
201770
Center, Jordan
2016
Multiple centres in England Aug 8, 2014-Jan
Bailey 201771
32 (4%)
34 (4%)
and Wales
31, 2016
Knight 201873
Oxford Transplant Centre
Jan-Mar 2016
NR
2 (4%)
Habbous 2018 London Health Sciences
Jan 2013 – Dec
4 (1%) with a donor in the
13 (4%) with a donor in the
(unpublished
Centre, London, Ontario
2016
evaluation
evaluation
data)
Canada
NR – not reported; N/A – not applicable
*these were studies primarily mapped to the living donor experience with the living donor evaluation

Seventeen studies (45%) reported evaluation times using various metrics, estimated using
data or stated anecdotally. Common evaluation times included the time until approval to
donate, donation, or rejection, although the definition of the starting point varied (Table
4).35,47,48,65,72 The time until donation ranged from 4-14 months across studies and
transplant programs. One report described a single recipient who received a kidney from
her father (before) and her mother (after) the living donor evaluation process was
redesigned to be completed in one day.3 The results of this redesign were highly positive,
showing a reduction in the evaluation time from 2 years to 3 months, an increase in the
number of preemptive transplants from <10% to >50%, a rise in the number of living
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donor kidney transplants per million population from <5 to >32, and a reduction in the
prevalence of patients on dialysis.2
Table 4: Summary of studies reporting on the duration of the living donor
evaluation
Reference
Saunders
200035
Trevitt 200137
Calder 200440
*Williams
200745
Ferriman
200847
Larsen 200948
*Sanner
201155
Romagnoli
201363
Weng 201665
Alsulaiman
201667
*Bailey 20163
Al-Rabadi
201770
Bailey 201771

Transplant
centre
Leicester General
Hospital, Leicester UK
Barts and The London
NHS Trust, London,
UK
St. George’s Hospital,
UK
Edith Cowan
University and Sir
Charles Gairdner
Hospital
Royal Free Hospital,
London UK
Rigshospitalet,
Denmark
Karolinska University
Hospital, Stockholm
Sweden
Catholic University,
Rome, Italy
Saint Barnabas
Medical Center in
Livingston, N.J., USA
Christchurch Hospital,
New Zealand
Belfast City Hospital,
UK
King Hussein Medical
Center, Jordan
Multiple centres in
England and Wales

Time period

Evaluation time

1994-1998

time until donation: mean 9.3 (SD 6.5) months

1997-1999

~4 months from the time of initial crossmatch until donation (estimated
from graph)

1997-2001

process designed to take a minimum of 3 months (some with <3 months if
coming from abroad and had testing done elsewhere already)

Not reported

most cases between 1-2 years, shortest was 6 months

~2007-2008

116 days

Jan 2002-Dec
2006

median 4 (IQR 1-24) months time until approval; median 3 (IQR 0-9)
months from approval to donation; median 3 (IQR 0-48) time until rejection

Jan 2004-July
2008

11.0 (SD 8.6), range 1-48 months

Jan 2005-March
2012

Not reported (but acknowledged it is time consuming and resource
intensive)

2007-2010

163 days (time from referral to donation, but unclear what referral means)

Jan 2004-Jun
2008

3-9 months

Not reported
Jan 2008-June
2016
Aug 8, 2014-Jan
31, 2016

Graham
20172

Ireland

2010-2015

Habbous
201872

Multiple centres in
Canada and Australia

Sept 2009-Jan
2015

9-10 months, down to <3 months for a healthy willing donor at the time of
writing
process designed to take a minimum of 2 months, but not measured
median 308 days for donors; median 61 days for non-donors
2-3 months for work-up
median 10.3 months (total evaluation time), 7.9 months (time until
approval), 0.7 months from approval until donation, 4.8 months from
computed tomography angiogram until donation, and 3.0 months for time
between consults
median 132 days from first contact until decision; median 204 days from
first contact until donation

Oxford Transplant
Jan-Mar 2016
Centre
Habbous
London Health
time from evaluation start until donation was a median 9.2 (6.1, 14.0)
2018
Sciences Centre,
Jan 2013-Dec
months; time until withdrawal or decline was a median 4.3 (1.4, 9.1)
(unpublished
London, Ontario
2016
months
data)
Canada
*these were studies primarily mapped to the living donor experience with the living donor evaluation
IQR – interquartile range (25th-75th percentile); SD – standard deviation
Knight 201873
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4.3.5 Studies describing the living donor experience
Twelve studies asked prior donors about their experience with donation.3,45,55,74–82 One of
the most common comments related to the evaluation process was that the evaluation was
lengthy, and a prolonged evaluation was a source of strain on both the donor and the
recipient:
“It just has to be soon as possible because we are not able to do
anything right now. X (the recipient) is so bad that we never know in
advance if we can carry out the plans we’ve made but have to wait and
see on the day.”74
“... it actually disrupted our whole life ... I had to keep taking time off
work ... like each time we went for tests ... when ... they were going to
have the first operation, I took holidays and then it was cancelled and
then I tried to ring my boss and get back to work again so I could save
my holidays. It was pretty hard ... you sort of have to try and switch off
your family life to get on with the job.”45 (mother donating to her child)
“At the first appointment, we were told that the process takes
approximately 9 or 10 months, and all I could think of was whether we
had this amount of time, as our daughter’s kidney was failing and she
was determined not to have dialysis if she could avoid it.”3
“I wish the process could be quicker, there are people dying and it
shouldn’t take so long to get checked out as a donor.”81

The length of time needed to reconsider the act of donation (the ‘cooling off’ period)
varies by donor, but three months may be sufficient for most.76 Some donors have
expressed wanting less time to think about the decision to donate because of the
additional anxiety it produces: “the longer you wait, the longer you worry about it”.76
Once the decision is made, donors often want the surgical procedure as quickly as
possible. Several donors blamed the healthcare system for conducting an inefficient and
poorly executed evaluation process (concerning an evaluation time of six months or
longer).55,74 Moreover, the time between donor approval and donor surgery was
prolonged for several donors, which injected an additional source of anxiety for both the
donor and recipient.45,74
Some donors reported being frustrated that a prolonged evaluation resulted in their
intended recipient spending an unnecessarily longer time on dialysis.55 One study
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reported donor responses in favor of preemptive transplant (i.e., better for recipient
health), while others favoured transplant after some time on dialysis (i.e., more likely for
the recipient to be compliant with medications and to better understand the value of a
kidney).76

4.4 Information on living donor program websites
We reviewed the websites for 296 living donor programs in Canada, U.S., U.K., and
Australia (Appendix B), focusing on issues related to an efficient living donor evaluation.

4.4.1.1

Time to complete the evaluation

9/296 (3%) of the websites provided information on the duration of the donor evaluation
process, time until results are obtained, and the time to complete the evaluation (i.e.,
number of days of testing at the hospital). Most websites only provided a low level of
information, stating either the number of days of testing required or the total evaluation
time. Some representative examples are listed in Table 5. Twenty-one programs
acknowledged the evaluation may take up to 6 months, sometimes providing very broad
ranges (e.g. 6-12 months; 1-6 months; 3-18 months; up to 6 months). Others described
evaluations <4 months. Although some of these may accurately represent the efficiency
of the program, we are only aware of published data from one centre (2-3 months in
Belfast City Hospital, Ireland, U.K.).2 One website stated a time of two months from
donor approval to surgery (Ohio State University Medical Center).
Ten transplant programs indicated that evaluation testing is completed in 1 day for most
candidates (depending on the candidates’ age; older candidates may require additional
testing). Eleven programs indicated up to 2 days were required, and 6 programs indicated
at least 3 days were required.
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Table 5: Representative information from the websites of living kidney donor
programs on the time to complete the evaluation process
Country

City, province

Hospital

Example

Qualitya

Canada

London, Ontario
Portland, Oregon

UK

Belfast, Ireland

Canada

Toronto, Ontario

USA

Columbus, Ohio

2-3 days for tests; 3-6 months for results; 6+
months total from start to surgery date
1 day for evaluation, 2-3 months plus a few weeks
to schedule surgery
1 day (1 full day, starts at 8am; the day’s schedule
provided); most results reported within a few days.
While our priority is always to make sure donation
is as safe as possible for the donor, we can actually
complete all of this within 2-3 months if necessary.
There may be an appropriate delay before you have
the 1-day assessment process if we need additional
information or blood tests. Other times it may be
too early for you to have other investigations
depending on the person that you are hope to give a
kidney to
2-3 months, (3-6 months before surgery can be
scheduled)
1 day for evaluation, 2 months from donor approval
to surgery

moderate

USA

London Health
Science Centre
Oregon Health and
Science University
Belfast City
Hospital

Canada

Vancouver,
British Columbia
Hershey,
Pennsylvania

3+ months

very low

USA

Toronto General
Hospital
Ohio State
University Medical
Center
St. Paul’s Hospital

Penn State Milton
4-6 months
S Hershey Medical
Center
UK
Leeds, England
Leeds St James's
3-6 months
University Hospital
a the quality of reporting was subjective, based on the relative detail of information provided

4.4.1.2

moderate
moderate

low
low

very low

very low

Medical history form online

Seventy-two websites provided their medical history intake form online (71 from the
U.S.). Of these, 49 (68%) could be completed and submitted directly to the program
coordinators online. Twenty-two of these used the same third-party system (Breeze
Transplant™) to facilitate collection of the online health history questionnaire.

4.4.1.3

Number of candidates evaluated simultaneously

Twenty-five websites stated their general procedure for assessing candidates when more
than one comes forward at the same time. Most stated the preferred candidate is the one
who is a better match (although the definition of “match” was not described), and few
programs involve a joint decision by the healthcare team and the intended recipient. Most
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programs stated only evaluating one candidate at a time, but screened up to 10 candidates
at the outset.

4.5 Discussion
There is limited data on the efficiency of the living donor evaluation in the literature and
the websites of living donor programs. Based on available information, we summarized
several areas that have the potential to improve the living donor evaluation process,
which may promote better recipient outcomes, improve donor satisfaction, and reduce
costs to the healthcare system.
A prolonged living donor evaluation may cause anxiety for donor candidates who want to
minimize the dialysis time for the intended recipient (including avoiding dialysis
altogether).55,76 There is a paucity of information on the duration of the living donor
evaluation, but existing studies report evaluation times that are often long, used different
definitions of the evaluation start and end date, and rarely report more than one indicator.
For example, the time between donor approval and actual donation can take weeks in
some programs and months in others.48,72 Together with the time until approval, this can
explain some of the differences between the total time until donation between different
programs or can reveal hidden differences between programs who have similar total
evaluation times.72 Thus, more accurate estimates of the time to complete an evaluation
(using multiple metrics) are needed to facilitate quality improvement. Moreover, the
potential implications of a prolonged evaluation on recipient outcomes were infrequently
reported or were reported with insufficient detail to draw conclusions or use as a reliable
indicator for benchmarking. As a result, it remains only speculative whether the loss of
potential living donor kidney transplants due to recipient illness or death, due to receipt
of a deceased donor kidney transplant, or due to donor candidate withdrawal could have
been avoided if the evaluation was completed earlier.4 According to the websites of living
donor programs, many programs can conduct the evaluation in a single visit to the
transplant centre. However, whether they can do so and whether they actually do so is
uncertain.
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The necessity of measuring GFR in donor candidates with a radionuclide has been
debated. By eliminating unnecessary tests, the burden on candidates, the cost to the
healthcare system, and the timeliness of the evaluation process can all be improved.
Nuclear renography is useful to measure the split (left versus right) renal function.
However, CT volumetry can conceivably replace nuclear renography to measure the
relative function.27 Moreover, nuclear renography can be used to measure the GFR,
which may be unnecessary if the candidate has an eGFR associated with a high post-test
probability of having a level of GFR that permits or precludes donation.32 In the case
where a radionuclide is used to measure the total renal function, the split renal function
can be measured with little additional effort and cost. However, for programs that use
different contrast media for these two related tests, this may provide one strategy for
improvement.83,84 Better prediction of postdonation kidney function from predonation
eGFR is needed, which may be enhanced by incorporating variables like predonation
kidney volume.85,86
This scoping review has two main strengths. First, it highlights gaps in knowledge that
require further research, including the potential implications of an inefficient evaluation
process on health and cost outcomes. Second, it identifies areas for potential
improvement that warrant additional testing. However, there are a few limitations that
must be recognized. First, given the difficulty in performing a targeted search on this
topic, we may have missed relevant studies that were not captured by the search terms
chosen, or excluded some efficiency indicators. Future work is needed to establish
important and actionable metrics for quality improvement. Second, we did not assess the
quality of the included studies, as few studies had the primary objective of evaluating the
efficiency of the living donor evaluation. Third, we were unable to estimate the true cost
of an inefficient living donor evaluation on transplant activity. Although we found an
upper limit of 21% lost opportunities for transplant, this represents an upper limit because
we could never know if donor candidates: 1) would have completed their evaluation; 2)
would have been deemed eligible for donation; and 3) would have donated. Finally, the
cost of a more efficient living donor evaluation was unavailable. One study projected the
cost savings associated with a shorter time until living donor kidney transplantation, but
was based on hypothetical scenarios and only the costs due to recipient dialysis were
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modeled (Chapter 9).4 A second study used regression-based models to estimate the true
cost of living kidney donation to the healthcare system for donors and potential
candidates (Chapter 10).87 However, the cost of the living donor evaluation due to realworld efficiency improvements remains to be estimated.
In conclusion, there are promising opportunities to improve the efficiency of the living
donor evaluation process. Better efforts are needed to define, collect, and report
indicators of an efficient living donor evaluation for accountability, benchmarking,
quality improvement, and research.9 Individual programs can learn from the processes
used by other programs to improve their own practices (e.g. enable a 1-day evaluation),
but this requires individual programs to be more transparent on their evaluation
procedures. The evaluation should continue to focus on ensuring donor safety, including
completing tests that are costly or time-consuming if they are necessary to complete a
thorough evaluation for donor candidacy.
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Chapter 5

5

Research Objectives

The overarching goal of this thesis is to fill the gaps in the existing literature and to
inform stakeholders (e.g. patients, providers, and decision-makers) on the efficiency of
the living kidney donor evaluation process. We project that reducing the donor evaluation
time to 3-4 months is feasible for at least highly motivated healthy donors (i.e., those who
are essentially waiting for medical clearance).1–3 We expect this to result in numerous
benefits. First, a reduction in the donor evaluation time may result in fewer recipients
starting dialysis before transplantation (e.g. more pre-emptive transplants), which will
reduced the need for vascular access and the costs and complications associated with
dialysis initiation.4,5 Second, we expect less time on dialysis overall, which will improve
the health outcomes of recipients and reduce costs associated with maintenance dialysis
to the healthcare system.6,7 Third, we expect fewer deaths on the transplant wait-list and
increased living kidney donor transplantation rates, as fewer intended recipients are likely
to receive a deceased donor transplant or lose eligibility for transplant entirely (e.g.
through health deterioration).2 For this overarching goal to be feasible, we propose three
research objectives to provide an environmental scan of the current state of the living
kidney donor evaluation in Ontario.

5.1 Objective 1: To understand and evaluate the living
donor evaluation process
The first aim of Objective 1 is to measure how long it takes the complete the living donor
evaluation using multiple metrics. Multiple metrics (process and outcome indicators) are
needed to fully understand a process and identify any bottlenecks.8,9 It is also critical to
understand why different metrics vary across individuals and programs. Thus, the second
aim of Objective 1 is to identify modifiable and non-modifiable factors associated with
longer evaluation times.
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5.2 Objective 2: Implications of a prolonged living donor
evaluation
The process indicators used to measure the evaluation process should be linked to
meaningful outcomes.10,11 Moreover, any improvements in the quality indicators should
result in improved outcomes. Healthcare agencies are moving towards such an evidencebased quality improvement strategy to improve the healthcare of its citizens.12,13 A recent
study has suggested that a longer evaluation time is related to fewer pre-emptive
transplants and living donor transplants overall, but no such work has been done in a
Canadian context and numerous outcomes remain to be measured.2 Thus, for this
Objective we will estimate some of the possible implications that a longer evaluation can
have on transplant outcomes and financial outcomes. We will use real data to estimate
how frequently the recipient starts dialysis despite having a living donor. To our
knowledge, this is a metric that has not been reported before but has been asked of us by
patients. We will also conduct scenario analyses to explore the potential implications of a
quicker evaluation.

5.3 Objective 3: Cost of living donor evaluation
The cost of the living donor assessment is a key component to informing decisions on
modifying the evaluation process. Examples include implementation of rapid
assessments, which may result in more tests completed for candidates who do not donate
or evaluating multiple candidates simultaneously rather than sequentially.2 These
potential process designs may increase costs due to donor evaluations, but may also
reduce costs by increasing living donation and reducing time on dialysis. Thus, an
accurate assessment of the cost of living donation is needed, and this will be the goal of
Objective 3.

5.4 Future directions
Once these objectives are complete, possible solutions to improve the living kidney donor
evaluation process can be proposed, prioritized, and ultimately tested. This research
therefore follows the framework of Six Sigma – a quality improvement guide that is
increasing being applied to a healthcare setting.14,15 First, we identify and define the
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problem (e.g. the living donor evaluation process is inefficient). Then we measure and
analyze key indicators before and after improvements are made. Alongside interventions
to address other barriers to living kidney donation as mentioned in the Introduction
(1.2.1), successful quality improvement strategies following this research will result in
increased transplantation rates and better transplant outcomes (health gains), substantial
cost savings to the healthcare system (financial gains), and an improved living donor
experience and overall quality of life (quality gains).16,17
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Chapter 6

6

Duration of Living Kidney Transplant Donor
Evaluations: Findings From 2 Multicenter Cohort
Studies††

6.1 Introduction
Kidney transplantation for patients with kidney failure is associated with improved
survival and better quality of life at a fraction of the cost compared to dialysis.1–4
Compared to deceased donor kidney transplantation, living donor kidney transplantation
offers many advantages including superior rates of patient and graft survival and a shorter
time until transplant.5
The evaluation of a living kidney donor candidate begins when they contact a
transplant center. What follows is a series of screening tests (questionnaires, blood and
urine tests), diagnostic tests (ultrasound, chest x-ray), and specialist consultations
(nephrologist, surgeon, and an assessment of psychosocial health).6–8 During the
evaluation, a donor candidate often makes multiple trips to local clinics or the transplant
center, and there may be frequent periods waiting for appointments or test results. We
consider an efficient living donor candidate evaluation as one that is completed in as
timely a manner as possible, is clinically appropriate, and promotes patient and provider
satisfaction. At a recent international consensus conference, the efficiency of the donor
evaluation was highlighted as a high-priority area for improvement.8,9 Not surprisingly,

††

A version of this chapter has been published: Habbous S, Arnold A, Begen MA, Boudville N, Cooper
M, Dipchand C, Dixon SN, Feldman LS, Goździk D, Karpinski M, Klarenbach S, Knoll GA, Lam NN,
Lentine KL, Lok C, McArthur E, McKenzie S, Miller M, Monroy-Cuadros M, Nguan C, Prasad GVR,
Przech S, Sarma S, Segev D, Storsley L, Garg AX. “Duration of Living Kidney Transplant Donor
Evaluations: Findings From 2 Multi-center Cohort Studies”. Am J Kidney Dis. 2018: 72(4):483-498.
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several donors view the evaluation process as the worst phase of the donation
experience.10,11
In response to such concerns, the 2017 Kidney Disease: Improving Global
Outcomes Guideline on the Evaluation and Care of Living Kidney Donors recommends
transplant programs conduct as efficient a donor evaluation as possible, to meet the needs
of donor candidates, intended recipients, and transplant programs.12 Guidelines from the
United Kingdom set a more tangible goal: by the year 2020, all donor candidates should
have the opportunity to complete their evaluation within 4-5 months whenever possible.13
In order to put these recommendations into context we require knowledge of current
performance. To date, the time to complete the living kidney donor evaluation has
received limited attention as an outcome or as a focus for quality improvement.14,15
To address this knowledge gap and advance a patient-driven research priority,16
we estimated the time to complete the donor evaluation process using data from multiple
transplant centers in two cohorts. We also assessed the variability in donor evaluation
times between transplant centres, and individual and transplant centre factors associated
with longer evaluation times.

6.2 Methods
6.2.1 Data sources
Prospective cohort: Donors who donated between September 2009 and January 2015
were prospectively enrolled from 16 transplant centers in Canada and Australia
(Appendix C). Participants were recruited prior to donation, spoke and read English or
French, and were deemed good candidates for post-donation follow-up. Data were
obtained from medical records (evaluation test results, consultation notes, operative
records) and questionnaires. No data on recipient characteristics were used for this study.
All records were de-identified and sent to a coordinating center for abstraction and
analysis. All participants provided written informed consent and centers obtained ethics
approval before starting recruitment (Appendix D; Table 6).
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Table 6: Comparison of prospective and retrospective cohorts
Characteristic Prospective Cohort

Retrospective Cohort

Overall characteristics:
Sample size: 849
Study design:

1140

Observational cohort

Observational cohort

Prior living kidney donors

Prior living kidney donors

September 2009 – January 2015

April 2004 – March 2014

Identification by research personnel.
Donors enrolled into the study prior to
donation.

Identification through TGLN databases
through ICES

Catchment area:

12 Canadian and 4 Australian transplant
programs

5 Ontario transplant programs

Patient consent:

Required

Waived

Ethics approval:

#6056 (see Appendix D)

Not applicable

First contact with transplant centre (proxy)
until donation

First contact with transplant centre
(proxy) until donation

Population:
Time period:
Cohort
ascertainment:

Observational
period:

Strengths and limitations:
center-to-center 16 transplant programs
variability
Outcomes

Key dates
Scope of data

5 transplant programs

total evaluation time, time until approval,
time from approval until donation, time
from CT until donation, time between
consults
Evaluation start and approval dates derived
by proxy (limitation)
Individual-level factors available unique to
this cohort, including smoking, BMI, blood
pressure, kidney paired donation, marital
status, education, employment (strength)

Data collection:

Convenient sample of medical records;
self-reported questionnaires (limitation)

Subgrouping by
recipient dialysis
status

Recipient data not available (limitation)

total evaluation time, time from CT until
donation, time between consults

Evaluation start date derived by proxy;
no approval date (limitation)
Individual-level factors available unique
to this cohort, particularly recipient data
including demographics, kidney
function, cause of illness, date of referral
(strength)
Comprehensive list of healthcare
utilization in Ontario from ICES data
holdings (TGLN, CORR, OHIP, CIHI)
(strength)
Stratification by pre-emptive transplant
and dialysis-dependent status (strength)

TGLN – Trillium Gift of Life Network; ICES – Institute for Clinical Evaluative Sciences; CORR - Canadian Organ
Replacement Register; CIHI – Canadian Institute for Health Information; BMI – body mass index
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Retrospective cohort: We obtained linked healthcare administrative data for living donors
who were evaluated and donated at one of Ontario’s five transplant centers between
March 2004 and April 2014. Data were obtained from Ontario’s organ procurement
organization Trillium Gift of Life Network17 and multiple datasets available at the
Institute for Clinical Evaluative Sciences (ICES). All recipients were Ontario residents
who received a first-time kidney transplant (described previously).18 This study was
approved by the research ethics board at Sunnybrook Health Sciences Centre, Toronto,
Canada (patient consent was waived; Table 6). A summary of each cohort is provided in
Table 6.

6.2.2 Measures of evaluation time
Total evaluation time was defined as the time the donor started the evaluation until
donation. Total approval time was defined as the time from evaluation start to the date
the donor was approved to donate. Since the date the evaluation started and the date of
approval were unavailable (and may not be well defined), we used tests relevant to the
evaluation process to inform these dates (tests usually performed early or late in the
evaluation; Table 7 for the prospective cohort; Habbous et al for the retrospective cohort
– reproduced in Appendix E).18 Time to donation post-approval was defined as the time
from approval to donation. Time from computed tomography (CT) until donation was
defined as the time from first CT angiogram (to assess kidney anatomy and vasculature)
until donation. Time between consults was defined as the period between the first and last
of the nephrologist, surgeon, and psychosocial assessments (restricted to donors with all
three consults).
Table 7: Procedures for donors (N=849)
Procedure
Consultations
Surgery consult
Nephrologist consult
Psychosocial consult
Other health professional consult
Cardiac evaluation

N (%) with
procedure

N (%) as first
procedure
(all tests)

N (%) as last
procedurec

804 (95%)
834 (98%)
753 (89%)
323 (38%)
211 (25%)

10 (1%)*
14 (2%)*
22 (3%)*
5 (<1%)*
5 (<1%)*

496 (58%)
132 (15%)
28 (3%)
93 (11%)
8 (1%)
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Procedures
Renal imaging
Nuclear medicine (GFR)
24-hr blood pressure
Renal biopsy
Cystoscopy

844 (99%)a
692 (82%)
227 (27%)
22 (3%)
21 (2%)

101 (12%)
20 (2%)
23 (3%)
0 (0%)*
0 (0%)*

9 (1%)
23 (3%)
16 (2%)
1 (<1%)d
2 (<1%)

Laboratory tests
Histocompatibility test
Spot urine test
Biochemistry
Cholesterol (fasting)
24-hr urinalysis
Oral glucose tolerance test

839 (99%)
839 (99%)
829 (98%)
702 (83%)
708 (83%)b
379 (45%)

346 (41%)
23 (3%)
4 (<1%)
116 (14%)
96 (11%)
43 (5%)

–
–
42 (4%)
–
33 (4%)
8 (1%)

First contact datee
395 (46%)
21 (2%)
–
a
any of renal/abdominal ultrasound (n=659) or CT angiogram (n=834)
b
289 had one and 419 had two 24-hr urinalysis tests documented
c
only tests indicated in column without “–“ were considered as a possible last procedure to define
approval date
d
exceeding 10 days prior to donation to ensure not an implant biopsy
e
the date the donor first phoned or emailed the transplant program, restricted to Ontario donors.
This was only considered as the first procedure if no other appropriate test was identified.
*not considered an appropriate start date (these donors were excluded from total evaluation time
and time until approval)

6.2.3 Individual-level and center-level characteristics
We obtained individual-level donor, recipient, and transplant characteristics by
abstracting medical records (prospective cohort) or linking across healthcare databases
(retrospective cohort). Socio-demographic factors included age at donation, sex, marital
status, race, and smoking status at the time of study recruitment. Individual-level
socioeconomic factors included education, employment status, and rural residence.
Neighbourhood-level median household income quintile was obtained from the 2006
Canada Census (Canada only). Other socioeconomic indicators were assessed, including
the Canadian Marginalization Index (Can-MARG) and the Australian Socio-economic
Index for Areas (SEIFA); both derived using several variables from each country’s 2006
Census.19,20 Pre-donation clinical factors included donor and recipient estimated
glomerular filtration rate (eGFR) calculated using the CKD-EPI (Chronic Kidney Disease
Epidemiology Collaboration) equation.21 Based on at least five systolic (SBP) and
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diastolic (DBP) blood pressure measurements prior to donation, donors were considered
normotensive if SBP <120 mmHg and DBP <80 mmHg, pre-hypertensive if SBP 120 to
<140 mmHg or DBP 80 to <90 mmHg, and hypertensive if SBP ≥140 mmHg or DBP
≥90 mmHg. Other factors included the year of donation, distance to the transplant center
(Euclidean distance between postal codes), the donors’ relationship to the intended
recipient (which may differ from the actual recipient if the donation occurred through
paired donation), participation in kidney paired donation, the surgical technique, the
recipient’s referral date to a transplant centre for evaluation, and the recipient’s primary
cause of kidney failure.
Transplant center characteristics were obtained for the prospective cohort for the year
2012 (mid-year and peak of participant recruitment), including transplant center volume
(number of living and deceased donor kidney transplants) and resources (number of fulltime equivalent living donor nurse coordinators).

6.2.4 Statistical analysis
We present continuous data as mean (SD) or median (25th, 75th percentile). Differences
between cohorts on categorical variables were compared using chi-squared tests from
contingency tables. To evaluate individual-level predictors, we used generalized
estimating equations to accommodate clustering by transplant center (identity link;
normal distribution). Point estimates with 95% confidence intervals (CI) were presented.
Multivariable models included all covariates yielding unadjusted p-values <0.2 (no
selection algorithm was employed) or variables considered important. We used randomeffects models to explore transplant center-level factors associated with evaluation times
(random intercept for transplant center; center-level factors were treated as fixed effects).
Random effects models without any individual-level or center-level covariates
(unconditional means models) were used to compute the proportion of the total variability
in evaluation times that could be accounted for by differences between transplant centers
(the intracluster correlation coefficient, ICC). We evaluated model fit using a variety of
indices, which showed use of linear regression was appropriate (Pregibon link test
p=0.19; Hosmer-Lemeshow test p=0.9, Pearson’s test p=1.0).22 We used Statistical
Analysis Software SAS v9.4 or SAS Enterprise Guide 6.1 (2013 SAS Institute Inc., Cary,
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NC, USA) and STATA v13.0 (StataCorp LP, Texas, USA). This study was conducted
and reported per recommended guidelines (Appendix F).

6.3 Results
From the prospective cohort, 849/851 (99%) donors were included (two donated outside
of Canada or Australia). Donors were recruited a median (25th, 75th percentile) 2.3 (1.3,
7.5) weeks prior to donation. From the retrospective cohort, 1109/1140 (97%) living
donors from Ontario were included (31 recipients could not be identified). The
characteristics of the prospective and retrospective cohorts are presented in Table 8.
Table 8: Living Kidney Donor Characteristics
Prospective
cohort
(N=849)
Donors

Donors

Recipients

Demographic factors
Mean age at donation, years

47.8 (11.4)

45.1 (11.0)

44.2 (14.4)

Sex
Female
Male

558 (66%)
291 (34%)

716 (63%)
424 (37%)

415 (36%)
725 (64%)

Smoking status at recruitment (within last 30 days)*
Not smoking
Recently quit
Still smoking

624 (80%)
47 (6%)
107 (14%)

na
na
na

na
na
na

Marital status
Married/common-law
Not married

610 (78%)
168 (22%)

na
na

na
na

Race
White
Non-white**

745 (88%)
101 (12%)

428 (77%)
131 (23%)

375 (75%)
124 (25%)

Socioeconomic factors
Highest education
University/college
Trades/high school or less

451 (58%)
326 (42%)

na
na

na
na

Employment status
Full-time
Other

499 (64%)
280 (36%)

na
na

na
na

Residencea
Urban
Rural

642 (81%)
151 (19%)

959 (84%)
181 (16%)

954 (87%)
148 (13%)

Median income quintileb
5, highest
4
3
2
1, lowest

162 (26%)
152 (24%)
140 (23%)
91 (15%)
74 (12%)

257 (23%)
289 (25%)
239 (21%)
183 (16%)
172 (15%)

246 (22%)
255 (23%)
132 (21%)
193 (18%)
173 (16%)
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Retrospective cohort
(N=1140)

Pre-donation clinical factors
estimated GFR, mL/min/1.73m2c
≥90
80-89
<80
mean estimated GFR from serum creatinine, mL/min/1.73m2c
mean measured (nuclear) GFR, mL/min/1.73m2c

548 (64%)
177 (21%)
124 (15%)
96 (14.0)
108 (21.2)

665 (62%)
166 (15%)
251 (23%)
97.3 (14.9)
na

na
na
na
16.2 (8.4)
na

Recipient co-morbidities
Cardiovascular disease
Ischemic heart disease/ coronary artery disease
Heart failure
Diabetes
Hypertension

na
na
na
na
na

na
na
na
na
na

592 (53%)
123 (11%)
86 (8%)
222 (20%)
925 (83%)

Body mass index, kg/m2
Underweight (<18.5)
Normal (18.5-24.9)
Pre-obese (25-29.9)
Obese (30-34.9)
Very obese (BMI ≥ 35)
mean body mass index, kg/m2

9 (1%)
321 (38%)
366 (43%)
134 (16%)
16 (2%)
26.3 (3.90)

na
na
na
na
na
na

na
na
na
na
na
na

Blood pressured
Normal
Pre-hypertensive
Hypertensive

420 (49%)
405 (48%)
24 (3%)

na
na
na

na
na
na

Other factors
Relation to intended recipient
First degree relative
Spouse
Other (friend, other relative)
Non-directed anonymous donation

408 (48%)
166 (20%)
200 (24%)
68 (8%)

571 (50%)
246 (22%)
323 (28%)
na

na
na
na
na

Participated in Kidney Paired Donation
No
Yes

748 (89%)
91 (11%)

na
na

na
na

Days until recipient referrale

na

na

26 (-81, 160)

Surgery type performed
Laparoscopic
705 (84%)
na
na
Open
135 (16%)
na
na
Presented as number (percent) or mean (standard deviation).
a restricted to donors with a valid Canadian postal code. For donors in this table, rural status was derived from
the second digit of the postal code (rural if zero, urban otherwise). Rural status is generally defined in the
retrospective cohort as a municipality having <10,000 persons [990 (87%) of was urban with this definition].
b Median household income was obtained from the 2006 Canada Census
c GFR –glomerular filtration rate estimated using the CKD-EPI equation; recipient estimated GFR was
measured a median 0 (-14, 17) days before the donor evaluation start date; measured GFR was restricted to
donors with a radioisotope measurement (n=555)
d
normal if systolic <120 mmHg or diastolic <80; pre-hypertensive if systolic 120-139 or diastolic 80-89;
hypertensive if systolic ≥140 or diastolic ≥90
e calculated as the time from the donor evaluation start date until the recipient referral date. Negative values
mean the recipient was referred to the transplant center before the donor evaluation started.
* donors were recruited a median (25th, 75th percentile) of 2.3 (1.3, 7.5) weeks prior to donation.
** in the prospective cohort, non-whites included 58 (7%) Asians, 20 Aboriginals (2%), 17 Blacks (2%), and 6
Hispanic/Latino (<1%). In the retrospective cohort, non-whites included 69 (12%) Asians, and 22 (4%) Blacks
[the ethnicity of remaining donors was suppressed due to small cells (<6 individuals) to comply with privacy
requirements to minimize the risk of re-identification.]
na – not available
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For the prospective cohort, the mean (SD) age at donation was 47.8 (11.4) years, most
donors were married (78%), white (88%), and female (66%). Many donors were educated
(58% with a college or university degree), employed full time (64%), and were of high
socioeconomic status (26% in the highest neighbourhood-income quintile). Most (87%)
donors underwent a laparoscopic nephrectomy and 11% donated through kidney paired
donation. In terms of health status indicators 18% were classified as obese (BMI ≥30
kg/m2); and 2% were very obese (BMI ≥35 kg/m2); 64% had a pre-donation eGFR ≥90
mL/min/1.73 m2. Most intended recipients were first-degree relatives (48%), while 8%
were non-directed (anonymous).
Donors from the retrospective cohort were similar to the prospective cohort with respect
to age (mean 45.1 years), sex (63% female), residence (84% urban), income (23% in the
highest neighbourhood-income quintile), pre-donation eGFR ≥90 mL/min/1.73 m2
(64%), and relationship (50% were donations to a first-degree relative). However,
Ontario donors were more likely to be non-white (23%) than donor participants in the
prospective cohort (10%, p<0.001). Recipients in the retrospective cohort were similar to
donors with respect to age, race, rural status, and neighbourhood-income quintile, but
were more likely to be male (64% vs. 37%). Recipients were referred to a transplant
centre a median (25th, 75th percentile) 26 (-81, 160) days after the start of their donor’s
evaluation (recipient referral date was available for 290/1256 (23%) of recipients).

6.3.1 Living kidney donor evaluation times
The distribution of evaluation times across transplant centres from the prospective cohort
is presented in Figure 11 and Table 9.
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Figure 11: Evaluation times by transplant centre. Boxplots showing the distribution
of evaluation times stratified by transplant center. A) The total wait time was
defined as the time the donor completed the evaluation, from first contact until
donation surgery; B) total approval time was calculated as the time from first
contact until the donor was approved to donate; C) the time to donor surgery after
approval was calculated as the difference in total wait time and total approval time;
D) the time from CT (computed tomography) scan until donation; E) the time
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between consults was defined as the period between the first and last nephrology,
urology, and psychosocial consults (restricted to donors with all three consults).
Vertical axis was truncated for readability. Box represents interquartile range (25th
to 75th percentile). Horizontal line indicates median (50th percentile). Circle
represents mean. Vertical lines represent the upper fence (75th percentile plus 1.5×
interquartile range) and lower fence (25th percentile minus 1.5× interquartile
range). Five Austrialian centers were combined and presented as a single center for
this analysis.
The median (25th, 75th percentile) total evaluation time in the prospective cohort was 10.3
(6.5, 16.7) months (n=803) and varied across transplant centers (ICC=7.0%, p=0.04).
Among the subgroup of Ontario participants, the median evaluation time was 10.7 (6.6,
16.7) months, similar to the evaluation time from the retrospective cohort [median 10.8
(7.3-19.4) months].
In the prospective cohort, the median time until approval was 7.9 (4.6-14.1) months
(n=745, ICC 13.2%, p=0.02) and from approval to donation was 0.7 (0.3, 2.4) months
(n=745, ICC 20.6%, p=0.01). The approval date was not available in the retrospective
cohort.
The time from CT scan until donation was a median 4.8 (2.6, 9.2) months in the
prospective cohort (n=839, ICC 2.9%, p=0.05), which was similar to the 4.9 (2.8, 8.8)
months observed in the retrospective cohort (n=1054).
Among donors who completed a nephrology, surgery, and psychosocial assessment in the
prospective cohort, the median time between the first and last consultation was 3.0 (1.0,
6.3) months (n=716, ICC 11.0%, p=0.03). In the retrospective cohort, the median time
between consults was 3.3 months longer [median 6.3 (2.3-17.2) months (n=576)].
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Table 9: Comparisons of the donor evaluation process between transplant centers in the prospective cohort
Average time for different measures of the donor evaluation in months,
median (25th, 75th percentile)a

Frequency of
24-hour urine
tests in donors
(%)

Total
evaluation
time, N=803

Total approval
time, N=745

Time after
approval to
donation, N=745

Time from CT scan
to donation, N=839

Time between
consults, N=716b

All consults
completed ≤2
days, N=716b

0

1

2

Center A
Center B
Center C

8.1 (5.4, 12.9)
11.3 (6.2, 16.4)
9.4 (6.6, 16.7)

5.6 (3.5, 12)
10.7 (5.8, 15.4)
8.8 (6.0, 15.4)

1.0 (0.3, 3.5)
0.4 (0.3, 0.7)
0.3 (0.2, 0.5)

3.4 (1.5, 7.6)
4.5 (2.7, 8.3)
5.5 (3.3, 12.3)

0.7 (0.3, 2.3)
4.8 (2.1, 9.1)
4.7 (2.5, 11.9)

15%
1.3%
0%

2
6
6

19
78
80

78
16
14

Center D
Center E
Center F

9.3 (6.1, 14.1)
15.9 (11.4, 26.1)
11.9 (7.1, 14.9)

8.6 (5.3, 12.9)
15.2 (9.7, 25.3)
9.6 (7.7, 14.9)

0.5 (0.3, 1.0)
0.2 (0.1, 1.8)
0.5 (0.3, 1.0)

3.3 (1.6, 7.1)
6.2 (3.2, 10.2)
7.0 (3.4, 9.3)

4.3 (2.8, 8.5)
6.9 (4.6, 16.7)
5.1 (3.3, 7.9)

0%
0%
0%

0
15
2

0
72
7

100
12
91

Center G
Center H
Center I

10.8 (7.6, 15.9)
11.1 (7.6, 17.4)
9.9 (6.2, 18.6)

8.5 (6.1, 14.7)
10.2 (5.8, 14.6)
3.8 (2.6, 5.3)

1.0 (0.3, 1.9)
0.5 (0.4, 2.3)
4.5 (2.3, 8.1)

5.9 (3.7, 8.4)
4.3 (2.3, 7.3)
6.9 (3.4, 15.8)

5.9 (4.6, 9.9)
2.0 (0.6, 4.8)
0.1 (0.0, 1.1)

0%
10%
50%

0
0
92

4
13
2

96
87
6

Center J
Center K
Center L

14.4 (8.4, 23.7)
9.1 (6.1, 14.6)
8.2 (5.5, 14.4)

13.6 (7.8, 23.1)
7.2 (4.6, 12.1)
6.2 (4.6, 8.8)

0.5 (0.4, 1.0)
1.6 (0.8, 2.5)
1.2 (0.5, 3.5)

7.5 (3.2, 16.1)
4.5 (3.0, 8.1)
4.2 (1.6, 7.1)

7.3 (3.2, 17.2)
3.2 (1.8, 4.6)
3.0 (1.8, 4.4)

0%
0%
0%

46
16
1

29
76
24

25
9
75

All centers
10.3 (6.5, 16.7)
7.9 (4.6, 14.1)
0.7 (0.3, 2.4)
4.8 (2.6, 9.2)
3.0 (1.0, 6.3)
–
–
–
–
ICC (p-value)
7.0% (p=0.04)
13.2% (p=0.02)
20.6% (p=0.01)
2.9% (p=0.05)
11.0% (p=0.03)
–
–
–
–
a Five Australian centers were combined and presented as a single center so that there were a meaningful number of participants for analysis.
b Time from first to last consults with either a nephrologist, a surgeon, and a professional performing a psychosocial evaluation (restricted to donors with all three consults)
ICC – intraclass correlation coefficient (proportion of the variance in the outcome explained by between-center differences); a p-vale <0.05 was interpreted as significant variability
in the evaluation time between centers; CT – computed tomography

82

6.3.2 Transplant center characteristics associated with longer
evaluation times
Associations of transplant center characteristics were only assessed in the prospective
cohort. We found no association between the total evaluation time and the number of
living-donor and deceased-donor transplants performed at the center, the number of fulltime equivalent living donor coordinators, the number of 24-hour urine tests usually
performed at the center, and whether centers routinely performed nephrology, surgery
and psychosocial consults all within 24 hours of each other (p>0.2 for all). This did not
change after adjustment for individual-level donor age, sex, relationship to the recipient,
or whether the donation occurred through paired exchange (Table 10).
Table 10: Transplant center characteristics associated with donor evaluation times
in the prospective cohort
Average time for different measures of the donor evaluation in months,
median (25th, 75th percentile)a

#LD Txc,d
#DD Txc,d
FTEc,e

Total
evaluation
time,
N=803

Total
approval
time,
N=745

Time after
approval to
donation,
N=745

Time from CT
to donation,
N=839

Time between
consults,
N=716b

-0.4 (-2.2, 1.4)
0.6 (-0.7, 1.9)
4.0 (-2.7, 10.7)

-0.3 (-2.6, 2.0)
0.9 (-0.7, 2.6)
2.7 (-6.4, 11.8)

-0.1 (-0.8, 0.6)
-0.2 (-0.7, 0.3)
1.4 (-1.0, 3.8)

-0.4 (-0.4, 1.1)
0.1 (-0.5, 0.8)
2.2 (-0.1, 4.4)

-0.0 (-1.7, 1.7)
0.4 (-0.8, 1.7)
2.1 (-4.4, 8.7)

#LD Tx/FTEc
-0.1 (-0.2, 0.1)
-0.03 (-0.2, 0.2)
-0.03 (-0.1, 0.03)
-0.02 (-0.05, 0.1)
-0.01 (-0.1, 0.2)
# 24h urinesf
-1.1 (-4.9, 2.7)
-0.1, (-5.0, 4.8)
-0.6 (-2.0, 0.8)
-1.6 (-2.9, -0.3)
-1.2 (-4.7, 2.4)
Same-day consultsg
-2.5 (-8.8, 3.7)
-4.7 (-12.3, 2.8)
2.0 (-0.04, 4.1)
-1.1 (-3.9, 1.6)
-5.2 (-9.9, -0.6)
a Adjusted for donor age, sex, relationship to intended recipient, and donation through kidney paired donation. Five
Australian centers were combined due to the number of participants recruited. A positive number means the characteristic
is associated with a longer evaluation time, expressed in months of additional time. As an example of interpretation,
transplant centers that differ by 10 transplants performed per year also differ by -0.4 months in the total evaluation time.
b Time from first to last consults with either a nephrologist, a surgeon, and a professional performing a psychosocial
evaluation (restricted to donors with all three consults)
c Obtained from each institution in 2012 (the mid-year and most active year of study recruitment). The number of
transplants performed serve as indicators of the transplant center volume. Variables were treated as a continuous.
d
per 10 transplants
e per 0.5 FTE
f transplant centers were categorized as generally performing zero, one, or two 24-hour urine analyses based on the highest
proportion in the three rightmost column of Table 9 and treated as a continuous variable (estimate is per 24-hour urine
test).
g transplant centers were dichotomized as generally performing same-day consults if the nephrology, surgery, and
psychosocial evaluation was performed within 2 days for at least 10% of the donors (Centers A, H, and I from Table 9).
The reference group is “no”.
CT – computed tomography; LD Tx – living donor kidney transplant; DD Tx – deceased donor kidney transplant FTE –
full-time equivalent of living donor nurse coordinator
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6.3.3 Individual donor factors associated with longer evaluation times
We explored whether individual-level factors were associated with the total evaluation
time in unadjusted (Table 12) and adjusted (Table 13) analyses. The prospective cohort
was adjusted for donor age, sex, and relationship to the recipient. The retrospective
cohort was further adjusted for donor urban/rural status and median neighbourhoodincome quintile. In the prospective cohort we did not have information on whether the
recipient was receiving dialysis at the start of the donor evaluation. In the retrospective
cohort, we separated the results by whether or not the recipient was on dialysis at the time
the donor evaluation started, as this might influence the urgency of donation (if the goal
was pre-emptive kidney transplantation). For these analyses we also focused on donors
who received a pre-emptive kidney transplant (N=311), separating out those who started
dialysis while the donor evaluation was underway, as for the latter many patients take
some time to acclimatize to dialysis after it is initiated, which may delay the time to
complete the transplant evaluation and confound associations measured in the present
study.18
After adjustment, the evaluation took longer if the donor was older (by 0.7 to 2.0 months
per 10-years of age). The evaluation time was shorter among rural versus urban donors [2.7 (95% CI: -0.3, -5.1)] in the pre-emptive transplant cohort, with the trend of a shorter
time in the dialysis-dependent cohort [-1.4 (-3.0, 0.2)]. There was a non-linear
relationship between neighbourhood-household income and the time to complete the
evaluation, and results varied in the cohorts: in the prospective cohort, the most and least
affluent quintiles completed the evaluation in the shortest amount of time and the middle
group took the longest. In the dialysis-dependent cohort, the least affluent group took the
longest time to complete the evaluation [2.8 (0.8, 4.9) months longer than the most
affluent], while in the pre-emptive transplant cohort results were qualitatively different.
Sensitivity analysis in the prospective cohort using a deprivation index as a measure of
socioeconomic status did not change these results (Table 11). For every mL/min/1.73 m2
increase in recipient eGFR, the evaluation time was increased an average of 0.8 months
(p<0.001). For every 30-day delay in recipient referral, the time of donor evaluation
increased 0.4 (0.3, 0.5) months in the dialysis-dependent cohort and 0.9 (0.8, 1.0) months
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in the pre-emptive transplant cohort (p<0.001). Other factors included the relationship to
the intended recipient, the cause of kidney failure, and non-renal recipient co-morbidities,
which differed qualitatively depending on the cohort of study. The most influential
contributor was whether the donor participated in paired exchange, which prolonged the
average time until donation by 6.6 (1.6, 9.7) months. Finally, and of weaker importance,
was the association between female and non-white donors on longer evaluation times,
which was only observed in the dialysis-dependent cohort (although point estimates for
female donors were in a similar direction in all cohorts).
Table 11: Sensitivity analysis for neighbourhood-level deprivation index
(prospective cohort)
Canada
onlya
N (%)

Australia
onlyb
N (%)

Combined deprivation index
(Canada and Australia)
N (%)
beta
p-value

168 (27%)
150 (24%)
127 (20%)
98 (16%)
81 (13%)

21 (45%)
9 (19%)
9 (19%)
8 (17%)
0 (0%)

189 (28%)
159 (24%)
136 (20%)
106 (16%)
81 (12%)

Deprivation
1 (least deprived)
2
3
4
5 (most deprived)

0 (referent)
-0.9 (-3.6, 1.7)
0.5 (-2.1, 3.1)
1.7 (-3.1, 6.5)
-1.7 (-4.6, 1.3)

0.24

Residential Instabilityc
1 (least deprived)
126 (20%)
–
–
0 (referent)
0.02
2
150 (24%)
–
–
-1.2 (-3.8, 1.3)
3
138 (22%)
–
–
1.2 (-0.8, 3.2)
4
117 (19%)
–
–
2.5 (-1.3, 6.2)
5 (most deprived)
93 (15%)
–
–
-0.4 (-3.0, 2.3)
Deprivation quintiles derived at the national level from several socioeconomic variables from the 2006
national census
a
Canadian Marginalization Index derived from Statistics Canada (Matheson et al 1). Material
deprivation included six variables related to family structure, income, and employment. Residential
instability included seven variables primarily related to the home.
b
Socio-economic Indexes for Areas (SEIFA) as an index of relative socioeconomic disadvantage 2.
Deprivation index included variables related to family structure, income, education, and various others.

For every 3-month increase in the time between consults, the time to complete the
evaluation increased by 0.8 (0.5, 1.1) months in the pre-emptive transplant cohort
(p<0.001), 1.1 (0.2, 2.0) months in the dialysis-dependent cohort (p=0.02), and 2.8 (2.5,
3.1) months in the prospective cohort (p<0.001). After adjustment, the time between
consults was substantially shorter for rural donors in the pre-emptive cohort [-2.5 (-3.9, -
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1.0)] and the dialysis-dependent cohort [-3.2 (-4.6, -1.8)], but not in the prospective
cohort [4.2 (-1.5, 9.9)].
Table 12: Factors associated with total donor evaluation time, unadjusted estimates
Prospective cohort
16 transplant centers in
Canada and Australia
Unknown if recipient
was receiving dialysis at
start of donor evaluation
(n=849)

Retrospective cohort
5 transplant centers in
the province of Ontario, Canada
Recipient receiving
Recipient was not
dialysis at start of the
receiving dialysis at the
donor evaluation
start of the donor
(N=631)
evaluation, and a preemptive transplant was
achieved (N=311)

beta (95% CI)a

p-value

beta (95% CI)a

p-value

beta (95% CI)a

p-value

1.12 (0.34, 1.89)

0.005

0.33 (-0.17, 0.83)

0.20

2.19 (1.70, 2.68)

<0.001

na

na

0.66 (0.34, 0.99)

<0.001

-0.53 (-1.40, 0.35)

0.24

Female sex
donor
recipient

0.91 (-0.24, 2.07)
na

0.12
na

1.33 (0.41, 2.24)
0.77 (-0.79, 2.32)

0.005
0.33

1.85 (-0.93, 4.64)
0.94 (-2.13, 4.01)

0.19
0.55

Donor smoking status at
recruitment (within last
30 days)*
Not smoking
Recently quit
Still smoking

0 (reference)
-1.32 (-2.94,0.31)
-1.80 (-3.31, -0.29)

0.04

na

na

na

na

Donor marital status
e
not married

0 (reference)
-0.97 (-3.14, 1.20)

0.38

na

na

na

na

Non-white Race
donor
recipient

1.17 (-1.51, 3.85)
na

0.39
na

1.82 (0.16, 3.49)
0.59 (-0.47, 1.66)

0.03
0.27

0.20 (-4.45, 4.85)
-0.86 (-5.36, 3.63)

0.9
0.71

Rural residence
donors
recipients

-0.27 (-2.02, 1.48)
na

0.76
na

-1.24 (-2.84, 0.36)
-1.57 (-3.47, 0.32)

0.13
0.10

-2.14 (-4.09, -0.18)
-1.69 (-2.16, -1.22)

0.03
<0.001

0 (reference)

0.62

na

na

na

na

Demographic factors
Donor age, per 10 years
Recipient age, per 10
years

Socioeconomic factors
Donor highest
education
University/college
Trades/high school or
less

0.44 (-1.32, 2.21)

Donor employment
status
Full-time
other

0 (reference)
0.38 (-1.11, 1.88)

0.63

na

na

na

na

Donor income quintile
5, highest
4
3
2
1, lowest

0 (reference)
1.96 (0.24, 3.67)
2.98 (0.33, 5.63)
1.92 (-0.69, 4.52)
0.49 (-0.41, 1.38)

0.17

0 (reference)
0.24 (-1.00, 1.49)
0.36 (-0.65, 1.37)
0.12 (-1.35, 1.58)
2.36 (0.28, 4.44)

0.10

0 (reference)
-3.28 (-4.92, -1.64)
-0.68 (-5.2, 3.83)
0.85 (-0.84, 2.54)
-2.54 (-7.11, 2.02)

<0.001
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Recipient income
quintile)b
5, highest
4
3
2
1, lowest

na

na

0 (reference)
0.26 (-1.80, 2.32)
1.57 (0.15, 2.98)
0.10 (-1.42, 1.62)
2.89 (0.04, 5.73)

0.07

0 (reference)
-0.55 (-2.54, 1.44)
-0.95 (-5.63, 3.74)
1.06 (-3.37, 5.5)
2.8 (-2.86, 8.47)

<0.001

0.28

0 (reference)

0.75

0 (reference)

<0.001

Pre-donation clinical characteristics
Donor eGFRc
≥90 mL/min/1.73 m2
80-89 mL/min/1.73
m2
<80 mL/min/1.73 m2
Recipient eGFR at
donor first contact, per
mL/min/1.73 m2c
Recipient comorbidities
Cardiovascular
disease
Ischemic heart
disease/ coronary
artery disease
Heart failure
Diabetes
Hypertension

0 (reference)
-1.52 (-3.81, 0.78)

-0.73 (-2.62, 1.16)
-0.07 (-1.46, 1.33)

0.61 (-0.68, 1.91)
na

na

na

na

na
na
na
na

4.73 (1.30, 8.16)
2.87 (1.84, 3.90)

na

na

0.79 (0.66, 0.93)

<0.001

0.50 (-0.17, 1.18)

0.14

-1.37 (-4.18, 1.43)

0.34

na

1.85 (-0.91, 4.61)

0.19

5.16 (1.11, 9.20)

0.01

na
na
na

1.84 (-0.84, 4.51)
0.28 (-0.56, 1.13)
0.43 (-0.69, 1.54)

0.18
0.51
0.45

3.25 (-2.39, 8.89)
-3.95 (-5.78, -2.13)
-4.74 (-6.83, -2.65)

0.26
<0.001
<0.001

0.05

na

na

na

na

na

na

na

na

0.39 (0.27, 0.50)

<00001

0.82 (0.71, 0.93)

<0.001

Donor body mass index,
kg/m2
Underweight (<18.5)
Normal (18.5-24.9)
Pre-obese (25-29.9)
Obese (30-34.9)
Very obese (≥ 35)

-2.79 (-5.58, -0.01)
0 (reference)
0.85 (-1.47, 3.17)
0.46 (-0.82, 1.74)
2.07 (-2.31, 6.45)

Donor blood pressure
Normal
Pre-hypertensive
Hypertensive

0 (reference)
-0.01 (-1.41, 1.40)
3.28 (-3.39, 9.94)

0.61

na

na

0 (reference)
-2.07 (-5.71, 1.57)
-1.64 (-6.08, 2.81)
-4.12 (-8.80, 0.56)
-4.44 (-8.89, 0.01)
0.74 (-4.47, 5.95)

0.04

0 (reference)
-0.65 (-3.39, 2.09)
-1.22 (-3.0, 0.56)
1.13 (-0.65, 2.9)
-0.07 (-3.85, 3.71)
1.35 (0.01, 2.69)

0.03

0 (reference)
0.27 (-2.49, 3.03)
1.52 (-3.73, 6.77)
-4.1 (-8.39, 0.18)
-4.2 (-6.02, -2.38)
0.31 (-1.99, 2.62)

<0.001

7.00 (3.75, 10.3)

<0.001

na

na

na

na

0 (reference)
-1.23 (-3.07, 0.61)

0.19

na

na

na

na

na

na

0 (reference)
2.75 (-0.48, 5.97)
1.41 (-0.53, 3.35)

<0.001

0 (reference)
-0.95 (-4.76, 2.85)
-6.59 (-9.61, -3.56)

<0.001

Time to recipient
referral

Other characteristics
Relationship
Spouse
Sibling
Parent
Child
Other relation
Unrelated
Participated in kidney
paired donation
Surgery type performed
Laparoscopic
Open
Cause of kidney failure
GN/autoimmune
Polycystic
Diabetes
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Other
Unknown

1.53 (-0.28, 3.34)

0.03 (-4.16, 4.21)
-1.55 (-11.02,
7.93)

1.94 (1.19, 2.69)
Year of transplant, per
year

0.23 (-0.72, 1.17)

0.64

0.08 (-0.11, 0.27)

0.40

0.06 (-0.23, 0.36)

0.67

Distance to transplant
program, per 50 km
donor
0.05 (0.01, 0.10)
0.03
0.12 (0.02, 0.23)
0.02
-0.26 (-0.42, -0.11) 0.001
recipient
na
na
0.04 (-0.14, 0.21)
0.67
-0.20 (-0.36, -0.05) 0.009
The total evaluation time was defined as the time from the donor’s evaluation start date until donation. A positive number means
the factor was associated with a longer donor evaluation time, expressed in months of additional time. The median (25 th, 75th)
total donor evaluation time for the prospective cohort, dialysis-dependent cohort, and pre-emptive transplant cohort was 10.3
(6.5, 16.7), 10.6 (6.4, 21.6) and 9.5 (7.0, 14.3), respectively. a beta estimates with 95% confidence intervals (CI) obtained from
linear regression accounting for clustering by transplant center (generalized estimating equations). The beta estimate
corresponds to the average difference in total evaluation time for a change in category (compared to the reference category) or a
1-unit increment in a continuous variable (unless otherwise specified)
b neighbourhood-income quintile derived from the 2006 Canada Census (Canadian donors only)
c kidney function measured using CKD-EPI equation (mL/min/1.73 m2) from serum creatinine identified at any point in the
evaluation for donors and within 3 months of the donor’s evaluation start date for recipients.
* donors were recruited a median (25th, 75th percentile) of 2.3 (1.3, 7.5) weeks prior to donation.
eGFR – estimated glomerular filtration rate; GN – glomerulonephritis; na – not available

Table 13: Factors associated with total donor evaluation time, adjusted estimates
Prospective cohort
16 transplant centers
Canada and Australia
Unknown if recipient
was receiving dialysis at
start of donor evaluation
(n=849)

Retrospective cohort
5 transplant centers
Ontario, Canada only
Recipient receiving
Recipient was not
dialysis at start of the
receiving dialysis at the
donor evaluation
start of the donor
(N=631)
evaluation, and a preemptive transplant was
achieved (N=311)

beta (95% CI)a,b

p-value

beta (95% CI)a,c

p-value

beta (95% CI)a,c

p-value

Donor age, per 10 years

0.81 (0.39, 1.57)

0.04

0.67 (0.31, 1.02)

<0.001

2.02 (1.72, 2.31)

<0.001

Female donor sex

0.72 (-0.54, 1.99)

0.26

1.22 (-0.07, 2.51)

0.06

1.51 (-1.04, 4.06)

0.25

Donor smoking status at
recruitment (within last
30 days)*
Not smoking
Recently quit
Still smoking

0 (reference)
-1.31 (-2.89, 0.28)
-1.20 (-2.82, 0.41)

0.18

na

na

na

na

Non-white donor race

–

–

2.07 (0.86. 3.29)

<0.001

–

–

Rural donor residence

–

–

-1.41 (-3.02, 0.20)

0.09

-2.71 (-5.10, -0.31)

0.03

0 (reference)
2.17 (0.82, 3.52)
3.07 (0.47, 5.68)
2.64 (0.02, 5.26)
0.88 (-0.42, 2.18)

0.02

0 (reference)
0.41 (-0.95, 1.78)
0.65 (-0.11, 1.40)
0.29 (-1.43, 2.01)
2.84 (0.75, 4.93)

0.05

0 (reference)
-2.90 (-4.09, -1.71)
-0.59 (-5.82, 4.64)
1.33 (-1.08, 3.75)
-1.06 (-5.21, 3.09)

<0.001

Variable
Demographic factors

Socioeconomic factors
Donor income quintiled
5, highest
4
3
2
1, lowest
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Pre-donation clinical characteristics
Donor eGFRf
≥90 mL/min/1.73 m2
80-89 mL/min/1.73
m2
<80 mL/min/1.73 m2
Recipient eGFR at
donor first contact, per
mL/min/1.73m2f
Recipient comorbidities
Cardiovascular
disease
Ischemic heart
disease/ coronary
artery disease
Heart failure
Diabetes
Hypertension
Donor body mass index,
kg/m2
Underweight (<18.5)
Normal (18.5-24.9)
Pre-obese (25-29.9)
Obese (30-34.9)
Very obese (≥ 35)
Time to recipient
referral

–

–

–

–

0 (reference)

0.002

3.46 (1.48, 5.45)
1.46 (0.36, 2.56)
na

na

na

na

0.83 (0.71, 0.95)

<0.001

na

na

0.18 (-0.37, 0.74)

0.52

–

–

na

na

1.56 (-0.75, 3.88)

0.19

3.74 (-0.21, 7.70)

0.06

na
na
na

na
na
na

1.64 (-1.14, 4.41)
–
–

0.25
–
–

–
-4.17 (-6.98, -1.36)
-4.53 (-6.08, -2.98)

–
0.004
<0.001

0.10

na

na

na

na

na

na

0.38 (0.29, 0.51)

<0.001

0.86 (0.75, 0.97)

<0.001

0 (reference)
-1.63 (-5.20, 1.94)
-1.55 (-6.07, 2.97
-2.71 (-7.00, 1.57)
-3.97 (-8.21, 0.27
1.06 (-4.02, 6.14)

0.14

0 (reference)
-0.06 (-2.84, 2.71)
-0.95 (-2.63, 0.72)
2.17 (0.43, 3.92)
0.55 (-3.38, 4.49)
1.87 (0.51, 3.24)

<0.001

0 (reference)
1.07 (-1.74, 3.88)
1.06 (-4.34, 6.45)
-1.45 (-4.68, 1.77)
-3.94 (-5.70, -2.18)
0.94 (-1.54, 3.43)

<0.001

6.59 (1.61, 9.74)

<0.001

na

na

na

na

0 (reference)
-0.84 (-3.06, 1.39)

0.46

na

na

na

na

na

na

0 (reference)
2.39 (-0.30, 5.07)
0.96 (-1.11, 3.03)
1.58 (-0.27, 3.43)
2.16 (1.40, 2.92)

<0.001

0 (reference)
-2.45 (-5.79, 0.88)
-7.18 (-10.9, -3.50)
-1.06 (-5.01, 2.88)
-3.29 (-11.0, 4.42)

<0.001

-3.74 (-7.59, 0.12)
0 (reference)
1.10 (-1.42, 3.62)
0.47 (-0.89, 1.83)
2.05 (-2.67, 6.78)

Other characteristics
Relationship
Spouse
Sibling
Parent
Child
Other relation
Unrelated
Participated in kidney
paired donation
Surgery type performed
Laparoscopic
Open
Cause of kidney failure
GN/autoimmune
Polycystic
Diabetes
Other
Unknown

Distance to transplant
0.04 (-0.00, 0.08)
0.07
0.11 (-0.03, 0.25)
0.13
-0.19 (-0.46, 0.08)
0.17
program, per 50 km
The total evaluation time was defined as the time from the donor’s evaluation start date until donation. A positive number means
the factor was associated with a longer donor evaluation time, expressed in months of additional time.
a beta estimates with 95% confidence intervals (CI) obtained from linear regression accounting for clustering by transplant center
(generalized estimating equations). The beta estimate corresponds to the average difference in total evaluation time for a change in
category (compared to the reference category) or a 1-unit increment in a continuous variable (unless otherwise specified).
b adjusted for donor age, sex, and relationship to the recipient.
c adjusted for donor age, sex, urban/rural status, median neighbourhood-income quintile, and relationship to the recipient.
d neighbourhood-income quintile derived from the 2006 Canada Census (Canadian donors only).
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e

kidney function measured using CKD-EPI equation (mL/min) from serum creatinine identified at any point in the evaluation for
donors and within 3 months of the donor’s evaluation start date for recipients.
* donors were recruited a median (25th, 75th percentile) of 2.3 (1.3, 7.5) weeks prior to donation.
eGFR – estimated glomerular filtration rate; GN – glomerulonephritis; na – not available; analyses not done due to unadjusted
p>0.2 (from Table 12) are shown by a dash (–)

6.4 Discussion
Using data available on living kidney donors from 16 transplant centers, we assessed
living donor evaluation times using five different potential process indicators that can be
used to assess the timeliness of a living donor evaluation.
We found the total time to complete the evaluation was a median 10 months, with
25% of donors experiencing an evaluation period of 16 months or more. Some of this
time is appropriate and necessary to complete a quality evaluation. Sometimes there are
findings that require additional examination for a comprehensive living donor workup23,24, but we believe that at least the most common additional tests should not prolong
the evaluation by 3-9 months.10 Other reasons for a longer evaluation time may be
appropriate to reduce risks to the donor and recipient (e.g., weight loss, smoking
cessation, blood pressure control).25,26 However, some transplant programs may require
these issues to be resolved before the evaluation begins, which may explain why we did
not find any of our evaluation times to be associated with these factors. Other reasons that
influence the donor evaluation time such as age, sex, ethnicity and geography may be
non-modifiable, yet understanding why such factors lead to a longer evaluation may
influence how the evaluation is organized. For example, transplant programs may
perform multiple tests on the same day to respect the travel requirements of donors who
live far away. This may explain the weak association between distance and evaluation
times and the shorter total evaluation time and time between consults among rural donors
in the present study.27 Participating in kidney paired donation was the strongest predictor
of longer evaluation times, which has some implications to the emerging practice of
including compatible pairs.28–30
Recipient factors are also important. A delayed recipient referral significantly
delayed the living donor evaluation time, a finding which emphasizes the importance of
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improving patient education about living donor transplantation and increasing appropriate
and timely transplant recipient referrals from kidney clinics.31,32 A higher recipient eGFR
increased the donor evaluation time in the subset of pre-emptive transplants, which is
likely an appropriate pace to the living donor evaluation to extend use of the recipient’s
native kidneys until the transplant is needed. This was one reason why we presented
some of our results stratified by whether the intended recipient was on dialysis at the time
the donor evaluation started and whether the recipient received a pre-emptive
transplant.18
There was considerable between-center variability for all measures. Those with
the shortest time between consults (Centers I, A, and H) frequently performed these
consultations on the same day (I>A>H; Figure 11 and Table 9). Although these centers
may not have had the shortest total evaluation and approval times, there was a consistent
ordering amongst them for both of these metrics (I<A<H). Despite this, these centers had
the longest time between approval and donation (I>A>H). These results suggest that
although combining tests on the same day may be a viable and donor-centric process
improvement strategy, other factors are also important (e.g., the time needed to secure
operating time after donor approval). How one center is performing compared to another
must be interpreted cautiously given the centers may differ with respect to donor casemix (e.g., proportion of donors donating through kidney paired donation, the proportion
of donors who are obese), available resources (e.g., equipment and personnel), and the
protocols they use to evaluate and select living donor candidates (e.g., how much they
participate in kidney paired donation; their minimum requirements to evaluate a
candidate). Adjustment for individual patient-level factors did not substantially change
the point estimates, suggesting that center-level factors may be important drivers of
evaluation times. A more detailed understanding of how different programs evaluate
donor candidates is warranted. The living donor evaluation may be expedited under
special circumstances that were not detailed in the present study, including urgency to
avoid dialysis or to complete the evaluation before a deadline to enter a next matching
cycle for kidney paired donation. Transplant centres should organize themselves to have
the capacity to conduct a quicker donor evaluation when necessary.15
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There are many negative implications of a prolonged living donor evaluation that
remain to be reported. First, many donors report negative experiences that may be a
barrier to living kidney donation.10,11,15,16 Second, a prolonged living donor evaluation
may increase the likelihood of competing events, including deceased donor kidney
transplantation or the intended recipient becoming ineligible for transplant due to illness
or death.7,33,34 Finally, there are costs to the healthcare system related to a longer living
donor evaluation as recipients continue to accrue costs attributable to kidney disease
(e.g., dialysis).35 Reducing the donor evaluation time when appropriate is a priority for
patients, providers, and the healthcare system.
These two multi-centre studies provide new information not available elsewhere
by reporting multiple measures of potentially meaningful process outcomes, examining
factors associated with these outcomes, and demonstrating substantive center-to-center
variability.11,24,27,33,36,37 Many results are presented by transplant center, and other centers
can collect and compare similar measures of performance. However, this study has
several important limitations that should be addressed in future efforts. First, this study
only included donors and the findings do not reflect the time to determine the candidacy
of excluded donors, or the time to work-up donor candidates who were approved but
ultimately did not donate. Second, we lacked information on program-level factors that
may explain some variability in donor evaluation times (e.g., evaluation of multiple
donor candidates simultaneously or sequentially38). Such data would be important to
ascertain whether delays could be attributable to resources (i.e., human resources, waittime for testing) or differences in living donor program processes. Third, we lacked some
data on individual-level factors that may affect the living donor evaluation time (e.g.,
recipient illness that may have temporarily affected their transplant eligibility and their
donor’s evaluation process; various donor-driven reasons including financial or time
constraints). Fourth, we used proxy dates to estimate several evaluation times, which may
reduce the accuracy of some measures. Fifth, some of the center-to-center differences in
donor evaluation times may be explained by differential data completeness rather than
true differences. Finally, these results may not generalize to living donor programs in
other countries with different healthcare systems and processes that may impact
evaluation times.
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This study was prompted by a consensus that an evaluation time of six months is too long
for many donors.11,16 The transplant community needs to further explore and define the
reasons why some candidates experience prolonged evaluations and why some transplant
centers have much longer evaluation times than others. A better understanding of these
reasons can inform quality improvement initiatives to improve the experiences of
candidates going through the evaluation process.
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Chapter 7

7

The flow of living kidney donor candidates through the
evaluation process at a single centre

7.1 Introduction
There are several reasons why a transplant program may wish to assess the flow of living
kidney donor candidates through its evaluation process. Knowledge of trends in the
number of active open evaluations and the types of tests performed can be used to inform
human resource planning and the required volume of specialized tests such as computed
tomography (CT) angiography or nuclear renography.1 Information on the length of the
evaluation process for candidates who go on to donate as well as those who are deemed
ineligible to donate can be shared with candidates at the beginning of the evaluation
process as part of informed consent.2 To guide quality improvement initiatives, it can be
valuable to understand the reasons why the evaluation period is longer in some
candidates than others, and the implications that this may have on the likelihood a
candidate will complete their evaluation, or the length of time their intended recipient
continues to receive dialysis (or needs to begin dialysis).3–5 However, there is no accepted
way to assess the flow of living kidney donor candidates in a donor evaluation program,
and our detailed search of bibliographic databases in the form of a scoping review only
identified a limited number of illustrative examples (Chapter 4).6 These studies presented
a few key metrics that can be used to compare the relative efficiency between programs,
such as the time to complete the evaluation and the proportion of candidates who
ultimately donated. However, the lack of consistent definitions of key dates renders many
comparisons difficult, and lack of granularity of the data impairs interpretation.
With the paucity of available evidence to date, we conducted this case study of a single
program in Ontario, Canada, where we provide an example of how a program can review
4-years of prior data to gain valuable insights on the flow of donor candidates through its
evaluation process.
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7.2 Methods
7.2.1 Data sources and variables
We retrospectively reviewed the medical records for all living donor candidates who
contacted the London Health Sciences Living Donor program in Ontario, Canada
between January 1, 2013 and December 31, 2016 (herein referred to as “the study
period”). This included all evaluations which were open and ongoing at the beginning of
the study period (January 1, 2013), as well as evaluations which began during the 4-year
study period. Evaluations could be open and ongoing by the end of the study period
(December 31, 2016).
We collected data on donor demographics, social habits, and medical factors from their
medical records, which included clinic notes, diagnostic and lab test results, a preliminary
screening checklist, living donor coordinator notes, and a self-reported medical-social
questionnaire (MSQ). The preliminary screening checklist is conducted over the phone or
email, which ascertains general information about prior cancer history, hypertension,
diabetes, cardiovascular or cerebrovascular disease, body mass index (BMI), and history
of renal stones. The MSQ is a detailed (11-page) paper or electronic questionnaire that
ascertains a detailed account of the candidates’ social, medical, travel, and family history.
Many programs have some form of MSQ that may be paper-based, electronic, or
available through some online submission portal.6
Blood pressure and BMI were ascertained early in the evaluation phase, as these would
be most predictive of the trajectory of the evaluation. We used the BMI that was selfreported on the MSQ, and blood pressure readings were done at a clinic or local drug
store and readings were submitted with the MSQ; these measures would be similarly
reported for all candidates (donors and non-donors). Blood pressure was estimated from
an average of up to five measurements. The second digit of the Canadian postal code was
used as an indicator of rural or urban residence (rural if zero; urban otherwise). Persistent
hematuria was defined as the presence of blood in the urine in at least 50% of a minimum
of three random urine sample tests performed on different days (the presence of blood
was defined as per Table 14 to accommodate variability in reporting).
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Table 14: Classification of urine blood as positive, negative, or inconclusive
Positive
trace blood
3-5 RBC
blood (2)
3-10 RBC
moderate blood
<10 RBC
large blood
6-10 RBC
blood (1+)
3+ blood
6-11 RBC
3 RBC
small blood

3-4 RBC
5-15 RBC
1+ blood
mod blood
16-50 RBC
3 p/ul RBC
5-20 RBC
3-5 microscopic RBC/HPF
0.3 blood
>10mg/L blood
>50 RBC
2+ blood
16 RBC

4-6 RBC
3+ RBC
13 RBC
>10/uL RBC
11-20 RBC
20-30 RBCs
5-30 RBC
blood (2+)
25-50% dysmorphic RBC
10 blood
11-25 RBC
20-30 RBC
trace-intact blood

Inconclusive
1-5 RBC
0-5 RBC
<5 RBC
moderate blood (patient on menses)
trace blood (patient had menses)
1-3 RBC

small blood (menses started this day)
2-5 RBC
large blood - patient on menses
small blood, rare RBC
occasional RBC

Negative
1-2 RBC
trace blood (expected)
Classification of results as positive, inconclusive, and negative was based on expert opinion. If 50% of
a candidates’ results were positive then the candidate was said to have persistent hematuria.
RBC – red blood cell; HPF – high-powered field

Recipient data were obtained from a local transplant database, which included the date an
intended recipient started dialysis, the date transplant recipient candidates were referred
for transplant evaluation, and the date transplant candidates were placed on the deceased
donor wait-list. Information on intended recipients not referred to the program was
unavailable. Unlike what occurs in some other countries including the United States, in
Ontario a complete referral package is sent from the nephrologist managing the patient
with kidney failure to a transplant centre for an assessment of transplant eligibility. This
referral package includes the results of complete bloodwork, an electrocardiogram, an
echocardiogram, cardiac perfusion testing (when a patient has cardiac risk factors),
infectious disease and virology testing, complete cancer screening per Ontario guidelines,
a chest x-ray, and an abdominal/renal ultrasound. The transplant centre acknowledges
when they receive a complete referral package, which is the date a patient has been
‘referred’.
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7.2.2 The evaluation
The living donor evaluation was segmented into distinct phases. The evaluation began at
the time the candidate made contact with the program (phoned, emailed, in-person visit).
In this study, proceeding to the screening phase of the evaluation occurred if the program
received the MSQ (complete or incomplete). Proceeding to the evaluation phase was
defined as date the (completed) MSQ was reviewed by the program coordinators and a
decision rendered about proceeding to the next phase of the evaluation. The evaluation
phase started with the first laboratory test or consult after the screening phase, and ended
with a definitive decision on ineligibility, candidate withdrawal, or donation (since the
date of approval is not documented or defined).
Candidates were considered lost to follow-up if there was no progress with the evaluation
for at least three months and there was no indication that their evaluation was placed on
hold or was terminated because the candidate withdrew or was deemed ineligible. Thus,
we assumed they were no longer interested in becoming a donor but did not wish to
communicate this to the program explicitly. There was no system in place to attempt to
contact these candidates, although gentle reminders were sometimes solicited.
Reasons for a delayed evaluation were abstracted from the clinical notes whenever
encountered, although there was no systematic process for categorizing or documenting
the duration of the delay.

7.2.3 Statistical methods
This study is largely descriptive, and results are reported as mean (standard deviation,
SD) or median (25th, 75th percentile), where appropriate. Comparisons between donors
and non-donor candidates were conducted using chi-square tests for categorical data and
t-tests for continuous data.
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7.3 Results
A total of 1,069 living donor candidates were active for some portion of the study period.
Of these, 741 (69%) candidate evaluations were terminated without donation (e.g.
candidates were deemed ineligible, indicated they wanted to withdraw, or were lost to
follow-up); 138 (13%) were still undergoing evaluation by the end of the study period
(although 20 ended up donating by January 2018); 103 (10%) candidates donated during
the study period; and 87 (8%) candidate evaluations were on hold by the end of the study
period, although the reason was unknown.
Mean (SD) candidate age was 46 (14) years, and BMI was 27.0 (5.2) kg/m2. Candidates
were predominantly women (66%), white (85%), and lived in an urban neighbourhood
(76%) (Table 15). Most candidates wished to donate to a friend or non-relation (21%), a
sibling (20%), or a distant relation (19%). Only 8% of candidates intended to donate
anonymously (non-directed donation), two of whom had to have their kidney removed
for their own health. During the study period, the program had 2.0 full-time equivalent
living donor nurse coordinators, 1.0 full-time equivalent administrative assistant, and 2
nephrologists and 2 surgeons who were available to discuss open cases and see 8-10 new
living kidney donor candidates in consultation each month.
Table 15: Donor candidate characteristics (n=1066)
Characteristic
Age, years
BMI, kg/m2
SBP, mmHg
DBP, mmHg
Travel distance (km)
Euclidean distance
Driving distance

Donor (n=123)

Non-donor (n=946)

47.8 (11.1), n=121
26.6 (3.5), n=119
121 (9.9), n=115
76 (6.8), n=115

45.3 (14.1), n=809
27.0 (5.5), n=475
122 (11.8), n=369
76 (8.4), n=369

91 (42, 168), n=118
110 (54, 193), n=118

94 (23, 165), n=552
115 (27, 189), n=552

39 (32%)
84 (68%)

316 (34%)
607 (66%)

103 (89%)
3 (3%)
3 (3%)
1 (1%)
3 (3%)
3 (3%)

383 (84%)
21 (4%)
12 (3%)
13 (3%)
9 (2%)
16 (4%)

Sex
Male
Female
Race
White
Arabic
South Asian
East Asian
Black/Indo-Caribbean
Other
Urban residencea
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Urban
Rural

90 (76%)
28 (24%)

428 (76%)
134 (24%)

Married

105 (85%)

463b

Intended recipient relation
Friend or non-relation
Sibling
Distant relation
Spouse
Parent
Child
Non-directed (anonymous)c

10 (8%)
26 (22%)
23 (19%)
27 (22%)
10 (8%)
15 (13%)
10 (8%)

194 (22%)
169 (20%)
168 (20%)
86 (10%)
99 (11%)
80 (9%)
67 (8%)

Donor blood type
O
A
B
AB

66 (54%)
38 (31%)
14 (12%)
3 (3%)

288 (47%)
214 (35%)
88 (15%)
20 (3%)

Recipient blood type
O
A
B
AB

49 (42%)
44 (38%)
18 (15%)
6 (5%)

301 (44%)
269 (39%)
89 (13%)
25 (4%)

Enrolled in kidney paired donation

19 (23%)

29b

8 (7%)
0 (0%)

84 (9%)
10 (1%)

Anti-hypertensive medications
Type II diabetes

Smoking at screening
current
15 (13%)
101 (21%)
former
35 (29%)
130 (28%)
never
69 (58%)
239 (51%)
Results are reported as mean (standard deviation), median (25 th percentile, 75th percentile), or N
(percent), where appropriate
a
defined using second digit of Canadian postal code (rural if 0, urban otherwise)
b
no denominator
c
1 in each group had to get their kidneys removed for their own health

7.3.1 Healthcare encounters over the study period
The annual number of new candidates who contacted the program doubled from 167 in
2013 to 348 in 2016, with a concomitant 45% increase in the number of donations (22 in
2013 to 32 in 2016) (Figure 12). The average number of candidates coming forward for
the same recipient increased over time from a median of 2 (1, 7) (maximum 13) [mean
4.2 (SD 3.8)] in 2013 to 4 (2, 9) (maximum 24) [mean 7.0 (SD 7.3)] in 2016 (Figure 13).
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Figure 12: Number of contacts and donations that occurred between January 1,
2013 and December 31, 2016 at London Health Sciences Centre (N=935)

Figure 13: Number of contacts per recipient, restricted to candidates with a known
recipient (N=860)
102

The number of specific healthcare encounters also increased during the study period,
including the number of nephrology consults, psychosocial assessments, CT angiograms,
and initial crossmatch tests (Figure 14). In contrast, the number of surgery consultations
remained stable and the number of nuclear renograms decreased. The number of donors
performing two or more 24-hour urine tests decreased over time: 19/22 (87%) in 2013,
20/23 (87%) in 2014, 12/26 (46%) in 2015, and 5/32 (16%) in 2016.

Figure 14: Annual number of healthcare encounters by year

7.3.1.1

Donor candidate attrition for all new contacts during the
study period

We followed all candidates through their evaluation process, restricted to those with a
first contact date during the study period (n=939). After contacting the program, 427
(45%) candidates did not proceed to the screening phase, 203 (22%) did not proceed to
the evaluation, and 228 (24%) did not complete the evaluation (Figure 15). By January
2018, 95/939 (10%) donated. Loss of follow-up with the donor candidate was the most
common reason for attrition, which usually occurred during screening (e.g. not screened
out at initial contact, yet did not return the MSQ; Table 16). Based on medical or
psychosocial grounds, 7% of candidates were deemed ineligible by the program during
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the initial screening period (e.g. at initial contact), 15% were deemed ineligible following
a more detailed screening (results from the MSQ), and 21% were deemed ineligible
during the evaluation period. For candidates with an available date of withdrawal or
decline (n=290, excluding those who were lost to follow-up), the total time of the
evaluation was a mean 6.2 (SD 6.1) months and a median 4.3 (1.4, 9.1) months.

Figure 15: Flow of living donor candidates through the living donor program at
London Health Sciences Centre. All candidates first contacted the program between
January 1, 2013 and December 31, 2016. Candidates were considered active if they
did not donate, were not declined, were not placed on hold, or were not lost to
follow-up before December 31, 2016. Loss to follow-up was considered as 3 months
without contact with the program.
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Receipt of a deceased donor kidney transplant was recorded in the candidate’s medical
chart to be a reason for donor candidate attrition in 22 cases, 13 of whom had a candidate
in the evaluation phase. Loss of recipients due to death or ineligibility occurred in only
six instances, four of whom had a donor who had passed the screening phase (Table 16).
Table 16: Reasons for donor candidate attrition at different time-points in the
evaluation
Reason for attrition
No donor follow-up
Active donor in period
Donor deemed medically unsuitable
Will work up other donors first
Recipient not ready/not assessed
Unknown reason
Donor changing lifestyle (i.e., smoking
cessation, weight loss)
Donor no longer wants to continue with
donation
Other reasons
Recipient received a deceased donor
transplant
Recipient transplanted by other living donor
Incompatible (cross-matching) – not
interested in kidney paired donation
Donor impaired by support, stressors, and
responsibilities
Incompatible (ABO) – not interested in
alternatives
Recipient to wait for deceased donor kidney
with pancreas or liver
Recipient declined donor or transplant
Donor is to be worked up at another program
Recipient died or no longer eligible for
transplant
Incidental finding during evaluation
Donor is an international non-directed
anonymous donor (not accepted by our
program)
Recipient too healthy for a transplant

Initial
screening
period

Preliminary
After
Evaluation
screening
evaluation
period
period
period

290 (68%)
55 (13%)
30 (7%)
4 (1%)
2 (0%)
5 (1%)
1 (0%)

24 (12%)
27 (13%)
31 (15%)
25 (12%)
21 (10%)
10 (5%)
21 (10%)

10 (4%)
47 (21%)
49 (21%)
21 (9%)
6 (3%)
14 (6%)
5 (2%)

0 (0%)
1 (25%)
0 (0%)
0 (0%)
2 (50%)
0 (0%)
0 (0%)

11 (3%)

7 (3%)

7 (3%)

1 (25%)

4 (1%)
5 (1%)

9 (4%)
4 (2%)

10 (4%)
13 (6%)

0 (0%)
0 (0%)

3 (1%)
0 (0%)

4 (2%)
1 (0%)

9 (4%)
13 (6%)

0 (0%)
0 (0%)

2 (0%)

6 (3%)

5 (2%)

0 (0%)

4 (1%)

6 (3%)

2 (1%)

0 (0%)

2 (0%)

2 (1%)

5 (2%)

0 (0%)

3 (1%)
1 (0%)
1 (0%)

2 (1%)
3 (1%)
1 (0%)

2 (1%)
1 (0%)
4 (2%)

0 (0%)
0 (0%)
0 (0%)

0 (0%)
3 (1%)

0 (0%)
0 (0%)

4 (2%)
0 (0%)

0 (0%)
0 (0%)

1 (0%)

1 (0%)

1 (0%)

0 (0%)

Reasons for attrition were abstracted from clinic notes, whenever documented, and categorized as reported in
this table.
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7.3.1.2

Reasons for a delayed evaluation

The most frequently encountered reasons for a delayed donor evaluation occurred early in
the process (Table 17). The most common reason was a delay in the referral of the
intended recipient to the transplant centre (11% of candidates), as there was limited
interest in evaluating some living donor candidates in too much detail until their intended
recipient was referred to the transplant centre. The second most common reason was the
requirement for the candidate to lose some weight (8% of candidates) or other candidates
were prioritized when at least one other candidate contacted the program for the same
intended recipient (4% of candidates).
Table 17: Reasons for a delayed evaluation process
Reason for delay
Recipient was not assessed yet
Candidate needed to lose weight
Incidental finding during the evaluation
Other donors prioritized
Other reason
Smoking cessation
Personal reasons
Donor started the evaluation in another program
Language barrier
Donor coming from another country
Recipient was not ready to proceed
Donor had to get blood pressure under control
Donor intends to donate at another program
Recipient’s health had to improve
Operating room time difficult to get
Recipient kidney’s still function so transplant surgery can
be delayed
Donor needed time to think or discuss with recipient

7.3.1.3

General
timeline
early
early
middle-late
throughout
throughout
early
throughout
early
throughout
throughout
middle-late
early
early
throughout
late
early
early

All candidates
(N=939)
99 (10.5%)
74 (7.9%)
37 (3.9%)
35 (3.7%)
31 (3.3%)
30 (3.2%)
23 (2.4%)
21 (2.2%)
21 (2.2%)
19 (2.0%)
17 (1.8%)
14 (1.5%)
13 (1.4%)
6 (0.6%)
6 (0.6%)
2 (0.2%)
2 (0.2%)

Recipient dialysis status

Data were available from the transplant database for 860 (92%) intended recipients.
Among these, 359 (42%) were on dialysis before their donor candidate started their
evaluation, 316 (37%) were never on dialysis, and 185 (21%) started dialysis after this
date (91 did so after their candidate’s evaluation was completed and 58 within the first 3
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months of their candidates’ evaluation start date) (Figure 16). Among donors, 20% of
their intended recipient started dialysis before donation (29% for non-donors). Omitting
the 92-day buffer to complete the evaluation (a time sufficient to complete the
evaluation) increased this estimate to 35% for donors (37% for non-donors). The
proportion of living donor transplants that were pre-emptive increased over time: 18%
(4/22) in 2013, 27% in 2014 (6/22), 38% in 2015 (9/24), and 34% (11/32) in 2016. Of the
36 recipients who started dialysis after the evaluation was underway for at least three
months, this occurred a mean 356 (SD 197) days after the first contact date [median 351
(243, 419) days].

Figure 16: Classification of intended recipient by dialysis status
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Recipients were referred to the transplant centre a median 9 (-108, 104) days (n=667)
after their donor candidate first contacted the program, and were activated on the
deceased donor wait list a median 175 (63, 306) [mean 127 (SD 572)] days (n=532) after
their donor candidate first contacted the program.

7.3.2 The evaluation process
Among donors who donated during the study period who had a first contact date
available (97/103, 94%), the time from first contact until donation was a mean 13.7 (15.7)
months, median 9.2 (6.1, 14.0) months. The total evaluation time decreased over the
study period from a median 12.8 (7.5, 14.9) in 2013 to 7.1 (4.8, 12.4) in 2016
(Spearman’s rho=-0.24, p=0.02) (Figure 17).

Figure 17: Average time from first contact until donation (n=97)

7.3.2.1

Timeliness of the evaluation

The candidate contacted the transplant program usually by phone (65%) or email
(n=31%). Candidates completed the MSQ after a median 7 (IQR 1, 24) days (N=506) and
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the program received the completed questionnaire a median 8 (3, 18) days later (Figure
18). The overall process from first contact until the MSQ was reviewed with the
candidate took a median 40 (22, 90) days.

Figure 18: Overview of donor screening process
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Since delays in this step may be predominantly donor-driven, we express the time to
complete various components of the evaluation using the date the MSQ was received as
the point of reference (Figure 19). The renal ultrasound, chest x-ray and
electrocardiogram were completed a median 40 days after this time-point, the initial
crossmatch, psychosocial evaluation, and nephrology consult after a median of 50-57
days, and the CT, nuclear renogram, and surgical consult after a median of 82-89 days.
Donors completed these tests on a median 5 of different dates (range 2-9 days, mean 4.7
days, SD 1.4 days).

Figure 19: Time from receipt of the medical-social questionnaire (MSQ) until
various tests in the living donor evaluation were completed
The initial cross-match was conducted a median 118 (63, 203) days after first contact
(n=186), and the final cross-match was conducted a median 95 (56, 133) days afterwards.
The first recipient serum that was used for cross-match testing was obtained from the
recipient a median 19 (-43, 102) days after first contact. Since at least two samples
collected at least two months apart is required, the initial cross-match could potentially
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have been conducted 2 months after this date, a median of 48 (0, 115) days earlier than
actually performed.
For candidates with a nephrology, urology, and psychosocial assessment, the time
between consults was a mean 54 (74) days and a median 27 (4, 69) days (n=127) and was
similar for donors (median 27 days) and non-donor candidates (median 28 days).

7.3.2.2

Laboratory, imaging, and consultations

There were no differences in select serum biochemical parameters between donors and
non-donor candidates on their first blood test (Table 18). In contrast, donors had
significantly less urinary albumin (2.6 g/L versus 6.2 g/L) and a lower random urinary
albumin-to-creatinine ratio (0.16 mg/mmol versus 0.80 mg/mmol) than non-donors on
their first urine test. Donors were less likely to have persistent hematuria (8/71, 11%)
than non-donors (21/62, 34%) among those tested, but were more likely to continue with
the evaluation and have a urine cytology exam (microscopic analysis of urine for
evidence of malignancy), cystoscopy, or renal biopsy (Table 18).
There was no difference in 24-hour creatinine clearance (117 versus 114 mL/min/1.73m2)
or GFR measured by nuclear renogram (107 versus 92 mL/min/1.73 m2) between donors
and non-donors. The nuclear renogram was performed a median 0 (-35, 4) days from the
time of the CT scan (if negative, renogram preceded the CT angiography). The time from
CT until donation was a mean 127 (149) days [median 75 (36, 180) days] (n=74).
Other tests were required on an individual-level basis, including ambulatory blood
pressure monitoring (n=54), echocardiography (n=20), stress tests (n=19), and 24-hour
urine analysis for kidney stones (n=13). Consultation with other healthcare professionals
were required on an individual basis, including dietitians (n=20), obstetricians or
gynecologists (n=11), transplant infectious disease (n=11), cardiologists (n=9),
hepatologists (n=5), gastroenterologists (n=5), and respirologists with or without a
pulmonary function test (n=5).
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Table 18: Test results for donor candidates
Donor
(N=95)

Non-donor
candidate
(N=844)

Number of blood tests*
1
2
3
4
5
6

2 (3%)
30 (40%)
19 (25%)
9 (12%)
11 (15%)
4 (5%)

115 (59%)
60 (31%)
12 (6%)
5 (2%)
1 (1%)
2 (1%)

<0.0001

total protein (g/L)
albumin (g/L)
creatinine (μmol/L)
estimated GFR (mL/min/1.73 m2)a

71.0 (4.2)
44.2 (3.1)
68.9 (11.3)
97.0 (13.8)

71.5 (4.0)
44.1 (2.7)
72.3 (13.9)
94.0 (16.9)

0.47
0.91
0.03
0.12

random glucose (mmol/L)
fasting glucose (mmol/L)
2-hour glucose (mmol/L)
hemo a1c (%)

5.2 (0.7)
5.1 (0.5)
5.1 (1.3)
5.4 (0.4)

5.3 (1.3)
5.0 (0.7)
5.8 (1.9)
5.4 (0.4)

0.39
0.27
0.32
0.38

cholesterol (mmol/L)
triglyceride (mmol/L)
HDL (mmol/L)
LDL (mmol/L)

5.0 (0.9)
1.4 (0.9)
1.5 (0.5)
2.8 (0.8)

5.0 (1.0)
1.3 (0.8)
1.6 (0.5)
2.8 (0.8)

0.77
0.54
0.43
0.96

Number of urine tests*
1
2
3
4
5
6
7+

0 (0%)
4 (5%)
16 (21%)
16 (21%)
13 (18%)
15 (20%)
11 (15%)

74 (40%)
47 (26%)
31 (17%)
14 (8%)
9 (5%)
5 (3%)
3 (2%)

<.0001

albumin (mg/L)
creatinine (mmol/L)
random albumin/creatine ratio (mg/mmol)

2.6 (4.7)
9.9 (7.6)
0.16 (0.26)

6.2 (12.4)
9.3 (6.6)
0.80 (2.46)

0.001
0.56
0.0007

Number with persistent hematuriab*
Number with urine cytology*
Number with cystoscopy*
Number with renal biopsy*

8 (11%)
10 (13%)
10 (13%)
10 (13%)

21 (34%)
17 (2%)
10 (1%)
4 (1%)

0.002
<.0001
<.0001
<.0001

2 (3%)
37 (49%)
28 (37%)
8 (11%)
117 (33.4)

601 (82%)
78 (11%)
42 (6%)
7 (1%)
114 (55.1)

<.0001

75 (100%)
74 (99%)

129 (18%)
57 (8%)

<.0001
<.0001

p-value

Lab finding (blood tests)

Lab finding (urine tests)

Lab finding (24 hour urine tests)
Number of 24h urine tests*
0
1
2
3+
first measured creatinine clearance
(mL/min/1.73 m2)

0.59

Other investigations
Number with renal ultrasound*
Number with CT scan*
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Number with a nephrology consult*
Number with a psychosocial consult*
Number with a urology consult*

75 (100%)
73 (97%)
67 (89%)

90 (12%)
91(13%)
61 (8%)

<.0001
<.0001
<.0001

41 (55%)
107 (50.2)
51.7 (3.5)%

51 (7%)
92.4 (23.1)
49.3 (3.7)%

<.0001
0.14
0.004

Ever been treated, diagnosed with, or been
prescribed medication for a mental, psychiatric,
or emotional disorder
no
yes

64 (88%)
9 (12%)

324 (80%)
80 (20%)

0.13

In the past 5 years, have you ever been
prescribed anti-depressants, anti-anxiety or
other similar medications by a physician?
no
yes

63 (86%)
10 (14%)

308 (75%)
100 (24%)

0.04

Lab finding (nuclear renogram)
Number with nuclear GFR exam*
Measured GFR (mL/min/1.73 m2)
Left split renal function % (left)

Self-reported psychosocial historyc

a

estimated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
defined as at least 50% of urine samples positive for blood, restricted to those with at least 3 random
urine tests (see Table 14 for details)
c
self-reported on medical-social questionnaire
F
p-value calculated using Fisher’s exact test
W
p-value calculated using non-parametric Wilcoxon rank sums test
*restricted to donors (n=75) and non-donors (n=728) with a completed evaluation (e.g. donation date and
evaluation end-date within study period)
GFR – glomerular filtration rate
b

7.3.3 Living donor candidate expectations
Many donor candidates answered the MSQ question “Within what time frame are you
hoping to complete this process (i.e., when will be the best time for you to donate if you
are found suitable?)”. Many candidates were keen to donate as soon as possible (n=158,
39%) while others did not express any urgency and were available whenever needed
(n=246, 61%). Forty-four percent of candidates expressed that the ideal time to donate
was as early as 1 month from the time the MSQ was completed, whereas 38% required at
least 4 months and 18% preferred to donate anytime after 6 months. The ideal time to
donate was less than 4 months by 41% of candidates, while 47% preferred a time >6
months from the date the MSQ was completed. There were no differences in expectations
between donors and non-donor candidates (p>0.6).
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7.4 Discussion
In the present study, we conducted a detailed chart audit to understand the flow of living
donor candidates through our program. Although labor-intensive, the results are
informative, enabling us to identify the most frequent reasons causing delay that are
actionable or warrant further study.
One study reported a median (25th-75th percentile) time until approval of 4 (1-24) months,
a median time from approval until donation of 3 (0-9) months, and a median time until
rejection of 3 (0-48) months.7 Another study reported a mean (standard deviation) time
until donation of 9.3 (6.5) months.8 One study reported a median time until donation of
5.9 (3.7-10.6) months from the time of referral (although the referral date was not clearly
defined).9 One study reported a time from screening bloodwork until donation of 4.3
months, down from 7.4 months following quality improvement efforts of implementing a
clinical pathway.10 Finally, one multi-centred study reported multiple metrics for
evaluation times across multiple centres in Canada and Australia, demonstrating
substantial variability across programs and estimating a median time until donation of
10.3 (6.5-16.7) months.5
We reported a median time until donation of 9.2 months, consistent with previous
reports5, but also identified a small reduction in the total time until donation over time.
The number of living donor transplants increased over time, which may be explained
either by the rise in the number of candidates coming forward for the same recipient, a
reduction in the evaluation time, or both.11 We expect further efficiencies in the
evaluation process to result in a greater number of living donor transplants performed,
which is of itself an important performance indicator. Comparable to other studies, the
number of times the intended recipient started dialysis, died or became ineligible for
transplant, or received a deceased donor transplant before their donor candidate
completed their evaluation occurred often enough to warrant concern, and quality
improvement efforts should attempt to reduce these occurrences whenever possible.3,4,6
There are many areas for efficiency improvements. One potential solution is to provide
the MSQ on the program’s website; a practice used by several programs in the United
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States.6 Most living donor programs only evaluate one candidate at a time, but it is
unclear whether review of the completed MSQ is considered part of this evaluation.
Review of the MSQ is labor-intensive, requiring at least one hour of living donor
coordinator time (based on expert opinion). Although as many as 24 candidates came
forward for one recipient in 2016, we do not expect all of them to complete the MSQ
since many candidates do not follow up with the program after initial contact. Providing
the MSQ online with the ability to complete it entirely electronically may ease the
screening process and facilitate prioritization of candidates using pre-scored instruments
and flags to enable coordinators to focus on key issues.
For donor candidates whose evaluation was delayed because their intended recipient was
not assessed, their evaluation resumed 73% of the time (e.g. this was not a cause for
termination of the candidate’s evaluation). Nine percent of donors’ evaluations were
delayed for this reason – had the candidate’s evaluation begun immediately, we would
have expected some earlier living donor kidney transplants that may in turn improve
outcomes (particularly if the recipient is on or approaching dialysis).3 In addition to
earlier recipient referrals, decisions should be made whether to begin (and when to pause)
the donor candidate evaluation for candidates whose intended recipient was not yet
evaluated. Other reasons for delay include the need for the candidate to lose weight,
which is necessary for the safety of the donor and is largely non-modifiable.12,13 Our
program offers (but does not mandate) consultation with a dietitian in cases of obesity or
elevated cardiovascular risk factors. Although BMI cut-points may vary between
programs6, the evaluation is often begun if it is clear that the candidate is making strides
towards weight loss and the intended recipient has been approved for transplant. Finally,
another reason for delay was the prioritization of other donor candidates. In some cases, it
may be more cost-effective to evaluate multiple candidates simultaneously: in our
population, only 2 donors’ evaluations had a documented delay because other candidates
were prioritized. Future research is needed to examine this scenario. Future efforts are
needed to quantify periods of patient-driven and system-driven delay.
Strategies to improve the efficiency of the living donor evaluation process have been
discussed in prior reports.6,14 However, we believe the future of our program (and of
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others) is to enable a 1-day evaluation for willing candidates. Several transplant centres
already have such a strategy in place.6,11 A step-wise evaluation is certainly cost-saving to
the evaluation program, but from a broader perspective, the opportunity cost is high if the
recipient starts dialysis or continues to accrue costs related to dialysis while waiting for
their donor.3 Following the screening phase, all candidates are required to complete
random blood and urine tests. However, there is no consensus whether the requisitions
for these tests should be provided at the same time as the MSQ or after the MSQ is
reviewed by the living donor coordinators. Non-donors had significantly less favourable
urine test results than donors, suggesting a greater emphasis for conducting this test as
early as possible (perhaps during the initial screening phase). Following screening, all
candidates could be scheduled for 1-day testing (Figure 20). Some time is then needed to
establish candidacy, order additional tests on a second visit if needed, and schedule the
operating room. In this scenario, the candidate is required to visit the transplant centre
once or twice. Currently, candidates interacted with the healthcare system a median 5
times before the preoperative assessment (not including visits with a general practitioner
or other ad hoc tests or consults). Scheduling the operating room as early as possible may
help reduce the time until donation, which may be particularly important since the time
from CT angiography (one of the last tests) until donation was the longest segment of the
evaluation.5,15 This may be due to a number of factors, including donor and recipient
readiness in addition to scheduling challenges. If successful, a 1-day evaluation should
result in a time until donation of approximately 4 months: a realistic and optimal
target.11,16
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Figure 20: Proposed clinical pathway for a 1-day evaluation of living donor
candidates
One of the limitations of this study is the underreporting of reasons for delay. At our
centre, reporting reasons for delay became more routine over time as measures of
evaluation time were increasingly requested. Another limitation is the lack of data on the
date the donor candidate was approved. This is a critical date, as this separates delay due
to the donor evaluation itself from other factors related to scheduling the transplant.
These reasons are important for quality improvement efforts to streamline the evaluation
process and reduce possible inefficiencies. A further limitation of this work is the
unavailability of data regarding the donor candidate experience with the evaluation
process.
In conclusion, the living donor evaluation process remains a challenging and resourceintensive process. A “one-stop shop” testing strategy is one solution to improve the
efficiency of this process and improve recipient outcomes and the donor experience,
while potentially reducing costs to the healthcare system. Synoptic reporting of key
elements will enable future quality improvement efforts, and future work should focus on
developing these methods.
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Chapter 8

8

Initiating maintenance dialysis prior to living kidney
donor transplantation when a donor candidate
evaluation is well underway‡‡

8.1 Introduction
A pre-emptive kidney transplant avoids the risks of initiating dialysis and results in better
outcomes and patient experiences compared to other treatment options available to
patients with kidney failure.1,2 Deceased donor pre-emptive kidney transplants are rare, as
most patients wait on a list for several years before an offer for a deceased donor kidney
becomes available.3 For this reason, pre-emptive kidney transplants are typically
achieved from a living donor.
There are many challenges to receiving a pre-emptive living donor kidney transplant.
First, the intended recipient needs to be referred to a transplant program, thoroughly
evaluated, and approved to receive a kidney transplant. Second, the transplant should be
timed such that the intended recipient’s native kidneys have not failed to the extent of
initiating dialysis urgently, but not too early so that the recipient can make use of any
remaining native kidney function.4 Third, a living donor has to be identified.5 Finally, the
living kidney donor candidate needs to be thoroughly evaluated and approved for kidney
donation. For this last consideration, there is a growing appreciation that the living donor
evaluation process for many motivated donor candidates is lengthy, difficult to navigate,
and challenging.6–8 The 2017 KDIGO ‘Clinical Practice Guideline on the Evaluation and

‡‡

A version of this chapter has been published: Habbous S, McArthur E, Dixon SN, McKenzie S, GarciaOchoa C, Lam NN, Lentine KL, Dipchand C, Litchfield K, Begen MA, Sarma S, Garg AX. “Initiating
maintenance dialysis prior to living kidney donor transplantation when a donor candidate evaluation is well
underway” Transplantation. 2018;102(7):e345-e353.
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Care of Living Kidney Donors’ recommends that transplant programs should conduct as
efficient a donor evaluation as possible, meeting the needs of donor candidates, intended
recipients and transplant programs.9 Using data from a multi-centre study, the median
estimated donor evaluation time (time from first contact to nephrectomy) was 10.3
months (Chapter 6). In some cases a prolonged donor evaluation process may prevent a
pre-emptive transplant.
In this study, we focused on a cohort of patients with kidney failure, all who received a
living donor kidney transplant. We studied persons not receiving dialysis when their
donor candidate’s evaluation was well underway and determined how often maintenance
dialysis was initiated before receipt of the living kidney donor transplant. We assessed
the cost of dialysis treatments, and whether dialysis was started urgently in a hospital
setting. Finally, we explored whether some unmodifiable and modifiable factors were
associated with dialysis initiation prior to transplant.

8.2 Methods
8.2.1 Design and setting
We conducted a retrospective analysis of living donor kidney transplants using linked
databases for the entire province of Ontario, Canada. Ontario has a current population of
13.7 million people and residents receive access to publicly insured hospital and
physician services. In 2016 there were approximately 10,000 patients receiving dialysis,
and 20,000 patients followed in clinics for advanced chronic kidney disease; living
kidney donor transplants took place in five transplant centres. This study was approved
by the research ethics board at Sunnybrook Health Sciences Centre, Toronto, Canada.
Datasets were linked using unique encoded identifiers and analyzed at the Institute for
Clinical Evaluative Sciences (ICES). The study was conducted according to a prespecified protocol and reporting of the study followed standardized guidelines (Appendix
G).
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8.2.2 Variables and data sources
We ascertained demographic characteristics, clinical factors, and outcomes using several
linked databases. Information on all living kidney donors and recipients in Ontario were
obtained from Trillium Gift of Life Network10, chart abstraction, and the Canadian Organ
Replacement Register databases, and included race, blood type, and donor-recipient
relationship. Additional donor information included the donor’s estimated glomerular
filtration rate (eGFR) prior to donation. Additional recipient information included
primary cause of kidney failure, prior transplant history, and serum creatinine,
hemoglobin, and albumin at the time of dialysis initiation. Recipient referral dates were
available for recipients transplanted after 2010. Demographic variables were obtained
from the Registered Persons Database (age, sex, postal codes to calculate the Euclidean
distance to the transplant centre and to obtain neighbourhood income quintiles from the
2006 Canada Census). The Canadian Institute for Health Information Discharge Abstract
Database (CIHI-DAD) and the Ontario Health Insurance Plan (OHIP) datasets were used
to determine if and when dialysis was initiated (and whether it was started in the hospital
or outpatient setting), as well as to identify various non-renal comorbidities among
recipients (Appendix H).11 The ICES Physician Database and OHIP were used to
determine the start date of the living donors’ evaluation (Appendix I and Appendix J).
Linked laboratory databases were used to obtain the most recent recipient serum
creatinine at the time their donor initiated their evaluation (±3 months) and at the time of
referral (±3 months) in a subset of patients. This database, the Ontario Laboratory
Information System, includes inpatient and outpatient test values from hospital and
commercial laboratories, together accounting for 91% of Ontario’s lab results by 2016.
eGFR was calculated using the CKD-EPI (Chronic Kidney Disease Epidemiology
Collaboration) equation (in mL/min per 1.73 m2).12 Dialysis costs were estimated for
recipients who started dialysis after March 2006 (which was the first available date in our
data sources when dialysis costs could be reliably ascertained). Costs were tabulated from
the public payers’ perspective using OHIP billing codes (Appendix H) plus resource
intensity weights times the cost per weighted case to calculate the cost per case (i.e.,
consumable materials, nursing staff, machine costs).13
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8.2.3 Selection
The selection of living donor kidney transplants for this study is presented in Figure 21.
This study was restricted to patients who received a living kidney donor transplant, where
the transplants occurred between April 1, 2004 and March 31, 2014. In this study, we
focused on the subset of living donor transplants where the recipient was a first-time
kidney transplant recipient and was not on dialysis when the evaluation process of the
candidate who ultimately donated to them was well underway. Living donors were
required to be Ontario residents for at least two years prior to donation to ensure that
information on the donor evaluation process was complete and available in our data. We
excluded donors who were missing a donation date, a nephrology consult, or a surgery
consult (Figure 21), as these donors were likely from outside of Ontario or may have
participated in a national kidney paired donation program. We also excluded donors with
unreasonable patterns of procedures (i.e., nephrectomy codes before donation date) and
those with a late-stage procedure captured as the first procedure (i.e., a living donor
evaluation would not begin with a nephrology consultation).
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Figure 21: Overview of inclusion/exclusion criteria for living kidney donors in this
study.
a

Living kidney donors were identified through Trillium Gift of Life Network. All

living donors have a unique identification number that allows linkage across
datasets.
b

These exclusions are not mutually exclusive so do not sum to 358; nephrology

consults within two weeks of donation and surgical consults within two days of
donation were not considered true consults (part of the pre-admission process).
c

Healthcare procedures deemed appropriate start points for the living donor

evaluation.
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8.2.4 Measurements
In this study a pre-emptive transplant was defined as the absence of dialysis billing codes
for the recipient prior to their transplant. We considered a pre-emptive transplant
potentially possible if the recipient did not receive dialysis within 92 days following the
donors’ evaluation start date. For these recipients, if dialysis was initiated prior to
transplant it was considered a “potential unrealized pre-emptive transplant”. Our opinion
is that 92 days (three months) is a reasonable buffer time to complete the evaluation
(which would be the case if the donor was motivated and eligible to donate). In
sensitivity analysis, we extended this period to four and six months; the United Kingdom
2020 strategy suggests all potential donors should be offered to complete the donor
assessment within 4.5 months of referral (where appropriate).14 With the data available to
us we could not reliably assess how many unrealized pre-emptive kidney transplants were
preventable [i.e., there were modifiable reasons (inappropriate waiting) that could be
addressed to realize the pre-emptive kidney transplant]. For this reason we deliberately
use the wording “potential” unrealized pre-emptive kidney transplant in this paper.
We defined the total evaluation time as the time when the donor started the evaluation
(the earliest documented evaluation testing) until the nephrectomy. We defined the total
approval time as the time from the donor evaluation start until the last specialist consult
preceding nephrectomy. The procedures that defined the start of the evaluation and the
consults that defined the approval date are presented in Appendix E. We defined the time
for consults as the time from the first to the last nephrology, psychosocial, or surgical
evaluation; this was restricted to donors who had all three consults and was limited to the
most recent of the three consults. These three consults are a standard part of the donor
candidate evaluation in all Ontario transplant programs. All times were expressed in
months.

8.2.5 Statistical methods
Descriptive statistics included the mean (standard deviation, SD), median (25th, 75th
percentile), and proportion (95% confidence intervals, CI), where appropriate.
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We used a recommended approach to report risk ratios for the association between
characteristics and dialysis initiation (i.e., a potential unrealized pre-emptive kidney
transplant; yes/no) [estimates derived from modified Poisson regression models (proc
genmod using a log link, a Poisson distribution, and a repeated statement (for
individuals) for robust standard error estimation)].15 To assess whether the results
differed across the five Ontario transplant programs that performed living donor
nephrectomies during the study period, we calculated the intraclass correlation coefficient
using mixed models treating the transplant program as the clustering variable (as a
measure of the proportion of the variance of the outcome accounted for by differences in
transplant program).
To comply with privacy regulations for minimizing the chance of patient identification,
five or fewer participants are reported as <6. For similar reasons the names of the
transplant programs and the number of transplants per program were also suppressed. We
used Statistical Analysis Software Enterprise Guide version 6.1 (2013 by SAS Institute
Inc., Cary, NC, USA) for all analyses.

8.3 Results
8.3.1 Patient population
A total of 478 living kidney donor transplants were included in the primary analysis
(Figure 21). Donors were a mean 46 (SD 11) years of age at the time of donation, most
were white (79%), female (63%), lived in an urban area (87%), had higher
neighbourhood income (24% were in the highest income quintile versus 13% in the
lowest), and lived a median of 33 (16, 74) kilometers from the transplant centre where
they donated (Table 19). The pre-donation eGFR was >80 mL/min per 1.73 m2 in 79% of
donors. Recipients were similar to donors with respect to age at transplant [mean 44 (SD
14) years], percent living in urban areas (87%), and neighbourhood income (24% in the
highest income quintile), but were more likely to be male (63%).
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Most transplants occurred between spouses (28%), siblings (24%), or unrelated donorrecipient pairs (17%) (Table 19). The proportion of living donor transplants performed in
Ontario ranged from 6% to 31% across the five transplant programs.
Table 19: Donor, recipient, and transplant characteristics

Age at transplant (years), mean (SD)

Donor
(N=478)
46.3 (10.9)

Recipient
(N=478)
44.0 (14.2)

Sex
Female
Male

301 (63%)
177 (37%)

177 (37%)
301 (63%)

Race**
White
Other

197 (79%)
53 (21%)

171 (81%)
39 (19%)

Incomea
5 (highest)
4
3
2
1 (lowest)

116 (24%)
125 (26%)
96 (20%)
78 (16%)
63 (13%)

116 (24%)
126 (26%)
95 (20%)*
80 (17%)
61 (13%)

Rural residenceb
Urban
Rural

415 (87%)
63 (13%)

418 (87%)*
60 (13%)

Blood type
O
A
B
AB

155 (60%)
77 (30%)
<6
<6

160 (40%)
167 (42%)
51 (13%)
22 (5%)

Distance to transplant hospital
<20 km
20-39 km
40-89 km
>89 km
median (IQR)
mean (SD)

148 (31%)
115 (24%)
118 (25%)
97 (20%)
33 (16-74)
82 (142)

124 (25%)*
132 (28%)
104 (22%)
118 (25%)
29 (15-67)
77 (145)

Donor eGFR at donationc,**
>89 mL/min/1.73 m2
80-89 mL/min/1.73 m2
<80 mL/min/1.73 m2
mean (SD)

281 (61%)
80 (18%)
96 (21%)
96.5 (14.1)

–
–
–
–

Recipient eGFR at beginning of
donor evaluationc,d,**
>19 mL/min/1.73 m2
15-19 mL/min/1.73 m2
10-14 mL/min/1.73 m2
<10 mL/min/1.73 m2
mean (SD)

–
–
–
–
–

30 (21%)
33 (23%)
57 (39%)
24 (17%)
16.2 (8.4)

Recipient referral (days after donor
evaluation started)
126

–
–
–

178 (430)
22 (-66, 322)
136 (28%)

Recipient eGFR at time of recipient
referralc,d,**
>19 mL/min/1.73 m2
15-19 mL/min/1.73 m2
10-14 mL/min/1.73 m2
<10 mL/min/1.73 m2
mean (SD)

–
–
–
–
–

18 (18%)
24 (25%)
37 (38%)
19 (19%)
14.3 (5.2)

Recipient comorbidity
Cardiovascular disease
IHD/CAD
Heart failure
Cancer

–
–
–
–

186 (39%)
36 (8%)
17 (4%)
104 (22%)

Diabetes
Hypertension
Anemia
Anxiety/depression

–
–
–
–

63 (13%)
384 (80%)
29 (6%)
51 (11%)

Relationship to recipient
Sibling
Unrelated
Spousal
Parent
Child
Other relation

115 (24%)
79 (17%)
134 (28%)
60 (13%)
59 (12%)
31 (6%)

–
–
–
–
–
–

Cause of kidney failure**
Glomerulonephritis/autoimmune
Other
Polycystic
Diabetes
Unknown etiology

–
–
–
–
–

84 (26%)
78 (24%)
75 (23%)
47 (14%)
42 (13%)

Year of transplant
2004-2007
2008-2010
2011-2014

–
–
–

155 (33%)
145 (30%)
178 (37%)

mean (SD)
median (25th, 75th percentile)
n (%)

a

categorized into fifths of median neighbourhood income from the 2006
Canada Census
b defined as a municipality with <10,000 persons
c eGFR (estimated glomerular filtration rate) was calculated using CKD-EPI
equation, in mL/min/1.73 m2.
d recipient creatinine was measured ± 3 months of the evaluation start date or
the recipient referral date
e codified for privacy
<6 – suppressed due to privacy (either <6 or another cell is <6 for the same
variable)
*missing status assigned as ‘urban’, income quintile 3, or travel distance <20km
** highly missing variable
SD – standard deviation; IQR (interquartile range – 25th, 75th percentile);
IHD/CAD – ischemic heart disease/coronary artery disease
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8.3.2 Potential unrealized pre-emptive kidney transplant
A total of 478 persons (all who ultimately received a living kidney donor transplant) were
not on dialysis when the donor candidate (who ultimately donated to them) was being
evaluated for at least 3 months. Recipient eGFR at the start of their donors’ evaluation
was a mean (SD) of 16.2 (8.4) mL/min per 1.73 m2, and in those with available data the
recipient eGFR at recipient referral was 14.3 (5.3) mL/min per 1.73 m2. For pairs with
available data, the recipient referral predated the date the donor candidate first contacted
the transplant program 55/136 (40%) of the time (a mean (SD) of -5.2 (4.8) months).
Donor candidate first contact predated the recipient referral 80/136 (59%) of the time (a
mean (SD) of 13.5 (13.9) months). The transplant programs in Ontario typically put the
donor candidate evaluation on hold until the intended recipient is referred for transplant
evaluation (Chapter 7).
A total of 167 of 478 recipients (35%) initiated dialysis prior to receipt of their transplant,
which we consider potential unrealized pre-emptive kidney transplant. In sensitivity
analyses, requiring the donor candidate to be evaluated for at least 4 or 6 months when
their recipient (who was not on dialysis) entered the cohort, meant 144/451 (32%) and
111/412 (27%) of recipients, respectively, initiated dialysis before transplant.
The mean (SD) eGFR at the time of dialysis initiation was 8.5 (7.2) mL/min per 1.73 m2,
serum albumin was 35.2 (7.0) g/L, and serum hemoglobin was 105 (42) g/L. A total of 44
of the 167 recipients (26%) started dialysis as an inpatient in the hospital setting.
Recipients who started dialysis during their donors’ evaluation did so a median 9.7 (5.4,
18.7) months after their donor started the evaluation, were transplanted a median 8.8 (3.6,
16.9) months after starting dialysis, and accrued a mean of $48,717 (SD $55,249) in
dialysis costs, totaling $8.1 million for the cohort of 167 recipients (2017 Canadian
dollars). For recipients with available data, the transplant program received the referral
for recipient evaluation a mean of 68 (SD 913) days [median 363 (198, 448) days] before
dialysis started.
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8.3.3 Characteristics associated with a potential unrealized preemptive kidney transplant
Associations between various characteristics and a potential unrealized pre-emptive
transplant in an exploratory analysis are presented in Table 20. The recipient was more
likely to start dialysis if their donor was female [RR 1.30 (0.99-1.70)], if either the donor
or recipient was from a lower-income neighbourhood [respectively, RR 1.68 (1.16-2.43)
and RR 1.96 (1.35-2.85) for the lowest quintile versus the highest], and if the donor was
non-white [RR 1.53 (1.02-2.30)]. Recipient non-renal comorbidity was also a significant
predictor of starting dialysis, particularly the presence of cardiovascular disease [RR 1.31
(1.03, 1.66)] and diabetes [RR 1.37 (1.03, 1.83)]. Non-significant associations were
observed for anemia [RR 1.45 (0.98, 2.14)], ischemic heart disease or coronary artery
disease [RR 1.35 (0.94, 1.95)], and anxiety or depression [RR 1.33 (0.95, 1.88)]. For
recipients with available data, dialysis prior to transplant was more likely if there was a
longer delay between the donor’s evaluation start date and the date the transplant
program subsequently received the referral to begin the intended recipient’s evaluation
[RR 1.03 (1.02-1.04) per 30-day delay]. Furthermore, a lower recipient eGFR at referral
was associated with an increased likelihood of starting dialysis [RR 0.93 (0.86-1.00)],
while no such association was observed for recipient eGFR at the donor’s evaluation start
date. There were significant differences across transplant programs (p=0.01), where one
program was 29% less likely to have a potential unrealized pre-emptive transplant while
another program was 47% more likely to do so when compared to a reference. However,
between-centre variability only accounted for 2.8% of the total variability in potential
unrealized pre-emptive transplant rates (p=0.16). After adjusting for donor sex, donor
income, and clustering by transplant program, the strength of these associations changed
very little (Table 20).
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Table 20: Characteristics associated with an unrealized potential pre-emptive
transplant

Age at donation (years)c
Age at transplant (years)c

Pre-emptive transplant
Yes
No
N=331
N=167
46.0 (11.0)
46.8 (10.7)
44.3 (13.7)
43.5 (15.1)

Risk of an unrealized potential pre-emptive transplant
Unadjusted
Adjustedb
RR (95% CI)a
p-value
RR (95% CI)
p-value
1.04 (0.93-1.17) 0.44
–
–
0.98 (0.90-1.06) 0.59
–
–

Sex (donor)
Male
Female

125 (40%)
186 (60%)

52 (31%)
115 (69%)

1.0 (ref)
1.30 (0.99-1.70)

0.06

1.0 (ref)
1.29 (0.99-1.69)

0.06

Sex (recipient)
Male
Female

196 (63%)
115 (37%)

105 (63%)
62 (37%)

1.0 (ref)
1.00 (0.78-1.29)

0.97

–

–

Race (donor)
White
Other

146 (82%)
32 (18%)

51 (71%)
21 (29%)

1.0 (ref)
1.53 (1.02-2.30)

0.04

1.0 (ref)
1.58 (1.06-2.36)

0.02

Race (recipient)
White
Other

123 (83%)
25 (17%)

48 (77%)
14 (23%)

1.0 (ref)
1.28 (0.79-2.07)

0.32

–

–

Income quintile (donor)d
5 (highest)
4
3
2
1 (lowest)

81 (26%)
95 (31%)
59 (19%)
45 (14%)
31 (10%)

35 (21%)
30 (18%)
37 (22%)
33 (20%)
32 (19%)

1.0 (ref)
0.80 (0.52-1.21)
1.28 (0.88-1.86)
1.40 (0.96-2.05)
1.68 (1.16-2.43)

0.002

1.0 (ref)
0.79 (0.52-1.20)
1.27 (0.87-1.84)
1.41 (0.97-2.06)
1.65 (1.15-2.39)

0.002

Income quintile (recipient)d
5 (highest)
4
3
2
1 (lowest)

84 (27%)
89 (29%)
60 (20%)
47 (15%)
28 (9%)

32 (19%)
37 (23%)
30 (18%)
33 (20%)
33 (20%)

1.0 (ref)
1.06 (0.71-1.59)
1.21 (0.80-1.83)
1.50 (1.01-2.22)
1.96 (1.35-2.85)

0.007

N/A

–

Residence (donor)
Urban
Rural

268 (86%)
43 (14%)

147 (88%)
20 (12%)

1.0 (ref)
0.90 (0.61-1.32)

0.58

–

–

Residence (recipient)
Urban
Rural

266 (86%)
42 (14%)

147 (89%)
18 (11%)

1.0 (ref)
0.84 (0.56-1.27)

0.41

–

–

eGFR of donor at time of
donatione
>89 mL/min/1.73 m2
80-90 mL/min/1.73 m2
<80 mL/min/1.73 m2

187 (62%)
48 (16%)
65 (22%)

94 (60%)
32 (20%)
31 (20%)

1.0 (ref)
1.20 (0.87-1.64)
0.97 (0.69-1.35)

0.51

–

–

eGFR of recipient when…f
donor evaluation started
recipient referred

16.1 (7.7)
15.1 (4.7)

16.4 (10.3)
12.6 (6.0)

1.00 (0.97-1.04)
0.93 (0.87-1.00)

0.84
0.06

–
0.93 (0.86-1.00)

–
0.05

Recipient comorbidity
Cardiovascular disease
IHD/CAD
Heart failure
Cancer

111 (36%)
19 (6%)
sup
72 (23%)

75 (45%)
17 (10%)
sup
32 (19%)

1.28 (1.00-1.63)
1.39 (0.96-2.01)
0.84 (0.40-1.77)
0.85 (0.62-1.17)

0.05
0.08
0.64
0.33

1.31 (1.03-1.66)
1.35 (0.94-1.95)
–
–

0.03
0.10
–
–

Diabetes
Hypertension
Anemia
Anxiety/depression

34 (11%)
252 (81%)
15 (5%)
29 (9%)

29 (17%)
132 (79%)
14 (8%)
22 (13%)

1.38 (1.03-1.87)
0.92 (0.69-1.24)
1.42 (0.95-2.11)
1.27 (0.90-1.79)

0.03
0.60
0.09
0.17

1.37 (1.03-1.83)
–
1.45 (0.98-2.14)
1.33 (0.95-1.88)

0.03
–
0.06
0.10

Variable
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Time from donor evaluation
start until recipient referralg

-6 (-95, 67)

321 (40,
875)

1.03 (1.02-1.04)

<.0001

1.02 (1.02-1.04)

<.0001

Transplant centreh
1
2
3
4
5

–
–
–
–
–

–
–
–
–
–

0.93 (0.67-1.31)
1.0 (ref)
0.71 (0.46-1.10)
1.47 (1.09-1.99)
1.13 (0.66-1.93)

0.01

N/A

–

Relationship
Spouse
Sibling
Parent
Child
Other relation
Unrelated

87 (28%)
81 (26%)
38 (12%)
33 (11%)
21 (7%)
51 (16%)

47 (28%)
34 (20%)
22 (13%)
26 (16%)
10 (6%)
28 (17%)

1.0 (ref)
0.84 (0.59-1.21)
1.05 (0.70-1.57)
1.26 (0.87-1.82)
0.92 (0.53-1.61)
1.01 (0.69-1.47)

0.60

–

–

Cause of kidney failure
GN/autoimmune
Polycystic
Diabetes
Other
Unknown etiology

45 (26%)
41 (24%)
18 (10%)
41 (24%)
27 (16%)

39 (25%)
34 (22%)
29 (19%)
38 (24%)
15 (10%)

1.0 (ref)
0.98 (0.70-1.37)
1.33 (0.96-1.83)
1.04 (0.75-1.43)
0.77 (0.48-1.23)

0.18

1.0 (ref)
0.97 (0.70-1.35)
1.30 (0.96-1.77)
1.01 (0.73-1.39)
0.78 (0.49-1.24)

0.21

Year of transplant
2004-2007
2008-2010
2011-2014

101 (32%)
99 (32%)
111 (36%)

54 (32%)
46 (28%)
67 (40%)

1.0 (ref)
0.91 (0.66-1.26)
1.08 (0.81-1.44)

0.54

–

–

Distance to transplant
centre (donor)
<20 km
20-39 km
40-89 km
90+ km

93 (30%)
78 (25%)
77 (25%)
63 (20%)

55 (33%)
37 (22%)
41 (25%)
34 (20%)

1.0 (ref)
0.87 (0.62-1.21)
0.94 (0.68-1.29)
0.94 (0.67-1.33)

0.87

–

–

Distance to transplant
centre (recipient)
<20 km
83 (27%)
39 (23%)
1.0 (ref)
0.65
–
–
20-39 km
89 (29%)
43 (26%)
1.02 (0.71-1.46)
40-89 km
64 (20%)
40 (24%)
1.20 (0.84-1.72)
90+ km
74 (24%)
44 (27%)
1.17 (0.82-1.65)
a RR (risk ratio) estimated using modified Poisson regression (Poisson distribution, log link, robust standard error
estimation). A risk ratio greater than 1.0 refers to a higher risk of starting dialysis (a potential pre-emptive transplant lost).
b adjusted for donor sex and donor income quintile, and clustering by transplant centre
c risk ratio refers to 10-year increment
d categorized into fifths of median neighbourhood income from the 2006 Canada Census
e calculated using CKD-EPI equation (mL/min/1.73 m2). Clinical cut-points used
f calculated using CKD-EPI equation (mL/min/1.73 m2), creatinine was measured at the time the donors’ evaluation started
(±3 months) or at the time of recipient referral (±3 months). The RR corresponds to a 1 mL/min/1.73 m2 increment in
eGFR. Results were similar if categorized as 20+, 15-19, 10-14, and <10 mL/min/1.73 m2 (p=0.45 for eGFR at donor
evaluation start; p=0.06 for eGFR at recipient referral).
g calculated as the time from the donor evaluation start date until the recipient referral date. Negative values mean the
recipient was referred to the transplant centre before the donor evaluation started. Risk ratio reflects a 30-day increment.
h transplant centre codified for privacy
CI – confidence interval; N/A – not applicable (for recipient income quintile this is due to collinearity with donor income
quintile; for transplant centre, this variable is the clustering variable).; IHD/CAD – ischemic heart disease/coronary artery
disease
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8.3.4 Time to complete the living donor evaluation
The median total donor evaluation time among donors whose recipients were
transplanted pre-emptively was 10.6 (6.4, 21.6) months [mean 15.3 (12.0) months]. For
those who started dialysis during the evaluation, the median was twice as long: 22.4
(13.1, 38.7) months [mean 25.4 (14.0) months] (p<0.0001) (Figure 22). Similar results
were observed for the time until approval: respectively, median 9.13 (5.9, 20.2) months
[mean 14.3 (12.0) months] versus median 20.9 (11.7, 37.8) months [mean 24.2 (14.0)
months] (p<0.0001). In contrast, we did not observe a relationship with a prolonged time
to complete the major consultations with a higher likelihood of potential unrealized preemptive transplant: median 6.01 (1.77, 17.7) months [mean 11.0 (11.9) months] for preemptive transplants, median 6.47 (2.50, 15.8) months [mean 11.2 (11.4) months] for an
unrealized potential pre-emptive transplant (p=0.87).

Figure 22: Boxplots showing the distribution of donor evaluation times. The time to
complete the evaluation was defined as the period from evaluation start until
nephrectomy. Boxes represents interquartile ranges (25th to 75th percentile).
Horizontal lines indicate median (50th percentile). Circles represents means.
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Horizontal lines represent the upper fence (75th percentile plus 1.5× interquartile
range) and lower fence (25th percentile minus 1.5× interquartile range). Plus
symbols indicate points that fall outside the fence.

8.4 Discussion
To our knowledge no prior study has described recipient outcomes in the context of the
time to evaluate a living kidney donor candidate. To address this, we studied a group of
people across five transplant programs in Ontario, Canada for the period 2004 to 2014, all
who received living donor kidney transplants. We found that a third of persons not
receiving dialysis when their donor’s evaluation was well underway initiated dialysis
prior to receiving their living donor kidney transplant. This dialysis cost was $8.1 million
and 44/167 (26%) recipients initiated their dialysis urgently in hospital.
A recently published guideline in the United Kingdom has recommended that 50% of all
eligible recipients are transplanted preemptively, and that all donors are able to complete
their work-up in 18 weeks should they choose to do so.14 We agree with this and believe
that, for a healthy, motivated donor whose intended recipient has been cleared for
transplant, 4 months is sufficient to complete a thorough evaluation while providing
sufficient time for donor reflection. The time to complete the necessary nephrology,
surgery and psychosocial consultations therefore should not be measured on the order of
months and presents an opportunity for improvement. We are aware that some centers
(including ours) have transitioned towards scheduling these consults on the same day or
within 2 consecutive days of each other, particularly for donor candidates who live far
from the transplant center. There is some evidence to suggest that centers that conduct
same-day consults may have a faster time until approval (Chapter 6). There appeared to
be a fair amount of consistency on how Ontario transplant programs evaluate living
kidney donor candidates, which was evident when setting standards for the Canadian
national kidney paired donation program.16 However, operational decisions are made by
individual living donor programs, and there is currently no recommendation on the
timeliness of the evaluation.9 Thus, we do expect variability in pre-emptive
transplantation rates across transplant programs, much like variability in recipient referral
rates observed across dialysis centres.17 Some of this variability may be due to donor
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evaluation protocols at each program, and determining how protocols affect the
timeliness of the evaluation should be a focus of future work.
We believe these novel observations should be the focus of quality improvement
efforts.18 In the current study, we did not address the degree to which these dialysis starts
could have been prevented, nor did we have information on reasons for the length of the
evaluation for the donor or the intended recipient. Some of the delay in the donor
candidate evaluation process may be due to the unpredictable nature of kidney failure.
For example, it is possible the recipient’s health suddenly deteriorated, placing the living
donors’ evaluation on hold until the recipient was well enough after receiving dialysis to
receive a kidney transplant. This may avoid unnecessary donor work-up in case the
recipient is no longer eligible for transplantation or avoid expiration of some donor’s test
results until the recipient is eligible again. Conversely, deterioration of the recipient’s
health may result in an expedited living donor evaluation to transplant the intended
recipient before their health deteriorates further (i.e., before dialysis initiation, before
potential transplant ineligibility). Although the donor and recipient evaluations are mostly
independent, there is some communication that attempts to optimize coordination,
outcomes, resource utilization, and donor burden. Other reasons for delay may result
when more time is needed to complete a thorough evaluation, including initial test results
that required further investigation, clearance of the donor related to any pre-existing
comorbidity, or the requirement that some donor candidates change their lifestyle (e.g.,
lose weight or reduce their smoking).19,20 Delays due to these reasons are appropriate and
may be necessary to uphold the quality of the evaluation and the safety of donor
candidate approval. However, in this study the living donor evaluation was underway for
almost 10 months before 50% of the recipients in this group started dialysis, a sufficient
amount of time to complete an evaluation even in the presence of some delay. Moreover,
delays may stem from the donor or the intended recipient as they come to terms with
living donor kidney transplantation.21,22 Determining what factors are modifiable will be
critical to be able to modify them and reduce the proportion of recipients starting dialysis.
This study also has other important limitations that should be addressed in future studies.
First, the date of first contact and date of approval were obtained by proxy. While our
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estimates of the total evaluation time (which includes all the time until nephrectomy)
aligns with our clinical experience and is consistent with prior reports23, the validity of
this estimate needs to be substantiated using more accurate (and agreed-upon) start dates.
The date the living donor first contacted the transplant program was unavailable, but is
now being actively collected by Ontario transplant programs. The date of approval is
important because many factors can influence the time until donation even after the donor
has been approved to donate. Also, because evaluation practices in Ontario may differ
from those used in other regions, the time until approval may allow additional
comparisons to be made, and multiple metrics may be more informative than single
metrics in isolation. Second, only patients who received a living kidney donor transplant
were included in this study. It remains to be established whether improvements in the
time to evaluate donor candidates can prevent lost opportunity for living donor
transplants (e.g., due to competing events like intended recipient illness, death, or
deceased donor kidney transplantation)24,25 or influences candidates who drop out during
the evaluation process.18 Donor candidates who did not donate are not currently
identifiable from administrative datasets alone. Further, many data on recipient referral
dates were missing and we did not have information on when the intended recipient was
approved for transplantation. Finally, among recipients who had no relation to their
donors, we were unable to untangle the effects of non-directed anonymous donation
versus kidney paired donation.26,27
In our exploratory analysis, several characteristics were associated with a greater
likelihood of not realizing a potential pre-emptive living donor kidney transplant. Donors
who were female, non-white and lived in a low-income neighborhood were all less likely
to donate pre-emptively. These characteristics are all difficult or impossible to modify,
but understanding the mechanism may suggest areas where potential modifications may
be possible. We did find dialysis prior to transplant was more likely if the recipient was
referred with a lower eGFR and if there was a longer delay between the donor’s
evaluation start date and the date the transplant program subsequently received the
referral to begin the intended recipient’s evaluation. These suggest earlier recipient
referrals may prevent some recipients from starting dialysis. In Ontario, there is a
guideline for intended recipients to undergo several tests, including cardiac assessment
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organized by their nephrologist prior to submitting a referral package to a transplant
program for evaluation.28 Often, donor candidates contact transplant programs while this
pre-transplant-referral testing for their recipient is underway, but the transplant programs
usually do not advance the donor candidate evaluation until they receive a referral
package for the intended recipient (as is the general approach in Ontario). From one
perspective, it may not be worth while spending resources evaluating donors before their
intended recipient is referred because many of these recipients may not be eligible for
transplant or may never be referred, thereby wasting time and resources that could be
spent on other donor evaluations. On the other hand, the potential implications of a late
referral could at least partly be offset by a donor evaluation that is either quicker or starts
before the recipient is referred. If the recipient is never referred or is not a transplant
candidate, then this may result in some donor candidates pursuing non-directed donation
instead. There is clearly a trade-off here that should be studied, as this is a potentially
modifiable area for quality improvement. In this study we only reported data from five
transplant programs in Ontario; our impression is these programs are similar to others
throughout Canada, but we do not have data to corroborate this. We believe that this
metric (the proportion of potential pre-emptive transplants that were unrealized) should
be measured and reported by all programs nationally and internationally to facilitate
comparisons and quality improvement efforts.
In conclusion, by linking donor evaluation times with recipient outcomes, this study
raises the possibility of some modifiable adverse impact of a prolonged living donor
evaluation process. These effects might not only be restricted to recipient health
outcomes, but also may extend to the living donor’s experience and to healthcare costs
attributable to starting and/or maintaining dialysis until transplantation.29,30 These
findings inform future research and quality improvement activities that aim to help
patients with kidney failure improve their chances of realizing a pre-emptive kidney
transplant from a living donor.
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Chapter 9

9

Potential implications of a more timely living kidney
donor evaluation§§

9.1 Introduction
For eligible patients with end-stage kidney disease, living donor kidney transplantation
improves patient survival and quality of life and reduces healthcare costs compared to
maintenance dialysis.1–3 However, completing a living kidney donor evaluation according
to current standards takes time and effort.4 For many donor candidates and their intended
recipients, the time to complete this evaluation is currently too long, which may have
several unintended consequences for patients and the healthcare system. We have
illustrated these consequences in Figure 23 for different types of recipients, where the
black horizontal bars represent current living kidney donor candidate evaluation times
from start (subscript s) to finish (donation; subscript f). First, the potential recipient may
no longer be able to receive a transplant due to illness or death (Figure 23, patient af).5–9
Second, the recipient may remain on dialysis longer than otherwise necessary, which may
result in adverse outcomes following transplantation, reduced quality of life, ongoing risk
of complications related to dialysis, and higher healthcare costs (Figure 23, patient
bf).10,11 Third, the recipient may initiate dialysis before their donor is approved,
potentially jeopardizing the benefits of pre-emptive transplantation, reducing quality of
life, and increasing healthcare costs (Figure 23, patient cf).12 Finally, the recipient may
receive a kidney from a deceased donor, an organ that could have gone to another
recipient in need if the living donor transplant had been realized.6,13 A poorly timed or

§§

A version of this chapter has been published: Habbous S, McArthur E, Sarma S, Begen MA, Lam NN,
Manns B, Lentine KL, Dipchand C, Litchfield K, McKenzie S, Garg AX. “Potential implications of a more
timely living kidney donor evaluation”. Am J Transplant. 2018:18(11):2719-2729.
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prolonged living kidney donor evaluation can contribute to any of these adverse
outcomes.

Figure 23: Potential effects of a more efficient living kidney donor evaluation
process. Possible effects of a more efficient living donor evaluation (a’-d’) for different types of
potential recipients (a-d). Subscript s indicates the start of the living kidney donor candidate
evaluation and subscript f indicates when the evaluation is finished. Recipient “a” is receiving
maintenance dialysis when the living donor candidate evaluation begins and dies during the
evaluation without receiving a transplant. Recipient “b” is receiving maintenance dialysis when the
donor candidate evaluation begins and receives a living donor transplant. Recipient “c” is not
receiving maintenance dialysis and has a low estimated glomerular filtration rate when the donor
candidate evaluation begins, starts maintenance dialysis during the evaluation, and receives a living
donor transplant. Recipient “d” is not receiving maintenance dialysis and has a low estimated
glomerular filtration rate when the living donor candidate begins and receives a living donor
transplant at a time when they could have lived longer with their native kidneys prior to initiating
maintenance dialysis. For each of the potential recipients (a to d) the period from subscript “s” to
subscript “f” represents a current donor candidate evaluation time (black horizontal bars); the
period from subscript “s prime (s’)” to “f prime (f’)” represents a new shorter evaluative time (red
horizontal bars). A more efficient living donor evaluation is completed in a shorter time and is better
timed to promote optimal recipient outcomes (i.e., avoid dialysis or minimize the time spent on
dialysis). Transplants occurring at time-point af’ instead of af may prevent some deaths; transplants
occurring at time-point bf’ compared with bf will reduce the time the recipient spends on dialysis;
transplants occurring at time-point cf’ instead of cf may prevent some people from starting dialysis
altogether; evaluation df’ instead of df will reduce the amount of time the recipient lives with his/her
native kidney prior to renal replacement therapy. Note: this diagram is a generalized simplification
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by necessity. Individual recipients may progress differently and may die or receive dialysis (e.g. at a
time of developing acute kidney injury) at any time throughout the recipient’s kidney disease
progression.

The 2017 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline on
the Evaluation and Care of Living Kidney Donors recommends that transplant programs
“conduct as efficient a donor evaluation as possible, meeting the needs of donor
candidates, intended recipients and transplant programs.”4 However, this
recommendation remains ungraded because of insufficient evidence. In reality, the
definition of an “efficient” evaluation is subject to interpretation. We believe that an
efficient evaluation process is one that is completed in an appropriate time-frame (which
may depend on the donor and recipient candidates’ needs), achieves the best possible
outcomes for donors and recipients, and prudently uses healthcare resources.
In this study, we explored the potential effects of an earlier living donor evaluation
completion and donation date on recipient outcomes and healthcare costs attributable to
potentially preventable dialysis. We used current observed outcomes from Ontario,
Canada as the ‘base case’ scenario, and examined several “what if” scenarios for
comparison had the living donor transplant occurred earlier.

9.2 Methods
9.2.1 Setting and databases
Ontario is Canada’s largest province with a population of 13.6 million people; it has a
single-payer universal publicly funded healthcare system where healthcare encounters,
procedures and diagnoses are recorded for all Ontario citizens in large healthcare
databases. We used information held at the Institute for Clinical Evaluative Sciences
(ICES), which allowed linkage across multiple datasets in Ontario, Canada using a
unique identifier. All living kidney donors in Ontario were identified through a database
maintained by the provincial transplant agency Trillium Gift of Life Network.14 Using
physician billing codes from the Ontario Health Insurance Plan (OHIP) database, we
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estimated the date the donor candidate started the evaluation using a healthcare test
generally performed early in the living donor evaluation (described previously).12 The
physician claim database (OHIP) and the hospital-based Canadian Institute for Health
Information (CIHI) Same-Day Surgery and Discharge Abstract databases were used to
identify the date the recipient initiated dialysis.12 The study was approved by the research
ethics board at Sunnybrook Health Sciences Centre, Toronto, Canada.

9.2.2 Patient populations
All living donors in this study were Ontario residents for at least 2 years before donation,
started the living donor evaluation on April 1, 2006 or later, and ultimately donated
before April 1, 2014. They were divided into three mutually exclusive cohorts based on
the following information at the time when the living donor evaluation started: 1) donors
whose recipients were on dialysis (patient bs in Figure 23); 2) recipients who theoretically
could have been transplanted pre-emptively (were free from dialysis for at least 3 months
after the donor started their evaluation) but started dialysis before transplant (patient cs in
Figure 23); and 3) recipients who were transplanted pre-emptively (patient ds in Figure
23).12,15 Classifying the cohort in this way enabled the outcomes to be evaluated
separately for each cohort (outcomes described below).
We did not have data on donor candidates who did not ultimately donate to their intended
recipient using administrative databases at ICES. Instead, we conducted detailed medical
chart review for all living donor candidates who contacted the living donor program at
the London Health Sciences Centre in London, Ontario between 2013 and 2016 (medical
records were more complete during this time; Chapter 7). Donor candidate evaluation
start date was defined as the date a detailed medical-social questionnaire completed by
the candidate was reviewed by the program. If this date was unavailable, the date the
candidate first contacted the program was used. The date the evaluation ended was the
date the intended recipient died (patient as in Figure 23), was deemed no longer eligible
for transplant, or received a deceased donor kidney transplant. To be included, the living
donor candidate must have had at least 3 months of active evaluation (with any lab tests
performed after review of the initial medical-social questionnaire). Institutional ethics
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approval was obtained from Lawson Health Research Institute in London, Ontario
(Appendix K).

9.2.3 Outcomes
This study was undertaken from the perspective of the Ontario government, which
operates under a single-payer universal public healthcare system. Outcome data were
based on four domains: time, pre-emptive transplantation, healthcare costs, and available
additional kidneys for transplantation (summarized in Table 21 and described below). We
defined the total evaluation time as the time the donor first started the evaluation until
donation. We estimated the proportion of potential pre-emptive transplants lost as the
proportion of recipients who were not on dialysis when the donor evaluation was
underway for at least three months (the denominator) but started dialysis before
transplant (the numerator). We estimated the total recipient dialysis costs for recipients
from the time the donor started the evaluation until donation (costs described below). The
number of potential transplants lost was calculated as the number of times the intended
recipient died, became ineligible for transplant, or received a deceased donor kidney
transplant despite having at least one living donor candidate whose evaluation was
underway for at least three months. Since the number of potential transplants lost was
obtained from the medical records of a subset of all donors in Ontario, we extrapolated
these estimates to the entire Ontario population during the study period. Outcomes were
presented using the mean (standard deviation, SD), median (25th, 75th percentile), and
proportion (95% confidence interval), where appropriate.
Table 21: Definition of Outcomes
Term

Applied to

Definition

Domain: Time
Total evaluation time

base case

the time the donor first started the evaluation until
donation

total time recovered

scenario-specific

the difference in the total evaluation time between
the scenario and the base case for all donors

total time lost

scenario-specific

the difference in the total evaluation time between
the scenario and the base case for donors whose
recipients were transplanted pre-emptively in the
base case

dialysis time saved

scenario-specific

the difference in the total evaluation time between
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the scenario and the base case for donors whose
recipients were already on dialysis when their living
donor started the evaluation
Domain: Pre-emptive transplants
Potential pre-emptive
base case
transplants

recipients who were not on dialysis when the donor
first started the evaluation for at least three months

proportion of potential
pre-emptive transplants
lost

scenario-specific

the proportion of potential pre-emptive transplants
that did not occur (the recipient started dialysis
before transplant)

number of recipients
saved from starting
dialysis

scenario-specific

the difference in the number of potential pre-emptive
transplants and the number of potential pre-emptive
transplants lost

Domain: Healthcare costs
Total recipient dialysis
base case
costs
total recipient dialysis
costs saved

scenario-specific

Domain: Number of transplants
Number of living donor
base case
transplants lost

number of living donor
transplants gained

scenario-specific

the sum of all recipient dialysis-related costs to the
healthcare system
the difference in the total recipient dialysis costs
between the scenario and the base case

the number of recipients who died or were no longer
eligible to receive a transplant or who received a
deceased donor kidney transplant despite having a
living donor whose evaluation was underway for at
least three months
the difference in the number of transplants lost

We devised 13 hypothetical scenarios (described below) where the transplant date would
occur at an earlier date than the actual transplant date. Using Figure 23 to illustrate, a
recipient who was actually transplanted at time-point bf could instead have received a
transplant at time-point bf’. Using this new transplant date, we recalculated the outcomes
and compared them to the base case. We calculated the total time recovered as the
difference in the total evaluation time [(bf+cf+df)-(bf’+cf’+df’); the length of dark
horizontal bars minus the length of light horizontal bars in Figure 23]. The total time lost
was calculated as a subset of the total time recovered, restricted only to donors who
donated pre-emptively (df-df’ in Figure 23). This represents a lost period of survival only
with native kidney function prior to initiating dialysis due to an earlier transplant. We
calculated the dialysis time saved as a subset of the total time recovered, restricted only to
donors who were already on dialysis when the evaluation started (bf-bf’ in Figure 23). We
determined the number of recipients saved from starting dialysis as the difference in the

145

number of pre-emptive transplant failures (patients whose evaluation times corresponded
to category cf-cf’ in Figure 23). We estimated the total recipient dialysis costs saved as
the differences in accrued dialysis costs over the period [(bf+cf)-(bf’+cf’)] in Figure 23.
Finally, we estimated the number of transplants gained as the difference in the number of
transplants lost due to intended recipient death, loss of transplant eligibility, or receipt of
a deceased donor kidney transplant. For donor candidates who did not donate, we
assumed their evaluation would have been completed and they would have donated in a
time corresponding to each scenario’s median total evaluation time.

9.2.4 Scenarios
In scenarios 1-5, the time between consecutive healthcare visits related to the living
donor evaluation process were changed, which is shown pictorially in Figure 24. This
was done using a longitudinal dataset with each healthcare visit for each donor on a
separate row, sorted by date.12 We used the 25th and 50th percentile of the distribution for
all time-between-test transitions for Scenarios 1 and 2, respectively. For example, if the
median (25th, 75th percentile) time to transition from a nephrology consult to a surgical
consult was 23 (3, 66) days, then for all donors who had this specific chronological
transition, we replaced their actual observed time with 25th and 50th percentile values
(e.g., 3 days for scenario 1 and 23 days for scenario 2) and re-calculated the new
(hypothetical) transplant date (Figure 24A). The distribution of some of these transition
times is provided in Appendix L.
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Figure 24: Altering the timeliness of the living kidney donor evaluation in
hypothetical scenarios

147

We replaced the time between tests with a zero if two tests were to be modeled to occur
on the same day (scenarios 3-5; Figure 24B). For example, if a psychosocial evaluation
was modeled to occur on the same day as a nephrology consult, then the actual transition
time for all donors who had these two visits in succession would be changed to zero
(regardless of the order of tests). This occurred in 189+65=254 instances (Appendix L). If
a test was completely removed (nuclear renogram in scenario 6), we replaced the time
between this test and any other test (regardless of the order of tests) with a zero
(Appendix L).
In scenarios 7-10, we shifted the transplant date to occur 1-, 2-, 3-, and 6-months earlier
(Figure 24C). The resulting transplant dates reflect any combination of a quicker
evaluation and/or an evaluation that simply started earlier. In a sensitivity analysis, the 3month reduction in evaluation time was sampled from a gamma distribution (mean 3, SD
1) instead of being applied as a fixed value.
In Scenarios 11-13, we determined the hypothetical transplant date resulting from a
proportionate reduction in the total time to complete the evaluation (10%, 25%, and 50%
faster), setting a minimum evaluation time of three months (Figure 24D). In sensitivity
analysis, the 25% reduction in evaluation time was sampled from a probability
distribution [beta (mean 0.25, SD 0.02)] instead of being applied as a fixed value.

9.2.5 Costs
The ICES case-costing macro was used to tabulate recipient dialysis costs starting from
April 1, 2006, which included various facility costs associated with dialysis treatment
(i.e., dialysate, vascular access, nursing time) from the National Ambulatory Care
Reporting System (NACRS).16 The macro uses resource intensity weights multiplied by
the cost per weighted case to derive the cost per case for all healthcare in a hospital
setting.16 We combined these estimates with physician claim codes and dialysis facility
costs to obtain a final estimate of recipient dialysis costs.12 Costs were estimated from the
perspective of the provincial government and presented in $CAD 2016. We did not assess
the costs related to the evaluation or transplant surgery, as we expect those to accrue to
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all patients who receive a transplant (rather it is the timing of that transplant that affects
the costs related to dialysis waiting for the transplant to occur).

9.3 Results
9.3.1 Patient population
We used data on 877 living donors who began their evaluation after March 2006: 497
(57%) of recipients were already on dialysis when the living donor started the evaluation
(cohort bs in Figure 23), 360 (41%) were potential pre-emptive transplants (cohorts cs+ds
in Figure 23). We excluded 20 (2%) living donors who could not be classified (i.e., valid
linkage to recipient was not available). A total of 19 potential transplants lost were
identified from chart review over a 3-year period (6 corresponded to cohort as in Figure
23; 13 received a deceased donor kidney transplant).

9.3.2 The base case
The total time to complete the donor candidate evaluation was a median of 10.5 (6.93,
17.7) months [mean 14.2 (10.6) months], 122/360 (34%) recipients were potential preemptive transplants lost, and recipient dialysis costs were a median of $17,162 ($33,
$66,054) per recipient [mean $44,065 (SD $61,990)] (Table 2). The 122 recipients who
were potential pre-emptive transplants lost started dialysis a median 7.8 (5.0, 15.4)
months [mean 11.9 (9.9); minimum 3.0 months] after their donor started the evaluation
(Figure 25A) and were transplanted a median 8.7 (4.0, 16.3) months [mean 11.6 (10.1)
months; minimum 5 days] after dialysis started (Figure 25B). Thirty percent (36/122)
recipients started dialysis urgently in hospital. The total evaluation time for the 20 donor
candidates who did not donate (one recipient had two candidates being evaluated) was a
mean 4.8 (SD 7.9) and a median 8.0 (4.4, 11.3) months. Extrapolated to the whole
province over the 8-year study period, 172 potential transplants were lost because the
intended recipient died before receiving the transplant or lost transplant eligibility, and
372 potential recipients received a deceased donor kidney transplant.
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Figure 25: Time until dialysis since the donor started the evaluation (A); and time
until transplant after dialysis started among recipients who could have been
transplanted preemptively (B)

9.3.3 Scenarios
The mean time recovered, mean time lost, mean dialysis time saved, mean dialysis costs
saved, and mean costs saved per month saved are presented in Table 22 for each scenario
compared to the base case. The number of potential pre-emptive transplant failures saved
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and number of living donor transplants gained are presented in Table 23 for each scenario
compared to the base case.
The most effective scenario (from our list) in terms of absolute gains (differences in
outcomes) resulted when the transition times between all tests took on the value of the
25th percentile. This resulted in a median total evaluation time of 2.2 months (a very
optimistic scenario). More realistic scenarios reduced the total evaluation time by half
(scenarios 2, 10, and 13). These scenarios saved a mean $22,000-$26,000 in recipient
dialysis costs per recipient, prevented a minimum of 45 recipients from potentially
starting dialysis altogether during the study period (>5 per year), could have given at least
86 intended recipients a transplant they otherwise did not receive (>11 per year), and
introduced an additional 286 (>35 per year) kidneys to the organ donation pool.
The most effective scenarios in terms of relative gains (cost savings per month saved)
resulted when the evaluation time was shortened towards the end of the evaluation time –
the time during which more intended recipients are on dialysis. The mean intended
recipient dialysis costs saved per month recovered was highest if the transplant occurred
one month sooner ($4,116 per month recovered). This was associated with 0.27 (SD
0.45) months of native kidney time foregone, 0.58 (SD 0.50) months of dialysis time
averted, seven recipients potentially avoiding dialysis altogether, and savings of $4,116
(SD $4,642) in dialysis costs per recipient. This could have given at least 58 intended
recipients a transplant they otherwise did not receive (7.2 per year), and introduced an
additional 172 kidneys to the organ donation pool (21.4 per year). This was followed by
only slightly reduced marginal gains if the transplant occurred two months earlier
($4,011/month recovered) and three months earlier ($4,018/month recovered). A 10%
reduction in the time to complete the evaluation was more effective than performing the
transplant one month earlier since a greater absolute reduction took place for longer
evaluation times (those that are more likely to accrue more costs). A 10% reduction in the
time to complete the evaluation saved $5,689 (SD $8,636) in recipient dialysis costs, but
was more wasteful than performing the transplant one month earlier in terms of
performing a transplant when a patient’s native kidney function was sufficient not to
require dialysis initiation.
151

Table 22: Evaluation time, dialysis time, and cost savings by scenario

Total time
recovered
Mean (SD)

Time lost
Mean
(SD)1

Dialysis
time saved
Mean
(SD)3

Total time
until
transplant
Median (IQR)

Cost saved
Mean (SD)

Total Cost
Median (IQR)

recipient
dialysis costs
saved per
month
recovered
Mean (SD)

b,c,d

d

b

b,c,d

b,c,d

b,c,d

b,c,d

Recipient dialysis costs (2013
$CAD) (n=857)2

Total time (months) (n=877)
Description of scenario

Corresponding cohort in Figure 23
–

Observed transition times (base case)

–

–

–

10.5 (6.93-17.7)

–

$17,162 ($332-$66,054)

–

1.

Reduce/increase all transition times to the first
quartile (best-case scenario)

11.6 (9.71)

3.18 (7.56)

5.31 (7.08)

2.17 (1.54-3.24)

$37,092 ($54,764)

$1,079 ($0-$10,719)

$3,587 ($4,152)

2.

Reduce/increase all transition times to the median
transition-specific transition time

7.84 (8.58)

2.24 (6.05)

3.35 (5.62)

5.13 (3.70-7.77)

$25,951 ($44,031)

$3,818 ($0-$29,163)

$3,420 ($4,319)

3.

Psychosocial and nephrology consults done on the
same day

0.09 (0.85)

0.02 (0.23)

0.03 (0.24)

10.5 (6.93-17.7)

$241 ($2,266)

$17,038 ($262-$66,054)

$2,922 ($3,823)

4.

Psychosocial, nephrology, and surgical consults
done on the same day

0.65 (1.65)

0.16 (0.74)

0.34 (1.08)

9.95 (6.14-17.2)

$2,534 ($8,739)

$15,307 ($0-$61,846)

$3,580 ($4,688)

5.

Reduce time to see a cardiologist to zero (if
occurred after a nephrology consult)

0.06 (0.66)

0.03 (0.45)

0.03 (0.45)

10.5 (6.93-17.7)

$144 ($1,790)

$17,170 ($271-$65,571)

$3,063 ($4,314)

6.

Remove nuclear renograms from the evaluation
process

0.55 (1.21)

0.12 (0.4)

0.29 (0.70)

10.2 (6.93-17.0)

$2,121 ($6,813)

$16,501 ($0-$61,846)

$3,451 ($4,389)

7.

Overall reduction by 1 month

1.02 (0)

0.27 (0.45)

0.58 (0.50)

9.49 (5.91-16.7)

$4,116 ($4,642)

$14,299 ($0-$58,890)

$4,116 ($4,642)

8.

Overall reduction by 2 months

2.00 (0)

0.54 (0.89)

1.14 (0.99)

8.51 (4.93-15.7)

$8,021 ($9,093)

$10,837 ($0-$50,764)

$4,011 ($4,547)

9.

Overall reduction by 3 months

3.02 (0)

0.81 (1.34)

1.71 (1.50)

7.49 (3.91-14.7)

$12,055 ($13,594)

$7,490 ($0-$43,310)

$4,018 ($4,531)

2.92 (1.94)

0.81 (1.66)

1.66 (2.05)

7.80 (4.06, 15.0)

$9,533 (14,094)

$10,609 ($0, $45,836)

$3,594 (4,209)

6.01 (0)

1.62 (2.67)

3.41 (2.98)

4.50 (0.92-11.7)

$22,266 ($25,036)

$1,214 ($0-$22,006)

$3,711 ($4,173)

11. Reduction by 10%

1.41 (1.09)

0.38 (0.89)

0.67 (0.84)

9.46 (6.21-15.9)

$5,689 ($8,636)

$14,421 ($0-$56,364)

$3,954 ($4,657)

12. Reduction by 25%

3.52 (2.69)

0.96 (2.21)

1.66 (2.09)

7.89 (5.19-13.2)

$13,617 ($20,377)

$8,648 ($0-$44,389)

$3,833 ($4,485)

3.62 (3.94)

1.00 (2.76)

1.69 (2.57)

7.71 (5.05, 12.9)

$12,835 ($21,768)

$8,379 ($0-$43,201)

$3,795 ($4,430)

9a. Average reduction by 3 months
10. Overall reduction by 6 months

12a. Average reduction by 25%

4

4

13. Reduction by 50%
6.97 (5.43)
1.90 (4.40)
3.26 (4.17)
5.26 (3.45-8.84)
$24,823 ($35,424)
$4,313 ($0-$28,546)
$3,680 ($4,568)
CI – confidence interval; NS – not stated to comply with privacy regulations that limit reporting a small number of observations; IQR – interquartile range (25th-75th percentile); time was measured in
months, and costs presented in 2016 $CAD
1
restricted to recipients who were not on dialysis within 3 months of when the donor began the evaluation
2
restricted to recipients with valid identification number and complete costing data during the evaluation period
3
restricted to those who were already on dialysis
4
Reduction was modeled by randomly drawing from a distribution to allow for random variability. The 3 months reduction was sampled from a gamma distribution parametrized with a mean of 3
months and a standard deviation of 1 month; the 25% reduction was modeled using a beta distribution with a mean 0.25 and standard deviation 0.02. The number of living donor transplants gained was
not calculated due to small sample for sampling and extrapolation
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Table 23: Number of dialysis starts and missed opportunities for living donor transplant by scenario
Potential pre-emptive
transplants lost (n=360)1
Description of scenario

Number
saved

Number of living donor
transplants gained (N=19)2

Proportion lost (95%
CI)

recipient
death or
illness
(n=6)

deceased donor
transplant
(n=13)

Corresponding cohort in Figure 23

c

c

a

a,b,c,d

–

Observed transition times (base case)

–

33.9% (29.0-38.8%)

–

–

1.

Reduce/increase all transition times to the first quartile (best-case scenario)

111

3.1% (1.3-4.8%)

172

372

2.

Reduce/increase all transition times to the median transition-specific transition
time

75

13.1% (9.6-16.5%)

86

286

3.

Psychosocial and nephrology consults done on the same day

<6

NS

58

115

4.

Psychosocial, nephrology, and surgical consults done on the same day

8

31.7% (26.9-36.5%)

58

143

5.

Reduce time to see a cardiologist to zero (if occurred after a nephrology consult)

0

33.9% (29.0-38.8%)

58

115

6.

Remove nuclear renograms from the evaluation process

<6

NS

58

115

7.

Overall reduction by 1 month

7

31.9% (27.1-36.8%)

58

172

8.

Overall reduction by 2 months

15

29.7% (25.0-34.4%)

58

200

9.

Overall reduction by 3 months

21

28.1% (23.4-32.7%)

86

258

21

28.1% (23.4-32.7%)

–

–

10. Overall reduction by 6 months

46

21.1% (16.9-25.3%)

115

286

11. Reduction by 10%

12

30.6% (25.8-35.3%)

58

172

12. Reduction by 25%

29

25.8% (21.3-30.4%)

86

200

30

25.6% (21.0-30.1%)

–

–

62

16.7% (12.8-20.5%)

86

286

9a. Average reduction by 3 months

12a. Average reduction by 25%
13. Reduction by 50%

3

3

CI – confidence interval; NS – not stated to comply with privacy regulations that limit reporting a small number of observations; IQR – interquartile range (25th-75th
percentile); time was measured in months, and costs presented in 2016 $CAD
1
restricted to recipients who were not on dialysis within 3 months of when the donor began the evaluation
2
between April 2004 and March 2014, LHSC performed 7% of the province’s transplants. If X transplants were lost between 2013 and 2016 (4 years), then we expect
X*8/4 transplants were lost over the 8-year study period. This was divided by 0.07 (7%) to extrapolate the total number of transplants lost over the study period in the
entire province.
3
Reduction was modeled by randomly drawing from a distribution to allow for random variability. The 3 months reduction was sampled from a gamma distribution
parametrized with a mean of 3 months and a standard deviation of 1 month; the 25% reduction was modeled using a beta distribution with a mean 0.25 and standard
deviation 0.02. The number of living donor transplants gained was not calculated due to small sample for sampling and extrapolation
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9.4 Discussion
In this study, we project that a transplant occurring on average six weeks earlier (i.e., a
10% faster evaluation time) would result in average cost savings of $5,689 dialysis costs
per recipient. Such an improvement would reduce the current median living kidney donor
evaluation time from 10.5 to 9.5 months – a duration still believed by many to be too
long.17 For the approximately 220 living donor kidney transplants that occur every year in
Ontario, shortening the evaluation time by 10% translates to an annual cost savings of at
least $1.3M due to averted dialysis costs. In addition, up to 29 intended recipients each
year [(58+172)/8] could have received a transplant they otherwise did not receive (a
29/220=13% increase), adding an average of $40,000 in cost savings each year over the
lifetime of the transplant.18 By starting the evaluation earlier, we would expect even
greater gains. For instance, if a transplant occurred on average only three months sooner,
we would expect at least $2.7M in cost savings in Ontario every year. Furthermore,
avoiding or shortening dialysis time for recipients is expected to improve recipient health
outcomes. Thus, there is much to be gained from improving the efficiency of the living
kidney donor candidate evaluation process in beyond prompting earlier recipient
referrals, both of which have been recognized as significant barriers to optimal living
donor kidney transplantation.3,12,15,19,20
Where possible, pre-emptive kidney transplantation is the best treatment option for many
patients with failing kidneys. Over the last decade, the proportion of kidney transplants
that were pre-emptive increased to about one-third of all living donor transplants in the
United States.21,22 Despite this, pre-emptive transplantation only accounts for 3% of the
initial renal replacement treatment modality for all new cases of end-stage kidney disease
in Canada, an estimate that has remained stable over the last decade (Chapter 1).23
Inefficiencies in pre-transplant living kidney donor evaluation processes (prolonged
evaluation times, late recipient referrals) can result in wasted opportunities for preemptive transplantation, which may result in worse survival post-transplant and higher
costs and complications due to dialysis initiation.12,24,25 Evidence also suggests that
dialysis onset further delays the living donor evaluation.15 For patients with kidney
failure who are already on dialysis, every additional month on dialysis increases the risk
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of illness or death.26,27 Moreover, patients live with a poorer quality of life.28 Thus, an
earlier transplant is better for patients, healthcare providers, and the healthcare system.
There are many barriers to living donor kidney transplantation. Inefficient living donor
candidate and intended recipient evaluations should not be among them. These are often
healthcare systems-level barriers that require healthcare systems-level solutions. For
example, transplant education at dialysis centres or interdisciplinary chronic kidney
disease clinics is not standardized and healthcare professionals are often uninformed on
the benefits of living donor transplantation.29–31 Although transplantation may not be the
appropriate treatment option for all patients, all transplant-eligible patients should be
provided the opportunity for high-quality ongoing education, and the nature of this
education should be documented. Another issue is the possible incentive that some forprofit dialysis facilities may enjoy by continuing to treat patients with dialysis.32–35
Although this situation is absent in a Canadian setting where there is universal healthcare,
there are additional complexities that may exist even after a transplant referral occurs.36,37
Finally, the wait time to see a nephrologist in Canada can range from 2-8 months.38–40
This wait time may be longer for living donor candidates, who are essentially seeking an
elective procedure (not urgent).
Although we used real data in our models and our conclusions are tenable, efforts to
reduce the duration of living donor candidate evaluations may not translate to an earlier
transplant for all recipients for a variety of reasons. The pace of the living donor
evaluation may be titrated to correspond to the status of the intended recipient (i.e., the
intended recipient must lose weight or clear an infection before being approved as a
transplant candidate; the recipient’s kidney function is sufficiently high to delay the
donor candidate evaluation). Moreover, many donor candidates schedule a donation date
to coincide with a time of the year when their responsibilities (i.e., workload, childcare)
can be managed by others. Some donors may also appreciate the time to contemplate
their decision and may not want a quicker evaluation for personal or health-related
reasons. However, a quicker evaluation should nevertheless be an option for those who
want one. Future efforts should focus on defining and capturing key dates in the
evaluation process, including the evaluation start and approval dates for both donor and
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recipient candidates, determining what factors are modifiable, and implementing changes
at the health system level.
Given the nature of this study, we had to make several assumptions that may limit the
accuracy of the estimates. First, the date the donor started the evaluation was obtained by
proxy using healthcare services utilized over a 4-year time-frame before donation.12
Second, the time between tests was used to model some scenarios, but the presence of a
temporally intervening healthcare procedure would have prevented the scenario from
being modeled accurately, thereby underestimating the effects of Scenarios 3-5. Third,
only persons who participated in a living kidney donor transplant surgery were available
in most of our databases. Until recently, most programs in Ontario did not systematically
capture and report data on living donor candidates (i.e., those who do not donate). Thus,
our provincial data sources did not capture donor candidate records for intended
recipients who died prior to ever receiving their transplant or who became ill and
ineligible to receive a transplant (patient as in Figure 23), or who received a deceased
donor transplant after the living donors’ evaluation started. To supplement our study data,
we conducted a detailed medical chart review for all donor candidates who contacted one
living donor transplant program in Ontario. Although we used medical chart review on all
donor candidates at this centre to extrapolate the findings to the entire province, the
number of events were small. We also assumed these estimates were generalizable, did
not change over the study period, and that all candidates would have donated. Finally, the
cost savings and improvement in outcomes presented in this report are likely
underestimates because reductions in morbidity attributable to chronic kidney disease and
dialysis are difficult to estimate (i.e., infection, hyperparathyroidism, anemia,
hospitalizations, procedural related complications).
In conclusion, a more efficient living kidney donor evaluation process is expected to
result in better recipient outcomes, more living donor transplants, and substantial cost
savings to the healthcare system.3,41 A small reduction in the waiting time to receive a
transplant can have a large impact on the number of pre-emptive transplants gained and
total recipient dialysis costs saved. This vitally important healthcare process will benefit
from quality improvement efforts.
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Chapter 10

10 Health care costs for the evaluation, surgery, and
follow-up care of living kidney donors***
10.1 Introduction
Patients with kidney failure live longer with a better quality of life after kidney
transplantation when compared to maintenance dialysis.1,2 Recipient outcomes are further
improved when the transplant comes from a living rather than deceased donor.3–5 As
shown in modeling studies, an increase in the rate of living donor kidney transplantation
is an effective strategy to ameliorate the burden of kidney disease, and remains costeffective even if donors are paid.6–17 Additional health care resources, however, are
needed to evaluate, perform donor nephrectomy, and follow living kidney donors after
donation.18,19
From a health system payer perspective, an accurate estimate of the costs of living kidney
donation is important for several reasons. First, a better understanding of the true health
care costs of donation would improve estimates regarding incremental costs and benefits
of living donor kidney transplantation. Second, as countries across the globe seek to
better address the demand for transplantable kidneys, a thorough understanding of
donation-related health care costs will help project the anticipated expenses that could
occur with initiatives aimed at increasing rates of living kidney donation. Third, detailed
cost estimates would better inform the funding allocated to hospitals or clinics which
provide the service. Finally, a better understanding of current costs may serve as an

***

A version of this chapter has been published: Habbous S, Sarma S, Barnieh L, McArthur E,
Klarenbach S, Manns B, Begen MA, Lentine KL, Garg AX. “Healthcare costs for the evaluation, surgery,
and follow-up care of living kidney donors”. Transplantation. 2018;102(8):1367-1374.
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important baseline measure for future efforts to improve the efficiency and cost of the
donor candidate evaluation.
Many prior studies only considered the surgical costs of donation and did not
fully account for the additional costs of the evaluation and follow-up care of living
kidney donors.9,16 Studies that did include donor evaluation costs used pre-specified
donor evaluation protocols of minimum required testing.6,7,15 This method of costing
underestimates the cost of donation because donors may require repeat tests, additional
tests due to incidental findings, and tests that are not standard to donor evaluation
protocols but are needed because of the donor’s personal medical history.
To contribute to the literature, we conducted this detailed costing study in a
universal health care system where most health care resource use and costs are incurred
by a single payer. We investigated donor costs in three time-periods: the pre-donation
evaluation period (beginning of the donor evaluation until donation), the perioperative
period [the nephrectomy and the perioperative period (30 days post-donation)] and the
follow-up period (after the perioperative period until one year following donation).

10.2 Methods
10.2.1

Design, population and setting

This was a retrospective analysis of living kidney donors who donated at one of Ontario’s
five transplant centres between April 1, 2004 and March 31, 2014.20,21 Ontario residents
have access to universal health insurance coverage through a public payer system, which
includes all aspects of pre- and post-donation care. All living donors in this study were
required to be Ontario residents for at least two years prior to donation. As per donor
evaluation criteria, all donors had at least one nephrology consult and one surgery consult
during the evaluation period (described in detail previously21).
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10.2.2

Costing periods

The cost of living kidney donation was estimated separately for three time periods,
corresponding to three phases of the donation process: 1) the evaluation period (from the
date the donor started the evaluation until the day before donation), which captures costs
associated with the living donor assessment; 2) the perioperative period (from the day of
nephrectomy to 30 days post-donation), which captures costs related to the donor surgery,
hospitalizations, and any possible perioperative complications (including early
readmissions); and 3) the one-year follow-up period (from day 31 post-donation until 1year post-donation), which includes costs related to longer-term or ongoing
complications and any routine plus as-needed follow-up care.

10.2.3

Data collection and costing sources

All costs were measured from the perspective of the Canadian payer. Donors were
identified from the Trillium Gift of Life Network (TGLN) database through the Institute
for Clinical Evaluative Sciences (ICES).20 Several health administrative datasets at ICES
were used to link the data using unique encoded identifiers. These databases included the
Ontario Health Insurance Plan (OHIP), which captures all primary care and specialist
physician billings, Canadian Institute for Health Information (CIHI) Same-Day Surgery
and Discharge Abstract Database (hospitalizations); National Ambulatory Care Reporting
System (emergency visits); Ontario Drug Benefits (prescription drug costs for citizens 65
years of age and older or receiving social assistance); National Rehabilitation Services;
Complex and Continuing Care; and Long-Term Care. The ICES-derived costing method
was used to obtain all costs from the various linked databases for a specified time-period
(inpatient and outpatient costs for the time periods described above). In addition to
individual billing, this costing method uses resource intensity weights multiplied by the
cost per weighted case to derive the cost per case.22

10.2.4

Cost estimation

We derived the frequency of each health care procedure received and calculated the cost
of each procedure using the physician claims database codes deemed relevant to the
donor evaluation.21 These costs were totaled for each donor’s evaluation period (we
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restricted this to the evaluation period only as we could not pre-specify relevant health
care use during the perioperative and follow-up periods). To estimate the total cost of
donation, all costs (instead of pre-specified procedures) from the above databases were
summed over each costing period. By including all costs accrued by the living donor,
there is risk that some costs may have accrued for reasons unrelated to the evaluation
(i.e., consulting the general physician for a non-specific viral illness). To account for this
potential over-estimation of costs, a baseline non-donation-related health care cost was
estimated using a cohort of matched healthy non-donor controls (i.e., individuals with
similar indicators of baseline health as the donors; described in the Matching section
below). To estimate the cost of donation with the baseline cost (the cost of the controls)
removed, we developed a series of regression models (described in Statistical Methods
below).

10.2.5

Matching

All Ontario residents were considered possible controls if they were alive, <80 years of
age as of April 1, 2006, were not missing sex, and had no prior history of living kidney
donation themselves. The eligible 17,092,895 control candidates were assigned a random
date (a fake “donation date”) to match the distribution of donation dates observed in the
donors. Controls who were >79 years or died before their assigned donation date were
excluded (ineligible to donate), resulting in 16,640,699 potential controls. Since donors
are a highly selected healthy subset of the population, controls with any diagnostic,
procedural, or intervention codes which suggested ill health or a contraindication to
donation were excluded. These included codes related to dialysis, cancer, cardiovascular
disease, human immunodeficiency virus, nephrectomy, renal biopsy, pulmonary disease,
liver disease, systemic lupus erythematosus, rheumatoid arthritis, genitourinary disease,
or alcoholism (full list of codes in Appendix M).
Potential controls were excluded if they were not Ontario residents for at least 2
years prior to their donation date or gave birth between 2 months prior and 6 months after
the donation date (similar exclusions were previously applied to the donors). A total of
6,151,385 potential controls and 1,214 donors were available for matching (not missing
matching covariates). Matching was done by donation date (±6 months), age at donation
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date (±2 years), sex, rural/urban status, and neighbourhood-level income quintile. Four
controls were matched to each donor.

10.2.6

Statistical methods

To estimate the cost of living donation, we used a series of multivariable regression
models applied to the matched cohort and conducted various statistical tests to assess the
fit of each model (described below). This approach is recommended for cost data because
of its positive and skewed distribution.23,24 Covariates included an indicator for
donor/control status, age at the donation date, sex, urban/rural status, the year of donation
(2003-2007, 2008-2010, and 2011-2014), neighbourhood-level income quintile, and the
total evaluation time in months. The effect of a variable on costs was reported using the
marginal effects post-estimation procedure in STATA, which uses the method of recycled
predictions to provide estimates of mean cost. We were interested in the marginal effect
of the dichotomous variable donor/control status, which represents the additional cost
associated with living kidney donors (compared to controls). The marginal effect of any
other covariate is interpreted as the incremental cost associated with a change in one unit
of that covariate, holding the other factors constant. To assess whether the cost for donors
was different from controls across levels of a covariate, we introduced an interaction term
with the donor indicator in a separate model. A significant interaction term (pint<0.05)
means that the cost of the donor is significantly different from controls across levels of
the covariate included in the interaction. In the case where the predictor is only present in
donors (i.e., recipient’s dialysis status21,25, transplant centre), then the analysis is
automatically restricted to donors only and the marginal effect is reported (pint is not
available).
We tested and compared the fit of ordinary least squares (OLS) regression on
untransformed costs, log-transformed costs, and square-root-transformed costs. Nonlinear models included the exponential conditional means model and Poisson regression
with maximum likelihood estimation. We fit a variety of generalized linear models
(GLMs) using a combination of link functions (identity, square-root, log) and
distributional families (Gaussian, gamma, inverse Gaussian, and Poisson). We also
attempted to fit the generalized gamma model assuming homoskedastic and
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heteroskedastic versions, extended estimating equations, and two-component finite
mixture models using gamma distributions.24 If more than one GLM had similar indices
of fit, we performed a Park test to choose the best fit model. We also explored various
statistical indices of badness of fit, including the Pregibon link test, a modified HosmerLemeshow test, and the Pearson’s correlation p-value.23,24 For each of these tests, a
higher p-value is more desirable. We also considered statistics such as R2, root mean
square error (RMSE), and mean absolute percentage error (MAPE), where a lower value
is desired. To guard against potential over-fitting, we assessed statistics following crossvalidation, including RMSE and MAPE (lower is better), mean prediction error (MPE;
zero is desirable), and the p-value for the Copas test (a test for over-fitting; higher is
desirable).23,24 Ultimately, GLMs were selected for each analysis: log-normal for the
evaluation period, square-root-Poisson for the perioperative period, log-gamma for the
follow-up period, and square-root-gamma for the entire duration period. Robust standard
errors were calculated in all models to accommodate clustering by transplant centre
where the donation occurred.
We reported mean (standard deviation, SD), median (25th, 75th percentile), and the
mean difference (95% confidence interval, CI) from marginal effects, where appropriate.
All costs are reported in 2017 Canadian dollars.

10.2.7

Sensitivity analysis

As of April 1, 2006, the ICES-derived costing method improved to accommodate primary
care physician payments under capitation following primary care reform to the costing
data, in addition to dialysis facility visit costs and cancer clinic visit costs.22 We
conducted sensitivity analysis in the subset of our cohort with an evaluation start date of
April 1, 2006 or later using the updated costing method to accommodate these costs.
Sensitivity analyses were also performed on the model chosen to estimate the donor costs
since more than one model may fit the data for some analyses.

10.2.8

Software and privacy

We used Statistical Analysis Software SAS v9.4 or SAS Enterprise Guide 6.1 (2013 SAS
Institute Inc., Cary, NC, USA) and STATA v13.0 (StataCorp LP, Texas, USA).
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Procedures and consultations for 5 or fewer donors are not reported to comply with
privacy requirements for minimizing the chance of patient identification. The study was
approved by the research ethics board at Sunnybrook Health Sciences Centre, Toronto,
Canada.

10.3 Results
We identified 1,256 living kidney donors who completed the evaluation and donated in
Ontario during the study period (Figure 26). Donors had a median of 28 (20, 39) health
care procedures (tests and consults) during the evaluation phase, performed during a
median 16 (11, 24) separate visits (which meant the procedures/tests were performed on
different dates). Donors were a mean 45 (SD 11) years of age, were mostly female (63%),
white (78%), lived in urban areas (87%), and lived in higher-income neighbourhoods
(23% in the highest quintile versus 15% in the lowest).

Figure 26: Donor selection and matching flow chart. *Using the Ontario Health
Insurance Plan (OHIP) database, the health care utilization patterns for these
donors were described for the evaluation period (n=1256), perioperative period
(n=1240), and follow-up period (n=1223). **fake nephrectomy date was assigned to
match the distribution of nephrectomy dates of the donors
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10.3.1

Health care utilization patterns

Appendix N presents the list of procedures considered relevant to living kidney donation
and the frequency of use during the evaluation (1256/1256, 100%), donation (1240/1256,
99%), and follow-up (1223/1256, 97%) periods. The most costly health care procedure
during the evaluation was consultation with a nephrologist, with a mean 1.91
consultations per donor at a mean cost of $135 per consultation, accounting for 15% of
the total evaluation cost (Appendix O and Appendix P). The second most costly test was
computed tomography, which were performed a mean 1.08 times per donor, representing
10% of the total evaluation at mean a cost of $170 per exam. This was followed by
nuclear medicine glomerular filtration rate test (9.0%), consultation with a surgeon or
urologist (8.1%) and bloodwork (7.9%).

10.3.2

Cost of the living donor transplantation process

A total of 1099/1214 (91%) donors were successfully matched to 4396 controls (4
controls per donor; Figure 26). The matched donors were similar to the unmatched
donors with respect to age (p=0.47), sex (p=0.27), urban status (p=0.82), and
neighbourhood income quintile (p=0.13) (Table 24). The mean total health care costs
during the evaluation period for donors and their matched controls were $4,522 (SD
$1,073) and $881 (SD $3,061), respectively. The mean adjusted total cost attributable to
the donor evaluation process was $3,596 (95% CI $3,350-$3,842) (Table 25). Similarly,
the mean cost attributable to the perioperative period was $11,694 (95% CI $11,415$11,973) and the mean cost attributable to follow-up in the first year after donation was
$1,011 (95% CI $793-$1,230). The incremental cost of living donor-related care to the
payer across all observation periods was $16,290 (95% CI $15,814-$16,767) (Table 25;
Figure 27A-D). Using pre-specified health care procedures, the cost of the living donor
evaluation was a mean $2,108 (SD $968) (n=1214).
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Table 24: Living donor characteristics (n=1099)
Age at donation

Donors (N=1099)
45.1 (11.1)

Sex
Women
Men

694 (63%)
405 (37%)

Race
White
Non-white

480 (78%)
135 (22%)

Income quintilea
5, highest income
4
3
2
1, lowest income

238 (22%)
275 (25%)
231 (21%)
182 (16%)
173 (16%)

Urbanization
Urban
Rural

959 (87%)
140 (13%)

Era

2004-2007
2008-2010
2011-2014
a

286 (26%)
399 (36%)
414 (38%)

rural was defined as having a population <10,000 persons
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Figure 27: Distribution of health care costs for A) the pre-donation evaluation
period (start of evaluation until the day before donation); B) perioperative period
(day of donation until 30-days post-donation); C) one year of follow-up period (after
perioperative period until 1-year post-donation); and D) the entire period from
evaluation start until 1-year post-donation. Controls were matched to donors and
were comprised of healthy non-donors with similar indicators of baseline health as
donors.
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Table 25: Cost of living kidney donation (n=4396 controls and 1099 donors)
Median
(25th, 75th percentile)

Mean difference
(95% CI)

$881 ($3,061)
$4,270 ($3,846)
–
–

$149 ($0, $634)
$3,115 ($2,305, $4,843)
–
–

–
–
$3,641 ($3,701-$3,898)
$3,596 ($3,350-$3,842)

$62 ($374)
$11,757 ($4,869)
–
–

$0 ($0, $0)
$11,427 ($10,542, $12,224
–
–

–
–
$11,695 ($11,407-$11,984)
$11,694 ($11,415-$11,973)

$139 ($0, $577)
$977 ($562, $1,683)
–
–

–
–
$933 ($682-$1,183)
$1,011 ($793-$1,230)

Mean (SD)
Pre-donation evaluation costs
Control
Donor
t-test
GLM-MEa,b

Perioperative costs
Control
Donor
t-test
GLM-ME a,c

One-year follow-up costs
Control
Donor
t-test
GLM-ME a,d

$753 ($2,421)
$1,686 ($4,057)
–
–

Total costs
Control
–
$1,696 ($4,541)
$470 ($25, $1,550
Donor
–
$17,966 ($8,401)
$16,116 ($14,539, $19,026)
t-test
–
–
$16,268 ($15,754-$16,784)
GLM-ME a,e
–
–
$16,290 ($15,814-$16,767)
GLM-ME – generalized linear model, marginal effects of donor status; SD – standard deviation; CI –
confidence interval.
Costs are presented in 2017 Canadian dollars.
Donors and their matched controls started the evaluation after March 31, 2003
a
adjusted for age, sex, urban/rural status, income quintile, year of transplant, and total evaluation time
(in months), p<0.0001 for all mean differences in the table.
b
log-normal
c
square-root Poisson
d
log-gamma
e
square-root gamma
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10.3.3

Predictors of costs

Over the total donation period, health care costs were higher for women [$534 ($179,
$890) higher than men], older persons [$316 ($172, $460) per 10-year increase in age],
and over a longer pre-donation evaluation period [e.g. a longer window for health care
utilization; $52 ($46, $58) per month] (Table 26). Health care costs were lower in more
recent years [-$718 (-$1,217, -$218) in 2011-2014 compared with 2004-2007]. Health
care costs did not differ by the person’s neighbourhood income quintile (p=0.66) or urban
versus rural residence (p=0.77). There was no significant difference in costs due to an
interaction between the donor/control indicator and sex, age, or duration of the evaluation
(pint>0.1 for all). There was a significant interaction with era: in 2011-2014 the
incremental cost of donation was $810 ($44, $1,577) higher than before 2008.
In the subset of donors (n=1,099), health care costs were higher if the recipient
started dialysis during the donor’s evaluation [$886 ($19, $1,752) compared with preemptive transplants], but this did not affect health care costs during the perioperative
(p=0.82) or follow-up (p=0.68) periods (Table 26). There was a non-significant trend in
different costs across transplant centres for the evaluation and follow-up periods (p=0.07
and p=0.09, respectively) (Table 26). Costs were significantly different across transplant
centres during the perioperative period, ranging from -$1,318 (-$1,971, -$664) to $599 ($502, $1,701) compared with one referent centre (p<0.0001).
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Table 26: Predictors of cost by donation period
Evaluation perioda

Perioperative periodb

pe,f

pint

f,g

pe,f

pint

f,g

Incremental coste,f

pe,f

pintf,g

0.01

0.47

$39 (-$22, $100)

0.21

0.57

$220 ($81, $360)

0.002

0.38

$534 ($179, $890)

0.003

0.67

Age, per 10-years

$77 (-$7, $160)

0.07

0.67

$55 ($30, $80)

<.0001

0.86

$196 ($123, $269)

<.0001

0.91

$316 ($172, $460)

<.0001

0.82

Evaluation time per
month

$52 ($46, $58)

<.0001

0.14

$1 (-$1, $4)

0.4

0.11

-$3 (-$9, $2)

0.24

0.45

$65 ($49, $81)

<.0001

0.21

Urban (vs. rural)
residence

-$185 (-$467, $97)

0.20

0.36

-$77 (-$239, $85)

0.35

0.87

$152 (-$37, $341)

0.12

0.31

-$76 (-$576, $425)

0.77

0.98

Income quintile
5, highest
4
3
2
1, lowest

0 (reference)
$26 (-$200, $251)
$24 (-$221, $269)
-$64 (-$310, $182)
$19 (-$264, $301)

0.95

0.35

0 (reference)
-$13 (-$106, $79)
-$20 (-$130, $90)
-$55 (-$155, $44)
-$61 (-$144, $23)

0.51

0.16

0 (reference)
$95 (-$86, $276)
$124 (-$70, $318)
$25 (-$173, $222)
$272 ($6, $538)

0.23

0.85

0 (reference)
$22 (-$419, $463)
$233 (-$314, $779)
-$215 (-$714, $284)
$231 (-$350, $811)

0.66

0.67

Era
2004-2007
2008-2010
2011-2014

0 (reference)
$89 (-$133, $311)
$106 (-$103, $316)

0.60

0.01

0 (reference)
$3 (-$75, $81)
-$81 (-$150, -$12)

0.02

0.42

0 (reference)
$78 (-$116, $271)
-$179 (-$353, -$4)

0.005

0.02

0 (reference)
$74 (-$469, $620)
-$718 (-$1,217, -$218)

0.0003

0.15

Recipient dialysis
statush
pre-emptive
dialysis-dependent
started dialysis

0 (reference)
$269 (-$233, $772)
$886 ($19, $1,752)

0.06

N/A

0 (reference)
-$224 (-$1,192, $743)
-$67 (-$825, $691)

0.82

N/A

0 (reference)
-$151 (-$521, $220)
$7 (-$454, $468)

0.68

N/A

0 (reference)
-$44 (-$1,203, $1,115)
$1,373 (-$175, $2,921)

0.19

N/A

Incremental

coste,f

All periodsd

$208 ($44, $372)

Incremental

coste,f

Follow-up periodc

Female (vs. male) sex

Incremental

coste,f

pe,f

pint

f,g

Transplant centre
1
0 (reference)
0.07
N/A
0 (reference)
<.0001
N/A
0 (reference)
0.09
N/A
0 (reference)
0.004
N/A
2
$63 (-$613, $738)
-$631 (-$938, -$324)
-$13 (-$432, $406)
-$559 (-$1,408, $290)
3
$390 (-$519, $1,300)
-$2,242 (-$2,746, -$1,739)
-$107 (-$685, $470)
-$1,997 (-$3,223, -$771)
4
-$561 (-$1,147, $25)
$599 (-$502, $1,701)
-$325 (-$846, $197)
-$406 (-$1,899, $1,087)
5
$236 (-$713, $1,185)
-$1,318 (-$1,971, -$664)
-$676 (-$1,143, -$209)
-$1,747 (-$2,878, -$616)
a-d
generalized linear model using a log link and normal distribution for the evaluation period (from the evaluation start until the day before donation); a square-root link and a Poisson distribution for the perioperative
period (from the date of donation until 30 days post-donation); a log link and gamma distribution for the follow-up period (from day 31 post-donation until day 365 post-donation); and a square-root link and gamma
distribution for the all periods (from the evaluation start until day 365 post-donation)
e
incremental costs and p-values were obtained from a marginal effects analysis
f
adjusted for donor/control indicator donor sex, age, time to complete the evaluation, urban/rural status, neighbourhood income quintile, and era of donation
g
p-value from an interaction term with the donor/control indicator (pint)
h
pre-emptive – recipients were not on dialysis before transplant; dialysis-dependent – recipients were on dialysis prior to (or within 3 months of) the time their donor starting their evaluation; started dialysis –
recipient started dialysis at least 3 months after their donor’s evaluation started.
N/A – not applicable (analysis restricted to donors only so interaction not possible)
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10.3.4
Estimated cost of the evaluation process for candidates
who did not donate
We estimated the cost of the evaluation assuming the donors were donor candidates who
only completed a portion of their evaluation. The donor candidate evaluation cost was
$1,633 ($1,452, $1,813) if the candidates completed 50% of the evaluation and $2,699
($2,463, $2,936) if they completed 90% of the entire evaluation (Table 27). There was a
nearly linear relationship between the proportion of the evaluation completed and the cost
of the donor evaluation (Figure 28).
Table 27: Cost of living donor evaluation donors by proportion of evaluation
completed (n=1099)
Proportion of evaluation
Median evaluation
Cost of evaluationa
completed
time (months)
0%
0 months
$0
10%
1.0 (0.66, 1.84)
$337 ($285, $388)
25%
2.7 (1.77, 4.76)
$865 ($773, $963)
50%
5.5 (3.61, 9.59)
$1,633 ($1,452, $1,813)
75%
8.2 (5.45, 14.4)
$2,320 ($2,102, $2,537)
90%
9.9 (6.54, 17.4)
$2,699 ($2,463, $2,936)
100%
11.0 (7.36, 19.4)
$3,596 ($3,350, $3,842)
a
costs reported in 2017 Canadian dollars using the marginal effects postestimation procedure following generalized linear regression with a log-link and
normal distributional family.
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Figure 28: Cost of the living donor evaluation assuming the donors completed only a
portion of their completed evaluation (n=1099). Costs are presented in 2017
Canadian dollars.

10.3.5

Sensitivity analysis

When we restricted the analysis to donations after April 1, 2006 to accommodate the cost
of capitation, the total cost of health care for living donors was very similar [mean
$16,666 (95% CI $15,799, $16,867)]. The cost of the evaluation, perioperative, and
follow-up periods were also similar: $3,565 ($3,319, $3,810), $11,741 ($11,409,
$12,073), and $989 ($747, $1,232), respectively.
In sensitivity analyses which altered the regression model selected, models that fit the
data as well or only slightly worse than the base case did not change the marginal effect
estimates for perioperative and follow-up donor costs, but the evaluation costs ranged
from a mean $3,414 ($3,229, $3,599) with the square-root gamma model to $4,239
($3,852, $4,626) with the log-gamma model.

10.4 Discussion
In this study from Ontario Canada, we found that the average cost to the health care
system attributable to a living kidney donor was $16,290. Most of these costs were
incurred in the perioperative period ($11,694), with costs also accrued during the

175

evaluation period ($3,596). The cost of the evaluation for potential donors who
completed 25% of their evaluation was $865.
After adjusting for the donor/control indicator, higher health care consumption was
observed during the evaluation period for women, older individuals, and those with a
longer evaluation period. These observations were expected and consistent with the
literature.26 We did not find any evidence that the cost of donation was different
concerning these factors (non-significant interaction terms). However, we found that the
evaluation costs were significantly higher for donors if their intended recipient started
dialysis partway through their evaluation. This may be due to incidental donor candidate
findings that require further work-up (e.g. characterizing ovarian or hepatic lesions
identified by renal ultrasound). In turn, a prolonged evaluation caused by the recipient
initiating dialysis may result in some tests being repeated, which is additional to
background health care consumption. While we did not observe any differences across
transplant programs for the cost of the evaluation, there was significant variability in the
cost of the perioperative period. As this is the most costly period of donation,
understanding the reasons for these differences and any effects on outcomes may identify
opportunities for cost-savings.
To the best of our knowledge, only one study attempted to describe the costs of the
evaluation, donation, and follow-up periods separately for a small sample of living donor
kidney transplants (n=130).8 The cost of donor candidates (those who did not donate)
were included in three studies.8,10,27 However, the cost of a partial donor assessment may
vary from centre-to-centre depending on their procedures for living donor work-up:
transplant programs that perform multiple tests on the same day28 or those that evaluate
multiple candidates simultaneously may incur higher evaluation costs since donor
candidates who did not donate will have a greater number of tests performed. We
reported the cost of partial evaluations, assuming non-donors would be scheduled to
receive the same evaluation process as donors. Individual programs can interpret these
costs in a manner that most closely fits their current or prospective operations.
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Previous studies have estimated the total cost of living donation-related care as $23,937
in Alberta Canada, $15,462 in France, and $15,850 in Spain (cf. $16,290 in this study, all
in 2017 $CAD).7,8,11 The donor evaluation period accounted for a significant proportion
of the total cost of living donation: 11% in the Alberta study, 12% in the Spanish study,
and 22% in this study (the periods differed in the French study). The estimated health
care costs in the current study are lower than the Alberta study8, particularly those related
to the perioperative period ($11,644 vs. $18,482). Our study captured the health care
utilization for donors more comprehensively, so it is unclear why the donation costs are
much higher in Alberta. Although we did not include the cost of partial evaluations, the
cost of the pre-donation phase was similar.
Having a non-donor control group and adjusting for covariates is a novel approach to
estimate the incremental costs associated with living donation. This methodology (where
all costs are included) guards against both underestimation (does not omit relevant costs
since all costs are captured) and overestimation (does not include irrelevant costs since on
average these are removed by the controls), and also provides a measure of precision.
However, there are some limitations that should be acknowledged. First, the
reimbursement costs for out-of-pocket expenses borne by the donors were not available.29
These costs are often remunerated by government-funded organizations and should be
included if a governmental perspective is desired.30 Second, in this study we only
considered persons who became donors. The health care utilization of donor candidates
who did not donate should be described in future work. Several candidates may be
evaluated to realize one kidney transplant, and some evaluations may not result in the
identification of a suitable donor. Summating all these candidate evaluation costs may be
important for some purposes. Third, the cost of running a living donor program was not
measured. This includes the cost of personnel (e.g., living donor nurse coordinator, social
work support, administrative assistant), equipment, and overhead. Fourth, we only looked
at one-year follow-up costs. Some costs related to donation may take decades to manifest
(i.e., possible donation-related kidney disease). Fortunately, the 15-year increase in the
absolute risk of kidney failure attributable to donation appears to be small.31 Finally,
these estimates pertain to a universal health care system, where 78% of donors were of
white race, and may not generalize well to other countries or health care systems.
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We found that the cost of living kidney donation in Ontario, Canada is on average
$16,290 per donor. The perioperative period is the largest component of the costs
($11,694 per donor) followed by the evaluation ($3,596 per donor) and follow-up periods
($1,011). While substantial costs of living donor care are related to the nephrectomy
procedure, comprehensive assessment of costs must include evaluation and follow-up
care. These estimates are informative for planning future work to support and expand
living donation and transplantation, and directing efforts to improve the cost efficiency of
living donor care.
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11 Discussion

11.1 Summary of the literature
The scoping review of the literature revealed a limited number of studies that reported on
the efficiency of living donor evaluations. We also did not find reporting of efficiency
metrics on the websites of living donor programs across Canada, the United States, the
United Kingdom, or Australia. The total time to complete the evaluation was infrequently
reported and measured using different time-points, some of which were only loosely
defined (Table 4). In addition, the number of intended recipients who may have missed
an opportunity for a living donor transplant (pre-emptive or otherwise) were sparsely
reported (Table 3). Only more recently has evidence emerged suggesting that a faster
evaluation process results in more living donor kidney transplants and more pre-emptive
transplants.1 Our results further support these claims. Following the consensus conference
on living donor transplantation, Moore et al provided several recommendations to
improve the efficiency of the living donor evaluation.2 The authors discussed the role of
the referring nephrologist in educating potential recipients and donor candidates on living
kidney donation. Providing such education as early as possible may enable potential
recipient candidates to pursue transplant evaluation and identify potential donors. This
may also provide more information for potential living donor candidates to consider
donation. However, the effect education has on the efficiency of the living donor work-up
remains unknown (e.g., does a more informed donor candidate complete the evaluation
quicker?). There is a trial underway to adapt the “Explore Transplant” and “Explore
Living Donation” programs from the United States for use in Ontario
(https://etontario.org/about-this-program/).3,4 Moore et al also suggest that various blood
tests and anthropometric assessments should be conducted before visiting the transplant
centre, particularly for candidates who live far away.2 In Chapter 3, we recognized that
this process design deserves merit (regardless of distance), and while many programs
already ask candidates to complete preliminary blood and urine tests at a local lab before
visiting the transplant centre, there is little evidence about when this request should be
made. For example, should laboratory requisitions be provided to all candidates at the
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outset or only after they pass the preliminary screening phase? Finally, the authors
recommended using community nephrologists, particularly for candidates who live far
from the transplant centre.2 Community nephrologists do not have the same experience
with living donation as transplant nephrologists, which may produce variability in the
selection and evaluation of living donor candidates (Appendix A).5–9 Without evidence of
the efficacy of placing more responsibility on community nephrologists in the work-up of
living donor candidates, we cannot endorse this as efficiency-improving recommendation
at this time, yet acknowledge this as a potential source of quality improvement. This
specific area requires further investigation, as the use of community nephrologists may
reduce wait times and travel burden for some candidates.

11.2 Summary of contributions to the field
Given the paucity of published data and the enthusiasm of patients surrounding this issue,
we conducted a series of studies to inform the efficiency of the living donor evaluation.
First, we estimated the time to complete the evaluation. Using data from multiple sources,
we established that the time until donation was a median 9-11 months across transplant
centres. For many donors, this time is often overwhelming and fraught with uncertainty.10
Although we explored individual-level (donor, recipient, and transplant) and some centrelevel factors associated with longer evaluation times, the strongest predictors of a longer
time until donation was participation in kidney paired donation. Some process
improvements may help improve the timeliness of this process (e.g. shipping kidneys
rather than donors; more frequent matching cycles).11 However, this is also reflective of
the fact that many recipients in paired donation programs are hard to match (e.g., AB
blood types, presence of antibodies against antigens prevalent among potential
donors).11,12 The second most noteworthy factor associated with a longer evaluation time
was a longer time until recipients were referred to the transplant centre. This suggests that
dialysis centres and multidisciplinary chronic kidney disease clinics could be more
proactive at educating and referring potential recipients for transplant evaluation.13,14 This
is consistent with the observation that recipient readiness (e.g. delayed recipient referrals)
was one of the most frequently encountered reasons for a delayed living donor evaluation
(Table 17). The time and effort for a donor candidate undergoing an evaluation may
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result in some candidates abandoning the process, a suspected outcome that remains
difficult to study.1,15 Thus, measuring the evaluation time allows living donor programs to
compare their performance with other programs and provides a starting point to guide
improvement efforts.
Second, we estimated the potential undesirable consequences that can occur with a
prolonged evaluation process. We found that the evaluation time was twice as long for
donors whose recipient started dialysis while their evaluation was underway. Although
poor recipient health may have prolonged the donor’s evaluation (e.g. recipient may have
become temporarily ineligible for transplant), we anticipate that a longer evaluation was
frequently a cause of recipients starting dialysis for several reasons. First, the donor’s
evaluation is often completed by a different healthcare team than the recipient’s
healthcare team.16,17 This is intended to ensure the donor healthcare team is focused on
donor safety without the pressures of promoting recipient health (the donor is being
harmed for the benefit of the recipient). Second, 50% of the recipients started dialysis at
least 9 months after their donor started their evaluation, ample time to complete a donor
assessment (Figure 25). All of these donors donated, meaning that they were all healthy
enough and motivated enough to complete the evaluation and donate a kidney. It is
therefore unclear why their evaluation wasn’t completed before their recipient started
dialysis. We also estimated the number of potential living donor transplants that could
have occurred if the evaluation was quicker. Under these scenarios, we assumed the
donor candidate was motivated and would have been deemed eligible to donate and
therefore provide an upper limit of the number of missed opportunities. Altogether, this
evidence suggests that a quicker evaluation is possible and would result in more living
donor transplants, more pre-emptive transplants, less time on dialysis (and therefore
better recipient outcomes), and reduced healthcare expenditures related to dialysis. These
conclusions are consistent with the sole report linking efficiency improvements to some
of these outcomes.1
Third, we estimated the cost to the healthcare system for a completed living donor
evaluation as well as for partial evaluations. Accurate costing is needed to help programs
project their budgetary requirements and their ability to cope with a more efficient living
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donor evaluation. For example, if the evaluation process was streamlined and completed
within 3-4 months, then more evaluations (completed or partial) would be conducted
during a given fiscal year1, thereby increasing costs. These projections may inform
capital and capacity planning to ensure resources are available to continue to conduct
timely evaluations and living donor transplants. These costs are also needed to inform
decision models on whether donor candidates should be evaluated sequentially or
simultaneously.
After summarizing the literature and generating novel results, we are able to explore
additional avenues to improve the efficiency of living kidney donation (Figure 5). I
briefly describe these efforts in the subsections below.

11.2.1

Sequential versus simultaneous evaluations

As demonstrated in Chapter 7, the number of living donor candidates coming forward for
evaluation for the same recipient increased over time. As prospective recipients are
increasingly advertising their need on social media, situations where multiple candidates
are available will become more common. Living donor programs usually evaluate one
candidate at a time and prioritize candidates who are considered more likely to donate
(4.4.1.3). This is done to save resources and avoid unnecessary testing for candidates who
ultimately would not donate. However, most candidates do not donate, and the evaluation
time for non-donor candidates was estimated to take a median 3 to 4 months (Chapter 7).
If the initial candidate does not donate, then the time until a true living donor is found
will be prolonged by at least this amount. During this additional time, the intended
recipient may start dialysis, will spend a longer time on dialysis, may lose eligibility for
transplant due to their illness, or may instead receive a deceased donor kidney transplant
(Chapter 8 and Chapter 9). Thus, the uncertainty of the outcome of living donor
candidates (donation or non-donation) combined with a lengthy evaluation process may
make simultaneous evaluations more cost-effective than sequential evaluations,
especially when the recipient is on dialysis, the cost of which can exceed $1,000 every
week.18
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To explore this decision, I constructed a decision tree with a Markov model to follow
donor candidate-recipient groups from the start of the first donors’ evaluation until the
intended or actual recipient dies (e.g. a lifetime time horizon). Quality-adjusted life-years
(QALYs) gained was determined using utilities derived from the literature for chronic
kidney disease (if not yet on dialysis), dialysis, and transplant. Costs included the cost of
dialysis over time and the cost of the living donor evaluation (partial for non-donors,
complete for donors), derived from the literature and the estimates from Chapter 10. The
time to complete the evaluation for donors and non-donors were derived from estimates
obtained in Chapter 6 and Chapter 7. We modeled several scenarios, varying the number
of candidates coming forward from 2-4 and the number of donors (candidates who would
donate upon completion of their evaluation) varied from 1-4 (versus non-donors, who
would not donate upon completion of their evaluation). We also considered the scenario
when the intended recipient was not on dialysis (potentially pre-emptive) when the first
donor candidates’ evaluation started, using data from Chapter 8 to inform the risk of
starting dialysis over time. We also conducted probabilistic sensitivity analyses to
accommodate parameter uncertainty.
The incremental cost-effectiveness ratio (ICER) was negative for all scenarios, driven by
higher cost savings and more QALYs gained with simultaneous evaluations. For
example, when 2 candidates came forward for the same candidate who was on dialysis
and 1 candidate was a donor, there was a 50% probability that the donor would be
selected first if they were evaluated sequentially. Simultaneous evaluations resulted in
greater cost savings over the lifetime of the recipient than did sequential evaluations
(cost = -$19,520) and also produced more QALYs (QALY = 0.44). By breaking down
some of the cost and effect components, the donor evaluation was more costly in the
simultaneous strategy ($5,261 versus $4,192 due to the cost of evaluating the non-donor),
but this was offset by the reduced dialysis cost ($56,290 versus $69,086) that resulted
from a quicker evaluation time (0.63 versus 0.78 years). Moreover, this prolonged time
until donation resulted in a greater proportion of recipients receiving a living donor
transplant (92.6% vs. 89.1%) under the simultaneous method, which may be attributable
to fewer recipients dying (5.9% versus 8.6%) or receiving a deceased donor transplant
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instead (1.7% versus 2.4%). In the potentially pre-emptive scenarios, the added cost of
dialysis in the sequential strategy may be exacerbated by the longer evaluation phase
when the non-donor is evaluated first, resulting in more intended recipients starting
dialysis before the donor evaluation was completed. The ICER was most sensitive to the
donor and non-donor evaluation times, the cost of dialysis, and the cost savings
associated with living donor transplantation. If the recipient was potentially preemptive at
the outset of the evaluations, the ICER was also sensitive to the probability of starting
dialysis. Regardless of the number of candidates coming forward, even if all candidates
were donors, simultaneous evaluations were still cost-effective (under probabilistic
sensitive analyses only) since the fastest donor was chosen.

11.2.2
Reducing the number of tests I – omit the nuclear
renogram for split renal function†††
Several studies were identified by the scoping review (Chapter 4) that assessed replacing
the split renal function assessment by nuclear renography with split kidney volume by
computed tomography (CT) imaging (Figure 8). The rationale behind this logic is: 1)
there is a relationship between kidney size and function; and 2) all donors must complete
a CT scan to assess the renal vasculature. Since a scoping review is inappropriate to
summarize the literature on this specific topic, we conducted a systematic review of the
literature, identifying a total of 18 studies for inclusion after applying exclusions. We
supplemented these studies with individual-level patient data from living donor
candidates assessed at London Health Sciences Centre between 2013 and 2016. We
measured the split renal volume from the actual CT images using the ellipsoid formula
and abstracted the split renal function from the nuclear renogram reports.

†††

A complete manuscript is currently under review with Canadian Journal of Kidney Health and Disease
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The Pearson’s correlation coefficient (r) was the measure of association reported by most
studies. For studies that did not report r yet presented a scatterplot or Bland-Altman plot,
we digitized the datapoints from the published figures and generated r using the digitized
(e.g., individual-level) data. We pooled this measure using Fisher’s z-transformation
using a random-effects model. For individual-level analyses (e.g., using digitized data),
we performed linear regression to obtain a more interpretable estimate of the association
between split renal volume and split renal function.
After pooling 19 studies (n=1,479), we obtained a pooled correlation of 0.74 (95%
confidence interval 0.61, 0.82). By linear regression using individual-level data, we
observed a 0.76 (95% CI 0.71, 0.81) percentage-point increase in split renal function
(SRF) percent for every 1% increase in split renal volume (SRV) percent. SRV had a
specificity of 88% for discriminating SRF% at a threshold that could influence the
decision of which kidney is to be removed (between-kidney difference ≥10%).
Predonation SRV% and SRF% similarly predicted kidney function 6-12 months
postdonation: r=0.05 (-0.02, 0.13).
SRV has the potential to replace SRF for some candidates. However, it is uncertain
whether it can do so reliably and routinely across different transplant centres. The impact
on clinical decision-making also needs to be determined in a well-designed prospective
study.

11.2.3
Reducing the number of tests II – omit the nuclear
renogram for glomerular filtration rate for some candidates
The second process redesign involved omitting the nuclear renogram for measured
glomerular filtration rate (mGFR) assessment among candidates with particular pre-test
characteristics (Figure 9).19 An algorithm was recently published online and tested in a
French cohort of donors.20 The rationale behind this algorithm is that a young donor
candidate with a very high estimated GFR (eGFR) will have a very high probability of a
mGFR exceeding the cut-point for acceptability, rendering this test superfluous. This
probability (the “pre-test probability”) is the probability of mGFR greater than a pre187

specified cut-point deemed acceptable to the living donor program (e.g. ≥80 mL/min/1.73
m2). The pre-test probability is based on age, sex, race and eGFR, factors that are
predictive of mGFR. Conversely, candidates with a very high pre-test probability of a
very low mGFR (e.g. <60 mLmin/1.73 m2, which is unacceptable for donation by all
programs) could be excluded without confirmation by nuclear renography.
Using data from living donors across Canada and Australia (Chapter 6) and for
candidates evaluated in London Ontario (Chapter 7), we determined the pre-test
probability of a mGFR at various cut-points (<60, <70, ≥80, and ≥90 mL/min/1.73 m2).
To avoid false negatives (e.g. having a mGFR <80 mL/min/1.73 m2 but confirmation by
mGFR is deemed unnecessary), we selected a pre-test probability cut-point that would
result in 100% sensitivity. Pre-donation eGFR and mGFR were weakly to moderately
correlated in the cohort of donors (r=0.38, n=768) and the cohort of donor candidates
(r=0.58, n=101). If the minimum mGFR threshold was 80 mL/min/1.73 m2, a pre-test
probability >99.94% was needed; only 7 donors had a pre-test probability above this cutpoint and would therefore not have needed a mGFR. Addition of a second eGFR to
improve the pre-test probability yielded slightly lower cut-point and could have
prevented 14-15 candidates from requiring a mGFR test (e.g. 4 exams per year). Using
the estimates from Appendix P (mean cost of $220 per nuclear medicine exam), this
translates to up to $880 in direct cost savings each year at London Health Sciences (a
medium-sized program).
Because the algorithm is based on categorization of key continuous variables (age and
eGFR), the pre-test probabilities become ordinal. This results in poor discriminative
ability and large “jumps” in the probabilities between categories. As a result, extremely
high threshold probabilities are needed to obtain 100% sensitivity. Thus, the current
prediction tool falls short of warranting its use in medical decision-making. Interpreting
our findings with the original study and the French validation study, I do not support the
widespread use of this online diagnostic tool to dictate the use of nuclear renography
without improvement in its discriminatory ability.19,20
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11.2.4

Time from referral to consultation or imaging

The time until a specialist is available for consult may differ across transplant centres and
type of specialist. Also, the time until CT imaging is available may also vary. The time
from referral until imaging or consultation is a common indicator used to measure quality
of care in Ontario. We attempted to obtain the time of referral from the transplant
department and the medical records at London Health Sciences, but data were
unavailable. These wait times are necessary to identify bottlenecks in the evaluation
process.21,22 Health Quality Ontario provides an interactive online interface for users to
look at various wait times across Ontario for surgeries and diagnostic imaging
(http://www.hqontario.ca/System-Performance). Although kidney donation did not
feature in these reports (e.g. time from referral until nephrectomy), priority-4 (lowest
priority) patients who should have had a CT scan within 28 days waited a median 31
days. The median time ranged from a minimum of 5 days (Oxford Advanced Imaging
Inc. – Ajax) to a maximum of 188 days (Ottawa Hospital).

11.3 Strengths and Limitations
11.3.1

Evaluation start date

One of the limitations of this research is the absence of a clear definition of the candidate
evaluation start date used to estimate the total evaluation time. Some experts believe that
the evaluation start date is the date the medical-social questionnaire (MSQ) is received by
the program. Some candidates take months to complete and return the MSQ (we reported
a median time of 40 days in Chapter 7), which may reflect the time required by
candidates to reflect on their decision to donate, wait for other candidates (e.g. other
family members) to proceed first, or complete their search for information about
donation. In contrast, other experts believe that this questionnaire is indeed part of the
evaluation process and the evaluation begins at the time the candidate first contacts the
program. As part of the evaluation process, the time from first contact until the MSQ is
received can therefore be subjected to quality improvement efforts by providing the MSQ
online, reducing the number of questions, or referring candidates to a reliable and up-todate source of information.
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To estimate the total evaluation time, we were therefore required to make some
assumptions since data on the first contact date or MSQ were rarely available. In one
cohort derived using administrative data, we used an algorithm based on healthcare
utilization patterns. This algorithm was based on expert opinion independent of the data.
In the cohort comprised of 16 transplant centres across Canada and Australia, we used the
earliest tests as a surrogate for the evaluation start date (typically blood or urine tests),
supplemented with first contact dates obtained for many Ontario donors. Finally, in the
single-centre cohort of living donor candidates in London, Ontario, we abstracted and
used the actual date the candidate reached out to the program. Despite these differences,
the estimated total evaluation time was consistent in all three cohorts. Furthermore, these
estimates aligned with expert opinion (face validity). Finally, these estimates were
corroborated using costing data, where the cost of partial evaluations approached zero as
the evaluation time decreased to zero (Figure 28). Had the evaluation start date been
estimated to be earlier or later than the true date, we would have expected the y-intercept
to be negative or positive, respectively (concurrent validity).

11.3.2

Between-centre comparisons

The large (>1000) Canadian/Australian cohort of living donors was the most appropriate
dataset to conduct between-centre comparisons because there were 12 transplant centres
for comparison (compared with the five programs available from Ontario administrative
data). Although we found statistically significant differences across transplant centres for
evaluation times, the proportion of potential pre-emptive transplants lost, and the cost of
living donor evaluations, we were unable to identify the drivers behind these differences.
Future research is needed, supported by more complete data on the program’s evaluation
practices and standardized collection and definition of key time-points. We propose one
approach common to management operations and economics: a data envelopment
analyses. This method uses linear programming to identify the technically efficient
programs by simultaneously combining important inputs (e.g. resources + protocols +
evaluation time) and outputs (e.g. number of transplants + number of pre-emptive
transplants + number of candidates completing the evaluation).23,24 Efforts are in place to
obtain these data from multiple transplant programs, and the findings are expected to
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identify the relatively inefficient programs and identify the inputs that should be targeted
for improvement. For example, Program A may produce the same outputs as Program B,
but may do so with fewer resources. In this case, Program A is more technically efficient
than Program B because it uses fewer resources to produce the same amount of outputs.
Program B can improve by either reducing its resources (e.g. personnel) while
maintaining the same level of production, or increase its level of production (e.g. more
transplants) while maintaining the same inputs.

11.3.3

Generalizability

The evaluation times estimated in this research may not be generalizable to other
transplant programs (e.g. programs that perform a 1-day evaluation; programs in the
United States where the CT scan is readily available and can be performed much earlier
in the evaluation, according to expert opinion). The estimates also may not be consistent
over time within the same program, as we anticipate all programs across Canada will
modify their practices to become more efficient (as a result of this research plus ongoing
engagement and collaboration).25
The potential cost savings of an earlier living donor transplant may also differ in other
regions because the distribution of dialysis modalities [e.g. proportion of the population
treated with peritoneal dialysis (less costly) versus in-centre hemodialysis (most costly)]
differs.18,26,27 This may also differ for countries where dialysis costs are not completely
covered by the primary payer: in multiple countries, patients pay some portion of dialysis
costs through an insurer or out-of pocket.28,29

11.4 Future directions
Throughout this thesis, I have argued that key quality indicators and definition of key
terms are needed to improve the efficiency of the living donor evaluation process. To
address this gap, we have launched a national Delphi study to identify and define key
process and outcome indicators that should be measured, monitored, and used to compare
performance between centres for accountability and quality improvement. 25,30–32 This is
important because multiple metrics are needed to better understand any process,
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participation in consensus-type methodology promotes buy-in across the country, and
data collection cannot be centralized.
The total time to complete the evaluation is a rather simple and crude metric: it serves as
a broad indicator of a programs’ efficiency but offers little information on bottlenecks.
Furthermore, because the definition of an efficient evaluation is so broad, multiple quality
indicators are needed. For example, Program A may have a prolonged evaluation (longer
time until approval), but once approved, the donor surgery can be scheduled quickly
(Figure 29). In contrast, Program B has a quicker evaluation (faster time until approval),
but has difficultly scheduling the operating theater. The total evaluation time does not
distinguish these two programs and offers no suggests for quality improvement.

Figure 29: Comparison of two different hypothetical living donor programs with
identical total evaluation times (defined as the time from evaluation start to
donation)
Several process indicators have been suggested and we estimated these where possible,
including the total time until donation, the time until approval, the time from approval
until donation, the time from CT angiography until donation, and the time between
consults. Most of the dates needed to measure process indicators are readily available and
easily defined (e.g. date of CT). Others were not routinely captured until only recently
(e.g. the donor candidate first contact date began to be recorded as of January 1, 2016
across Ontario). Others remain poorly defined (e.g. date of approval) and consensus is
needed before these are used for quality improvement initiatives.
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Outcome indicators (including those in Table 21) also require clear definitions to promote
generalizability. One such definition is a “potential” preemptive transplant (e.g. could the
donor candidate have completed their evaluation and donated before their intended
recipient started dialysis?).

11.4.1

Implementing a 1-day evaluation

We believe that the future of living kidney donor evaluation processes in Canada should
follow the 1-day evaluation in use by other programs. If a 1-day evaluation was
implemented for all candidates, some of these metrics would become obsolete, yet others
may weigh more heavily (e.g. time from CT until donation) or new metrics would be
needed (e.g. time from 1-day evaluation until approval).
After screening the websites of living donor programs, several programs were identified
that routinely conduct 1-day assessments, suggesting that this is a feasible process
improvement strategy that may improve patient outcomes. One program (Belfast,
Northern Ireland) provided a detailed schedule online.1 We also contacted four programs
from the United States for additional information, receiving a response from two:
University of California, Davis and the University of Iowa. Information about these two
programs were generously provided by the living donor coordinators.

11.4.1.1 Belfast
The day begins at 8am with a meeting with the living donor coordinators, blood tests and
urine tests after a 12-hour (overnight) fast (http://www.donatelife.co.uk/?page_id=306).
The candidate is then given breakfast and at 9am completes the renal ultrasound and is
given an injection of a contrast agent for nuclear renographic assessment of split kidney
function. At 9:30, an injection of another agent is given for total kidney function.
Between 10am and noon, the nuclear testing for both split function and total kidney
function are completed, along with a chest x-ray and an electrocardiogram. A
nephrologist reviews the results in the afternoon and meets with the candidate. A CT scan
may be performed, but is subject to cancellation if the nephrologist deems the candidate
is ineligible based on results of tests completed earlier in the day. There appears to be
quite a bit of movement between departments and floors (e.g. radiology on the first floor
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of the hospital, meeting with the coordinators and performing blood draws on the
eleventh floor, nuclear medicine in the cancer centre, and meeting the nephrologist in the
dialysis unit in another building). No mention is made about their requirements to
conduct routine psychosocial evaluations. The total evaluation time was reported to be 23 months.1

11.4.1.2 University of Iowa Organ Transplant Center:
During the course of the day, the candidate visits the living donor coordinator, social
worker, psychologist, and surgeon, and conducts a CT scan, chest x-ray, and
electrocardiogram. The candidate also visits with the independent living donor advocate
(who happens to be a primary care physician). The advocates perform the medical
examination, history and educate the potential donor about risk factors and issues related
to donation, including the ability to back out and issues surrounding confidentiality.33 The
advocate assumes the role of the nephrologist. As with the Belfast program, the CT scan
is subject to cancellation. The time from first contact until the 1-day evaluation was
stated to be 4-6 weeks, and the time until donation varies after the 1-day assessment.

11.4.1.3 UC Davis Transplant Center:
The day begins at 7:30am with labs (blood and urine tests). The clinical research center
registered nurse starts an intravenous line and injects the iohexol dose for nuclear
renography. At 8:00am, the candidate completes an educational session with the living
donor coordinators and at 9:00am meets with the nephrologist for a history and physical
exam. At 10:00am, the candidate meets with the social worker and independent living
donor advocate. This is followed by a nutritional evaluation and a 1-hour break for lunch.
In the afternoon, a CT scan is scheduled (can also be canceled if needed) and the
candidate completes “drop in” tests including chest x-ray and electrocardiogram. The
morning is completed in the clinic and the afternoon is completed in the hospital. The
total time from first contact until donation was stated to be approximately 3 months, but
data were unavailable to support this.
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11.4.1.4 Challenges to a 1-day evaluation
Some candidates may require additional testing (e.g. stress echo) that is not part of the 1day evaluation. In such cases, some tests may be scheduled on a second day and the 1day evaluation may be shortened to reduce the burden on the candidate (this is the case at
UC Davis Transplant Centre for candidates aged 50 years or older).
Although we anticipate the cost of evaluating non-donor candidates to increase costs to
the living donor program, such data were unavailable. If a 1-day evaluation does lead to
more living donor transplants, then while these costs are likely to be recuperated from
other departments (e.g. dialysis centres), the segmentation of operating costs and funding
models may hinder such quality improvement projects. Thus, the funding model needs to
be appropriately addressed to enable more living donor evaluations (e.g. for capital
planning).
The wait time for specialists or specialized testing has to be addressed. Conducting more
tests on candidates who ultimately do not donate represents not only a significant
financial cost, but also prevents other patients from receiving these consultations or
diagnostic exams. Thus, more work is needed to ensure healthcare resources are used
efficiently (e.g. capacity planning).
Another consideration is the availability of the operating room. If the evaluation process
was more efficient, we would anticipate more living donor transplants per year. The
operating room must be able to accommodate this capacity.

11.4.2

Other quality improvement designs

There are likely other solutions to improve the efficiency of the living donor work-up,
including partnering with local pharmacies to lease 24-hour ambulatory blood pressure
machines free of charge to donor candidates, or running outpatient clinics on weekends.
The final round of the aforementioned Delphi survey to is aimed to identify and prioritize
solutions to improve the efficiency of the evaluation process.
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11.5 Resource constraints
Unlike manufacturing processes, the flow of patients through a healthcare system is
subject to individual heterogeneity (e.g. unlike cars on an assembly line, each patient is
unique). Despite this challenge, multiple avenues for process improvement have been
discussed in the context of our findings and those from the literature. From the
experience of a single transplant centre (London Health Sciences Centre; Chapter 7),
there was a rise in the number of living donor transplants, more pre-emptive transplants,
and more living donor candidates contacting the program (e.g. more evaluations started).
However, this was not associated with a longer time to complete the evaluation (e.g. due
to resource constraints). In contrast, this was associated with a shorter time until
donation. This suggests existing capacity and resource availability, which was somehow
utilized to improve the efficiency of the evaluation. Without adding resources to the
system (e.g. more human resources, additional CT scanners), there is an upper limit of
efficiency that will preclude additional efficiency gains. Moreover, harm can be created
in other areas because one more CT scan for a living donor may come at the expense of
one less scan available for another patient. Although this was not in the scope of this
thesis, future work will inform these issues. If additional resources are warranted, this
will increase the overhead costs of running a living donor program. Thus, consideration
of resource constraints in a specific setting is critical to eliminate system constraints and
ensure the long-term success of a more efficient living donor evaluation process.
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Appendices
Appendix A: Variability on living donor eligibility criteria: summary of surveys of
multiple living donor programs
Age: There has been an upward shift in the age range for donor acceptability across
programs. Up to 58-59% of centres surveyed in the United States and Europe reported no
upper age limit.1–3 However, most living donor programs have a lower age limit for donor
acceptance. Some programs have a cut-off of 25 years of age, while others are willing to
accept minors under special circumstances.
Hypertension: Hypertension is a strong risk factor for kidney disease and cardiovascular
disease, and donor candidates with uncontrolled hypertension are typically excluded. If
hypertension is controlled (i.e., within normal limits while taking antihypertensive
medication(s)), then some centres may accept this donor, particularly if the candidate is
older. Variability exists regarding the number of anti-hypertensive medications permitted
(ranging from zero to three), the highest acceptable blood-pressure (ranging from 120/80
to 140/90), and the use of a 24-hour ambulatory blood pressure monitor to rule out whitecoat hypertension (hypertension in a doctor’s office).
Diabetes: Diabetes is one of the more common absolute contraindications to kidney
donation (72% across Europe and 64% across the United States2,3), as this is one of the
leading causes of kidney disease. The presence of pre-donation risk factors (i.e., high
blood glucose, family history of diabetes, donors of South Asian or Afro-Caribbean
extraction) often mandates a fasting glucose measurement or an oral glucose tolerance
test. The maximum glucose concentration used for donor exclusion varies across
programs, but the upper limit across programs does not exceed 7.0 mmol/L (126 mg/dL).
Kidney function: kidney function is one of the strongest predictors of kidney disease.
Kidney function is measured as the rate by which blood is filtered (the glomerular
filtration rate, GFR) adjusted to body size, in mL/min/1.73 m2. The minimum cut-point
for donor acceptance generally ranges from 80-100 mL/min/1.73 m2, but lower values
may be acceptable by some programs under certain circumstances (i.e., advanced age
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since GFR declines with age). There is little agreement on the best strategy to evaluate a
donor candidate’s kidney function. Some programs use measured GFR from urine
collected over a continuous 24-hour period, estimated GFR (eGFR) using different
equations, measured GFR using a nuclear renogram, or any combination of these.
Another indicator of kidney disease is proteinuria (protein in the urine), which may be
measured using a random urine sample for semi-quantification (i.e., negative, trace,
small, large) or quantification (g/L) using a dipstick or daily protein elimination using a
24-hour urine sample (g/day). Acceptance criteria vary across programs, but donors with
≥100mg/d albumin excretion or microalbuminuria (≥3 mg/mmol albumin-to-creatinine
ratio) are generally excluded.
Another indicator of kidney disease is hematuria (blood in the urine), which may be
measured using a random urine sample for semi-quantification using a dipstick (i.e.,
negative, trace, small, large) and confirmed using a microscopic analysis. Although
reported only by the American surveys, the definition of hematuria based on the
microscopic analysis ranges from a minimum of 2-10 red blood cells per high-powered
microscopic field.2,4 The definition of persistent hematuria may also vary, but presence of
persistent hematuria generally mandates further testing using a cystocopy or a kidney
biopsy to rule out underlying kidney disease.5 Urine cytology (looking for cancerous cells
in the urine) may be performed before cystoscopy or kidney biopsy.6
Obesity: obesity presents a surgical risk to the donor and also impacts the lifelong risk of
developing diabetes and kidney disease. The BMI cut-point for acceptance ranges from
30-40 kg/m2, but information was not provided on methods used by programs to help
motivated candidates reach the cut-point.3,4
Cardiac testing: an electrocardiogram and cardiac stress testing is usually reserved for
candidates with an indication for these tests (i.e., advanced age, cardiovascular risk
factors). However, some centres perform these tests routinely for all donor candidates.
Stones: A history of renal stones is a strong risk factor for kidney disease and has
typically been an exclusion criterion (for the safely of both the donor and the recipient).
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Although none of the European surveys offered perspective on acceptance criteria, this
has become less stringent over time in the United States. Many American centres (66%)
accept donors with a history of a single stone, but other programs may relax this
restriction based on absence of metabolic risk factors (i.e., hypercalciuria, hyperoxaluria,
cystinuria, metabolic acidosis, and hyperuricemia).2,4

References
1.

Bia MJ, Ramos EL, Danovitch GM, et al. Evaluation of living renal donors. The current
practice of US transplant centers. Transplantation. 1995;60(4):322-327.

2.

Mandelbrot DA, Pavlakis M, Danovitch GM, et al. The medical evaluation of living
kidney donors: a survey of US transplant centers. Am J Transplant. 2007;7(10):23332343.

3.

Lennerling A, Lovén C, Dor FJMF, et al. Living organ donation practices in Europe results from an online survey. Transpl Int. 2013;26(2):145-153.

4.

Brar A, Jindal RM, Abbott KC, Hurst FP, Salifu MO. Practice patterns in evaluation of
living kidney donors in United Network for Organ Sharing-approved kidney transplant
centers. Am J Nephrol. 2012;35(5):466-473.

5.

Gabolde M, Hervé C, Moulin AM. Evaluation, selection, and follow-up of live kidney
donors: a review of current practice in French renal transplant centres. Nephrol Dial
Transplant. 2001;16(10):2048-2052.

6.

Caliskan Y, Yildiz A. Evaluation of the Medically Complex Living Kidney Donor. J
Transplant. 2012;2012:1-6.

202

Appendix B: List of Websites
Country
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada

Province or State
British Columbia
British Columbia
British Columbia
Alberta
Alberta
Alberta
Saskatchewan
Manitoba
Manitoba
Ontario
Ontario
Ontario
Ontario
Ontario
Quebec
Quebec
Quebec
Quebec
Quebec
Nova Scotia/Prince
Edward Island

Centre or agency
St. Paul's Hospital
Vancouver General Hospital
BC Transplant Society *
Living Donor Services Program
Southern Alberta Renal Program
Northern Alberta Renal Program *
Saskatchewan Transplant Program
Transplant Manitoba
Health Sciences Centre *
London Health Sciences Centre
St. Joseph's Health Care System
St. Michael's Hospital
Toronto General Hospital
The Ottawa Hospital
Hôpital Ste-Justine
Montreal Children's Hospital *
Royal Victoria Hospital *
C.H. Universitaire de Sherbrooke
Transplant Quebec *
Queen Elizabeth II Health Sciences
Centre

Canada

Nova Scotia/Prince
Edward Island
Nova Scotia/Prince
Edward Island
New Brunswick

Legacy of Life *

Canada
Canada
Canada
Canada
Canada
Canada
USA
USA

Newfoundland and
Labrador
KFOC
KFOC
KFOC
Alabama
Alaska

USA
USA

Arizona
Arizona

USA
USA
USA
USA

California
California
California
California

USA
USA
USA
USA

California
California
California
California

USA

California

USA
USA
USA

California
California
California

USA

California

USA

California

Prince Edward Island Government
Website *
Réseau de santé Vitalité Health
Network
Western Memorial Regional
Hospital
Kidney Foundation of Canada
Canadian Blood Services
HealthLink BC
UAB Medicine
Providence

Phoenix Children's Hospital
Banner - University Medical Center
Phoenix and University Medical
Center Tucson
Scripps Center
Loma Linda Medical Center
Cedars-Sinai Medical Center
University of California at Los
Angeles Medical Center
Keck Hospital of USC
St. Vincent Medical Center
St. Joseph Hospital
University of California Irvine
Medical Center
Lucile Salter Packard Children's
Hospital
Stanford Health Care
Riverside Community Hospital
University of California Davis
Transplant Center
Sharp Memorial Hospital Kidney
Transplant
University of California San Diego
Medical Center
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City
Vancouver
Vancouver
Vancouver
Edmonton
Calgary
Edmonton
Saskatoon
Winnipeg
Winnipeg
London
Hamilton
Toronto
Toronto
Ottawa
Montreal
Montreal
Montreal
Sherbrooke
agency
Halifax (serves Nova
Scotia, New Brunswick,
PEI and Newfoundland
agency

Website
http://renal.providencehealthcare.org
http://www.vch.ca
http://www.transplant.bc.ca
http://www.albertahealthservices.ca
http://www.albertahealthservices.ca
https://www.kidney.ca
https://www.saskatoonhealthregion.ca
http://www.transplantmanitoba.ca
http://www.hsc.mb.ca
http://www.lhsc.on.ca
https://www.stjoes.ca
http://www.stmichaelshospital.com
http://www.uhn.ca/MOT
http://www.ottawahospital.on.ca
https://www.chusj.org
http://www.thechildren.com
https://muhc.ca
http://www.chus.qc.ca
http://www.transplantquebec.ca
https://www.cdha.nshealth.ca

agency

https://www.princeedwardisland.ca

New Brunswick

http://www.vitalitenb.ca

Corner Brook

http://westernhealth.nl.ca

agency
agency
agency
Birmingham
Anchorage, Eagle
River, Kodiak Island,
Palmer, Seward,
Valdez
Phoenix
Phoenix + Tucson

https://www.kidney.ca
https://blood.ca
https://www.healthlinkbc.ca
https://www.uabmedicine.org
http://alaska.providence.org

La Jolla
Loma Linda
Los Angeles
Los Angeles

https://www.scripps.org
http://medical-center.lomalindahealth.org
https://www.cedars-sinai.edu
http://transplants.ucla.edu

Los Angeles
Los Angeles
Orange
Orange

http://transplant.keckmedicine.org
https://stvincent.verity.org
https://www.sjo.org
http://www.ucirvinehealth.org

Palo Alto

http://www.stanfordchildrens.org

Palo Alto
Riverside
Sacramento

https://stanfordhealthcare.org
http://riversidecom
http://www.ucdmc.ucdavis.edu

San Diego

https://www.sharp.com

San Diego

https://health.ucsd.edu

http://www.legacyoflife.ns.ca

http://www.phoenixchildrens.org
https://www.bannerhealth.com

USA

California

USA

California

USA
USA
USA
USA

California
California
Colorado
Colorado

USA
USA

Colorado
Colorado

USA
USA

Colorado
Connecticut

USA
USA
USA

Connecticut
Delaware
Delaware

USA

District of Colombia

USA

District of Colombia

USA
USA
USA
USA
USA

Florida
Florida
Florida
Florida
Florida

USA
USA
USA
USA
USA

Florida
Florida
Florida
Georgia
Georgia

USA
USA
USA
USA
USA

Georgia
Georgia
Hawaii
Illinois
Illinois

USA

Illinois

USA

Illinois

USA
USA
USA
USA

Illinois
Illinois
Illinois
Illinois

USA
USA
USA

Illinois
Indiana
Indiana

USA
USA
USA

Indiana
Iowa
Iowa

USA

Iowa

USA
USA
USA

Kansas
Kansas
Kentucky

Rady Children's Hospital and
Health Center
University of California San
Francisco Medical Center
California Pacific Medical Center
Living Donation California
University of Colorado Hospital
University of Colorado Anschutz
Medical Campus
Children's Hospital Colorado
Centura Porter Adventist
Hospital
Presbyterian/St. Luke's
Hartford Hospital Transplant
Center
Yale New Haven Hospital
Christiana Care Health System
Alfred I duPont Hospital for
Children
Georgetown University Medical
Center
George Washington University
Hospital
Gulf Coast Medical Center
UF Health Shands Hospital
Mayo Clinic Jacksonville
Largo Medical Center
Jackson Memorial Hospital
University of Miami School of
Medicine
Florida Hospital Medical Center
Tampa General Hospital
Cleveland Clinic Florida Weston
Emory University Hospital
Children's Healthcare of Atlanta
at Egleston
Piedmont Hospital
AU Medical Center
The Queen's Medical Center
Rush University Medical Center
University of Chicago Medical
Center
Ann & Robert H. Lurie Children's
Hospital of Chicago
University of Illinois Medical
Center
Northwestern Memorial Hospital
Loyola University Medical Center
Advocate Christ Medical Center
OSF Saint Francis Medical
Center
Memorial Medical Center
Lutheran Hospital of Fort Wayne
St. Vincent Hospital and Health
Care Center
Indiana University Health
Iowa Methodist Medical Center
Mercy Medical Center-Des
Moines
University of Iowa Hospitals and
Clinics and Iowa City VA Medical
Center
University of Kansas Hospital
Saint Luke's Health System
University of Kentucky Medical

San Diego

https://www.rchsd.org

San Francisco

https://www.ucsfhealth.org

San Francisco
Aurora
Aurora

http://www.cpmc.org
http://livingdonationcalifornia.org
https://www.uchealth.org
http://www.ucdenver.edu

Aurora
Denver

https://www.childrenscolorado.org
http://www.porterhospital.org

Denver
Hartford

http://pslmc.com
https://hartfordhospital.org

New Haven
Newark
Wilmington

https://www.ynhh.org
https://christianacare.org
https://www.nemours.org

Washington D.C.

https://www.medstargeorg

Washington D.C.

https://www.gwhospital.com

Ft. Myers
Gainesville
Jacksonville
Largo
Miami

http://largomedical.com
https://ufhealth.org
http://www.mayoclinic.org
http://largomedical.com
http://www.jacksonhealth.org

Orlando
Tampa
Weston
Atlanta
Atlanta

https://www.fhtransplant.com
https://www.tgh.org
https://my.clevelandclinic.org
https://www.emoryhealthcare.org
https://www.choa.org

Atlanta
Augusta
Honolulu
Chicago
Chicago

http://www.piedmont.org
https://www.augustahealth.org
http://www.queenstransplantcenter.org
https://www.rush.edu
http://www.uchospitals.edu

Chicago

https://www.luriechildrens.org

Chicago

http://hospital.uillinois.edu

Chicago
Maywood
Oak Lawn
Peoria

https://www.nm.org
https://www.loyolamedicine.org
http://www.advocatehealth.com
https://www.osfhealthcare.org

Springfield
Ft Wayne
Indianapolis

https://www.memorialmedical.com
http://www.lutheranhospital.com
https://www.stvincent.org

Indianapolis
Des Moines
Des Moines

http://iuhealth.org
http://www.unitypoint.org
https://www.mercydesmoines.org

Iowa City

https://uihc.org

Kansas City
Kansas City
Lexington

http://www.kumed.com
https://www.saintlukeshealthsystem.org
http://ukhealthcare.uky.edu
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USA
USA
USA
USA
USA

Kentucky
Louisiana
Louisiana
Louisiana
Maine

USA

Maryland

USA
USA

Maryland
Maryland

USA
USA
USA
USA

Massachusetts
Massachusetts
Massachusetts
Massachusetts

USA
USA
USA
USA
USA
USA

Massachusetts
Massachusetts
Massachusetts
Massachusetts
Massachusetts
Michigan

USA
USA
USA

Michigan
Michigan
Michigan

USA

Michigan

USA
USA
USA
USA

Michigan
Michigan
Michigan
Minnesota

USA
USA

Minnesota
Minnesota

USA

Mississippi

USA
USA

Missouri
Missouri

USA
USA
USA
USA

Missouri
Missouri
Missouri
Missouri

USA
USA

Nebraska
Nevada

USA

New Hampshire

USA

New Jersey

USA
USA

New Jersey
New Jersey

USA
USA
USA
USA
USA
USA
USA

New Jersey
New Jersey
New Mexico
New Mexico
New York
New York
New York

Center
Jewish Hospital
Ochsner Foundation Hospital
Tulane Medical Center
Willis-Knighton Medical Center
Maine Medical Center
Transplant Program
University of Maryland Medical
System
Johns Hopkins Hospital
Walter Reed National Military
Medical Center at Bethesda
Massachusetts General Hospital
Brigham and Women's Hospital
Boston Children's Hospital
Beth Israel Deaconess Medical
Center
Boston Medical Center
Tufts Medical Center
Lahey Clinic Medical Center
Baystate Medical Center
UMass Memorial Medical Center
University of Michigan Medical
Center
Children's Hospital of Michigan
Henry Ford Hospital
Harper University Hospital
Detroit Medical Center
St. John Hospital and Medical
Center
Helen DeVos Children's Hospital
Mercy Health Saint Mary's
William Beaumont Hospital
University of Minnesota Medical
Center, Fairview
Abbott Northwestern Hospital
Hennepin County Medical
Center
The University of Mississippi
Medical Center
Children's Mercy Hospital
St. Luke's Hospital of Kansas
City
Research Medical Center
St. Louis Children's Hospital
Barnes-Jewish Hospital
SSM Health Saint Louis
University Hospital
The Nebraska Medical Center
University Medical Center of
Southern Nevada
Dartmouth-Hitchcock MC (Mary
Hitchcock Memorial Hospital)
Our Lady of Lourdes Medical
Center
RWJ Barnabas Health
Hackensack University Medical
Center
Saint Barnabas Medical Center
Robert Wood Johnson
UNM School of Medicine
Presbyterian Hospital
Albany Medical Center Hospital
Erie County Medical Center
North Shore University

Louisville
New Orleans
New Orleans
Shreveport
Portland

http://www.kentuckyonehealth.org
https://www.ochsner.org
http://tulanehealthcare.com
http://www.wkhs.com
https://mainehealth.org

Baltimore

http://www.umm.edu

Baltimore
Bethesda

https://www.hopkinsmedicine.org
http://www.wrnmmc.capmed.mil

Boston
Boston
Boston
Boston

http://www.massgeneral.org
http://www.brighamandwomens.org
http://www.childrenshospital.org
http://www.bidmc.org

Boston
Boston
Burlington
Springfield
Worcester
Ann Arbor

https://www.bmc.org
https://www.tuftsmedicalcenter.org
http://www.lahey.org
https://www.baystatehealth.org
https://www.umassmemorialhealthcare.org
http://www.uofmhealth.org

Detroit
Detroit
Detroit

https://www.dmc.org
https://www.henryford.com
https://www.dmc.org

Detroit

http://www.stjohnprovidence.org

Grand Rapids
Grand Rapids
Royal Oak
Minneapolis

https://www.spectrumhealth.org
http://www.smhealthcare.org
http://www.beaumont.edu
https://www.mhealth.org

Minneapolis
Minneapolis

https://www.allinahealth.org
http://www.hcmc.org

Jackson

https://www.ummchealth.com

Kansas City
Kansas City

http://www.childrensmercy.org
https://www.saintlukeshealthsystem.org

Kansas City
St. Louis
St. Louis
St. Louis

http://researchmedicalcenter.com
http://www.stlouischildrens.org
https://www.barnesjewish.org
http://www.ssmhealth.com

Omaha
Las Vegas

https://secure.nebraskamed.com
https://www.umcsn.com

Lebanon

http://www.dartmouth-hitchcock.org

Camden

https://www.lourdesnet.org

Edison, Rutherford
Hackensack

https://www.barnabashealth.org
http://www.hackensackumc.org

Livingston
New Brunswick
Albuquerque
Albuquerque
Albany
Buffalo
Manhasset

https://www.barnabashealth.org
http://www.rwjuh.edu
http://surgery.unm.edu
https://www.phs.org
http://www.amc.edu
http://www.ecmc.edu
https://www.northwell.edu
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USA
USA
USA

New York
New York
New York

USA
USA

New York
New York

USA

New York

USA

New York

USA

New York

USA

New York

USA

New York

USA

North Carolina

USA
USA
USA
USA

North Carolina
North Carolina
North Carolina
North Carolina

USA

North Dakota

USA

Ohio

USA
USA

Ohio
Ohio

USA
USA
USA

Ohio
Ohio
Ohio

USA

Ohio

USA
USA
USA
USA
USA
USA

Oklahoma
Oklahoma
Oklahoma
Oklahoma
Oklahoma
Oregon

USA

Oregon

USA
USA
USA
USA

Pennsylvania
Pennsylvania
Pennsylvania
Pennsylvania

USA

Pennsylvania

USA

Pennsylvania

USA
USA

Pennsylvania
Pennsylvania

USA
USA

Pennsylvania
Pennsylvania

Hospital/Northwell Health
Westchester Medical Center
Mount Sinai Medical Center
New York-Presbyterian
Hospital/Weill Cornell Medical
Center
Montefiore Medical Center
NY Presbyterian
Hospital/Colombia Univ. Medical
Center
New York University Medical
Center
State University of New York,
Downstate Medical Center
Strong Memorial Hospital,
University of Rochester Medical
Center
University Hospital of State
University of New York at Stony
Brook
State University of New York,
Upstate Medical University
University North Carolina
Medical Center
Carolinas Medical Center
Duke University Hospital
Vidant Health
Wake Forest Baptist Medical
Center
Sanford Bismark Medical
Center, Sanford Medical Center
Fargo
University of Cincinnati Medical
Center
The Christ Hospital
Children's Hospital Medical
Center
The Cleveland Clinic Foundation
University Hospitals of Cleveland
Ohio State University Medical
Center
University of Toledo Medical
Center
Integris Baptist Medical Center
OU Medical Center
Children's Hospital of Oklahoma
Saint Francis Hospital
St John Medical Center
Legacy Good Samaritan
Hospital and Medical Center
Oregon Health and Science
University
Lehigh Valley Hospital
Geisinger Medical Center
UPMC Hamot
Pinnacle Health System at
Harrisburg Hospital
Penn State Milton S Hershey
Medical Center
Thomas Jefferson University
Hospital
Temple University Hospital
Hospital of the University of
Pennsylvania
Albert Einstein Medical Center
Children's Hospital of

Mount Pleasant
New York City
New York City

http://westchestermedicalcenter.com
http://www.mountsinai.org
http://www.nyp.org

New York City
New York City

http://www.montefiore.org
http://www.nyp.org

New York City

http://nyulangone.org

New York City

http://www.downstate.edu

Rochester

https://www.urmc.rochester.edu

Stony Brook

https://www.stonybrookmedicine.edu

Syracuse

http://www.upstate.edu

Chapel Hill

http://www.uncmedicalcenter.org

Charlotte
Durham
Greenville
Winston-Salem

http://www.carolinashealthcare.org
https://www.dukehealth.org
https://www.vidanthealth.com
http://www.wakehealth.edu

Bismark, Fargo

http://www.sanfordhealth.org

Cincinnati

http://uchealth.com

Cincinnati
Cincinnati

https://www.thechristhospital.com
https://www.cincinnatichildrens.org

Cleveland
Cleveland
Columbus

https://my.clevelandclinic.org
http://www.uhhospitals.org
https://wexnermedical.osu.edu

Toledo

http://uthealth.utoledo.edu

Oklahoma City
Oklahoma City
Oklahoma City
Tulsa
Tulsa
Portland

http://integrisok.com
https://www.oumedicine.com
https://www.oumedicine.com
https://www.saintfrancis.com
http://www.stjohnhealthsystem.com
http://www.legacyhealth.org

Portland

http://www.ohsu.edu

Allentown
Danville
Erie
Harrisburg

https://www.lvhn.org
https://www.geisinger.org
http://www.upmc.com
http://www.pinnaclehealth.org

Hershey

http://hmc.pennstatehealth.org

Philadelphia

http://hospitals.jefferson.edu

Philadelphia
Philadelphia

http://kidney.templehealth.org
https://www.pennmedicine.org

Philadelphia
Philadelphia

https://www.einstein.edu
http://www.chop.edu
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USA
USA
USA

Pennsylvania
Pennsylvania
Pennsylvania

USA

Pennsylvania

USA
USA
USA
USA

Pennsylvania
Pennsylvania
Rhode Island
South Carolina

USA
USA
USA

South Dakota
Tennessee
Tennessee

USA
USA
USA
USA

Tennessee
Tennessee
Tennessee
Tennessee

USA

Texas

USA

Texas

USA
USA
USA
USA
USA
USA
USA

Texas
Texas
Texas
Texas
Texas
Texas
Texas

USA

Texas

USA
USA

Texas
Texas

USA
USA

Texas
Texas

USA

Texas

USA

Texas

USA

Texas

USA

Texas

USA
USA
USA

Texas
Utah
Utah

USA

Vermont

USA

Virginia

USA
USA

Virginia
Virginia

USA

Virginia

Philadelphia
Hahnemann University Hospital
Allegheny General Hospital
Children's Hospital of Pittsburgh
of UPMC
University of Pittsburg Medical
Center
Crozer-Chester Medical Center
The Lankenau Hospital
Rhode Island Hospital
Medical University of South
Carolina
Avera McKennan Hospital
Erlanger Medical Center
University of Tennessee Medical
Center at Knoxville
Methodist University Hospital
Centennial Medical Center
St. Thomas Hospital
Vanderbilt University Medical
Center and Nashville VA Medical
Center
UT Southwestern Medical
Center/William P. Clements Jr.
University Hospital
Children's Medical Center of
Dallas
Medical City Dallas Hospital
Methodist Dallas Medical Center
Baylor University Medical Center
Las Palmas Medical Center
Medical City Fort Worth
Baylor All Saints Medical Center
Texas Health Harris Methodist
Fort Worth Hospital
University of Texas Medical
Branch at Galveston
Houston Methodist Hospital
CHI St. Luke's Health Baylor
College of Medicine Medical
Center
Texas Children's Hospital
Memorial Hermann Hospital,
University of Texas at Houston
University Hospital, University of
Texas Health Science Center
Methodist Specialty and
Transplant Hospital
Christus Santa Rosa Hospital
Medical Center
Scott and White Memorial
Hospital
East Texas Medical Center
Intermountain Medical Center
University of Utah Medical
Center
The University of Vermont
Medical Center
University of Virginia Health
Sciences Center
Inova Fairfax Hospital
Sentara Norfolk General
Hospital
Children's Hospital of the King's
Daughters

Philadelphia
Pittsburg
Pittsburg

https://www.hahnemannhospital.com
https://www.ahn.org
http://www.chp.edu

Pittsburg

http://www.upmc.com

Upland
Wynnewood
Providence
Charleston

http://www.crozerkeystone.org
https://www.mainlinehealth.org
https://www.lifespan.org
http://www.muschealth.org

Sioux Falls
Chattanooga
Knoxville

http://www.avera.org
http://www.erlanger.org
http://www.utmedicalcenter.org

Memphis
Nashville
Nashville
Nashville

http://www.methodisthealth.org
http://tristarcentennial.com
https://www.sthealth.com
https://www.vanderbilthealth.com

Dallas

http://www.utswmedicine.org

Dallas

https://www.childrens.com

Dallas
Dallas
Dallas
El Paso
Fort Worth
Fort Worth
Fort Worth

http://medicalcityhospital.com
http://www.methodisthealthsystem.org
http://www.baylorhealth.com
http://laspalmasdelsolhealthcare.com
http://medicalcityfortworth.com
http://www.baylorhealth.com
https://www.texashealth.org

Galveston

https://www.utmbhealth.com

Houston
Houston

http://www.houstonmethodist.org
http://www.chistlukeshealth.org

Houston
Houston

https://www.texaschildrens.org
http://www.memorialhermann.org

San Antonio

http://www.universitytransplantcenter.com

San Antonio

http://sahealth.com

San Antonio

https://www.christushealth.org

Temple

http://www.sw.org

Tyler
Murray
Salt Lake City

https://www.etmc.org
https://intermountainhealthcare.org
https://healthcare.utah.edu

Burlington

https://www.uvmhealth.org

Charlottesville

https://uvahealth.com

Falls Church
Norfolk

https://www.inova.org
https://www.sentara.com

Norfolk

http://www.chkd.org
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USA

Virginia

USA
USA

Virginia
Washington

USA
USA
USA
USA

Washington
Washington
Washington
Washington

USA
USA

West Virginia
Wisconsin

USA

Wisconsin

USA

Wisconsin

USA
USA
USA
USA
USA
USA
UK
UK

Wisconsin
USA
USA
USA
USA
USA
Ireland
England

UK
UK

England
England

UK

Wales

UK
UK
UK

England
Scotland
Scotland

UK

England

UK

England

UK
UK
UK
UK
UK

England
England
England
England
England

UK
UK
UK
UK
UK
UK

England
England
England
England
England
England

UK
UK
UK

England
England
England

UK
UK
UK

England
England
agency

UK

agency

UK
UK

agency
agency

Medical College of Virginia
Richmond
Hospitals
Henrico Doctor's Hospital
Richmond
University of Washington
Seattle
Medical Center
Seattle Children's Hospital
Seattle
Swedish Medical Center
Seattle
Virginia Mason Medical Center
Seattle
Providence Sacred Heart
Spokane
Medical Center & Children's
Hospital
Charleston Area Medical Center
Charleston
University of Wisconsin Hospital
Madison
and Clinics
Aurora St. Luke's Medical
Milwaukee
Center
Froedtert Memorial Lutheran
Milwaukee
Hospital
Children's Hospital of Wisconsin
Milwaukee
National Kidney Foundation
agency
UNOS/Transplant Living
agency
National Kidney Registry
agency
American Transplant Foundation agency
Donate Life America
agency
Belfast City Hospital
Belfast
Queen Elizabeth Hospital
Birmingham
Birmingham
Bristol Southmead Hospital
Bristol
Cambridge Addenbrooke's
Cambridge
Hospital
Cardiff University Hospital of
Cardiff
Wales
Coventry University Hospital
Coventry
Edinburgh Royal Infirmary
Edinburgh
Queen Elizabeth University
Glasgow
Hospital Glasgow
Leeds St James's University
Leeds
Hospital
Royal Liverpool University
Liverpool
Hospital
Guy's Hospital
London
St George's Hospital
London
The Royal Free Hospital
London
The Royal London Hospital
London
West London Renal and
London
Transplant Centre
Manchester Royal Infirmary
Manchester
Newcastle Freeman Hospital
Newcastle
Nottingham City Hospital
Nottingham
Oxford Churchill Hospital
Oxford
Plymouth Derriford Hospital
Plymouth
Sheffield Northern General
Sheffield
Hospital
Other Leaflets from Sheffield Website
Great Ormond Street Hospital
London
Evelina London Children's
London
Hospital (Guy's)
Leeds Children's Hospital
Leeds
Nottingham Children's Hospuital
Nottingham
Organ Donation (part of NHS
website)
The Renal Association (link to
PDF)
Give a Kidney
NHS Blood and Transport
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https://www.vcuhealth.org
http://hcavirginia.com
http://www.uwmedicine.org
http://www.seattlechildrens.org
http://www.swedish.org
https://www.virginiamason.org
http://washington.providence.org
http://www.camc.org
http://www.uwhealth.org
https://www.aurorahealthcare.org
http://www.froedtert.com
http://www.chw.org
https://www.kidney.org
https://www.unos.org
http://www.kidneyregistry.org
http://www.americantransplantfoundation.org
https://www.donatelife.net
http://www.belfasttrust.hscni.net
https://www.uhb.nhs.uk
https://www.nbt.nhs.uk
http://www.cuh.org.uk
http://www.cardiffandvaleuhb.wales.nhs.uk
http://www.uhcw.nhs.uk
http://www.nhslothian.scot.nhs.uk
http://www.nhsggc.org.uk
http://www.leedsth.nhs.uk
http://www.rlbuht.nhs.uk
http://www.guysandstthomas.nhs.uk
https://www.stgeorges.nhs.uk
https://www.royalfree.nhs.uk
http://bartshealth.nhs.uk
https://www.imperial.nhs.uk
http://www.cmft.nhs.uk
http://www.newcastle-hospitals.org.uk
https://www.nuh.nhs.uk
http://www.ouh.nhs.uk
https://www.plymouthhospitals.nhs.uk
http://www.sth.nhs.uk
http://www.sth.nhs.uk
http://www.gosh.nhs.uk
http://www.evelinalondon.nhs.uk
http://www.leedsth.nhs.uk
http://www.emeesykidney.nhs.uk
https://www.organdonation.nhs.uk
http://www.renal.org
http://www.giveakidney.org
https://www.nhsbt.nhs.uk

UK
UK
UK
UK
Australia
Australia
Australia
Australia
Australia
Australia

agency
agency
agency
agency
New South Wales
New South Wales
New South Wales
New South Wales
New South Wales
New South Wales

NHS Choices
Kidney Research UK
Living Kidney Donation
Human Tissue Authority
John Hunter Hospital
Newcastle
Prince of Wales Hospital
Sydney
Royal North Shore Hospital
Sydney
Statewide Renal Services
?
Sydney Childrens Hospital
Sydney
The Childrens Hospital
Sydney
Westmead
Australia
New South Wales
Westmead Hospital
Sydney
Australia
Queensland
Queensland Renal Transplant Service
Australia
South Australia
Central Northern Adelaide Renal
Australia
Victoria
Alfred Hospital
Melbourne
Australia
Victoria
Austin Hospital
Melbourne
Australia
Victoria
Monash Medical (Adults)
Melbourne
Australia
Victoria
Monash Medical (Paediatric)
Melbourne
Australia
Victoria
Royal Childrens Hospital
Melbourne
Australia
Victoria
Royal Melbourne Hospital
Melbourne
Australia
Western Australia
Fiona Stanley Hospital
Perth
Australia
Western Australia
Sir Charles Gairdner Hospital
Perth
Australia
agency
Kidney Health Australia
Australia
agency
Donate Life Australia
Australia
agency
Transplant Australia
Australia
agency
The Department of Health
Australia
agency
Renal Resource Centre (ACI/Kidney Health Australia, PDF)
Australia
agency
ABC News (article)
Australia
agency
The Conversation (article)
Australia
agency
Organ Donation and Transplant Foundation of WA
KFOC – Kidney Foundation of Canada; NHS – National Health Services
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http://www.nhs.uk
https://www.kidneyresearchuk.org
http://livingkidneydonation.co.uk
https://www.hta.gov.uk
http://www.hnehealth.nsw.gov.au
http://www.princeofwalesprivatehospital.com.au
http://www.nslhd.health.nsw.gov.au
https://www.health.qld.gov.au
http://www.schn.health.nsw.gov.au
http://www.schn.health.nsw.gov.au
http://www.wslhd.health.nsw.gov.au
https://metrosouth.health.qld.gov.au
http://www.sahealth.sa.gov.au
https://www.alfredhealth.org.au
http://www.au
http://www.monashhealth.org
https://monashchildrenshospital.org
http://www.rch.org.au
https://www.thermh.org.au
http://www.fsh.health.wa.gov.au
http://www.scgh.health.wa.gov.au
http://kidney.org.au
http://www.donatelife.gov.au
https://transplant.org.au
http://www.health.gov.au
https://www.aci.health.nsw.gov.au
http://www.abc.net.au
http://theconversation.com
http://www.odatwa.org

Appendix C: List of Participating Centres
Canadian transplant centres
Dr. Amit X Garg
London Health Sciences Centre
London Ontario, N6A5W9

Dr. Christine Dipchand
Queen Elizabeth II
Halifax, Nova Scotia, B3H 2Y9

Dr. Liane Feldman
Royal Victoria Hospital
Montreal, Quebec, H4A 3J1

Dr. Greg Knoll
Ottawa General Hospital
Ottawa, Ontario, K1H 8L6

Dr. Darin Treleaven
St. Joseph’s Hospital
Hamilton, Ontario, L8N 4A6

Dr. Ramesh Prasad
St. Michael’s Hospital
Toronto, Ontario, M5B 1W8

Dr. Charmaine Lok
University Health Network
Toronto, Ontario, M5G 2C4

Drs. Martin Karpinski and Leroy Storsley
Winnipeg Health Sciences Centre
Winnipeg, Manitoba, R3A 1R9

Dr. Mauricio Monroy-Cuadros
Foothills Medical Centre
Calgary, Alberta, T2N 2T9

Dr. Scott Klarenbach
University of Alberta
Edmonton, Alberta, T6G 2R3

Dr. Chris Nguan
Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9

Australian transplant centres (these centres were combined due to sample size)
Dr. Neil Boudville
On behalf of
Monash Medical Centre Clayton, Clayton, Victoria, 3168
Fremantle Hospital, Fremantle, Western Australia, 6160
Royal Perth Hospital, Perth, Western Australia, 6000
Sir Charles Gairdner Hospital, Nedlands, Perth, Westeran Australia, 6009
Royal Adelaide Hospital, Adelaide, Southern Australia, 5000

210

Appendix D: Research Ethics Board approval for prospective cohort study
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Appendix E: List of first and last procedures per donor
Number (%)
Procedure
Intermediate assessment
Biochemistry
Cytology
General consult
Chest x-ray

First contact*
353 (28%)
175 (14%)
152 (12%)
138 (11%)
109 (9%)

Approval*
90 (7%)
–
–
–
–

Electrocardiography
Urinalysis
Counselling/psychiatry
Immunohematology
Ultrasound

96 (8%)
54 (4%)
50 (4%)
43 (3%)
35 (3%)

–
–
74 (6%)
–
–

Nuclear medicine
Surgery/urology consult
Nephrology consult
Computed tomography
Cardiac evaluation

27 (2%)
–
–
24 (2%)
–

–
913 (73%)
129 (10%)
–
23 (2%)

General surgery consult
Hematology consult
Pathology
Gastroenterology
Neurology

–
–
–
–
–

14 (1%)
<6 (0%)
<6 (0%)
<6 (0%)
<6 (0%)

Respirology
Endocrinology
Musculoskeletal consult
Rheumatology

–
–
–
–

<6 (0%)
0 (0%)
0 (0%)
0 (0%)

–
–
Echocardiography
–
–
Stress test
Plastic surgery
–
–
Pulmonary function
–
–
*visits not allowed to be a first contact date or approval
date are indicated by “–“
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Appendix F: STROBE Checklist of items that should be included in reports of
cohort studies

Title

Item
#
1

Recommendation
(a) Indicate the study’s design with a commonly used term in

Section
Title page

the title
Introduction
Background/rationale

2

Explain the scientific background and rationale for the

Background

investigation being reported
Objectives

3

State specific objectives, including any prespecified hypotheses

Background

Methods
Study design

4

Present key elements of study design early in the paper

Methods

Setting

5

Describe the setting, locations, and relevant dates, including

Methods

periods of recruitment, exposure, follow-up, and data collection
Participants

6

(a) Give the eligibility criteria, and the sources and methods of

Methods

selection of participants. Describe methods of follow-up
(b) For matched studies, give matching criteria and number of

N/A

exposed and unexposed
Variables

7

Clearly define all outcomes, exposures, predictors, potential

Methods

confounders, and effect modifiers. Give diagnostic criteria, if
applicable
Data sources/

8*

measurement

For each variable of interest, give sources of data and details of

Methods

methods of assessment (measurement). Describe comparability
of assessment methods if there is more than one group

Bias

9

Describe any efforts to address potential sources of bias

Methods

Study size

10

Explain how the study size was arrived at

N/A

Quantitative

11

Explain how quantitative variables were handled in the

Methods

variables

analyses. If applicable, describe which groupings were chosen
and why

Statistical methods

12

(a) Describe all statistical methods, including those used to

Methods

control for confounding
(b) Describe any methods used to examine subgroups and

Methods

interactions

Results
Participants

13*

(c) Explain how missing data were addressed

Methods

(d) If applicable, explain how loss to follow-up was addressed

N/A

(e) Describe any sensitivity analyses

N/A

(a) Report numbers of individuals at each stage of study—eg

Methods

numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing followup, and analysed
213

Descriptive data

14*

(b) Give reasons for non-participation at each stage

N/A

(c) Consider use of a flow diagram

N/A

(a) Give characteristics of study participants (eg demographic,

Table 8

clinical, social) and information on exposures and potential
confounders
(b) Indicate number of participants with missing data for each

Table 8,

variable of interest

Results

(c) Summarise follow-up time (eg, average and total amount)

Table 8,
Results

Outcome data
Main results

15*
16

Report numbers of outcome events or summary measures over

Table 9-

time

Table 13

(a) Give unadjusted estimates and, if applicable, confounder-

Table 9-

adjusted estimates and their precision (eg, 95% confidence

Table 13

interval). Make clear which confounders were adjusted for and
why they were included
(b) Report category boundaries when continuous variables were

Table 9-

categorized

Table 13

(c) If relevant, consider translating estimates of relative risk

N/A

into absolute risk for a meaningful time period
Other analyses

17

Report other analyses done—eg analyses of subgroups and

Table 11

interactions, and sensitivity analyses
Discussion
Key results

18

Summarise key results with reference to study objectives

Discussion

Limitations

19

Discuss limitations of the study, taking into account sources of

Discussion

potential bias or imprecision. Discuss both direction and
magnitude of any potential bias
Interpretation

20

Give a cautious overall interpretation of results considering

Discussion

objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence
Generalisability

21

Discuss the generalisability (external validity) of the study

Discussion

results
Other information
Funding

22

Give the source of funding and the role of the funders for the
present study and, if applicable, for the original study on which
the present article is based
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Title page

Appendix G: STROBE Checklist of items that should be included in reports of
cohort studies
Item

Recommendation

Section

1

(a) Indicate the study’s design with a commonly used term in
the title

Title page

Background/rationale

2

Explain the scientific background and rationale for the
investigation being reported

Background

Objectives

3

State specific objectives, including any prespecified hypotheses

Background

Study design

4

Present key elements of study design early in the paper

Methods

Setting

5

Describe the setting, locations, and relevant dates, including
periods of recruitment, exposure, follow-up, and data collection

Methods

Participants

6

(a) Give the eligibility criteria, and the sources and methods of
selection of participants. Describe methods of follow-up

Methods

(b) For matched studies, give matching criteria and number of
exposed and unexposed

N/A

Title
Introduction

Methods

Variables

7

Clearly define all outcomes, exposures, predictors, potential
confounders, and effect modifiers. Give diagnostic criteria, if
applicable

Methods,
Appendix
3-4

Data sources/
measurement

8

For each variable of interest, give sources of data and details of
methods of assessment (measurement). Describe comparability
of assessment methods if there is more than one group

Methods

Bias

9

Describe any efforts to address potential sources of bias

N/A

Study size

10

Explain how the study size was arrived at

N/A

Quantitative
variables

11

Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were chosen
and why

Methods

Statistical methods

12

(a) Describe all statistical methods, including those used to
control for confounding

Methods

(b) Describe any methods used to examine subgroups and
interactions

Methods

(c) Explain how missing data were addressed

Methods

(d) If applicable, explain how loss to follow-up was addressed

N/A

(e) Describe any sensitivity analyses

N/A

(a) Report numbers of individuals at each stage of study—eg
numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing followup, and analysed

Methods
and
Figure 1

(b) Give reasons for non-participation at each stage

N/A

Results
Participants

13
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Descriptive data

14

(c) Consider use of a flow diagram

Figure 1

(a) Give characteristics of study participants (eg demographic,
clinical, social) and information on exposures and potential
confounders

Table 1

(b) Indicate number of participants with missing data for each
variable of interest

Table 1

(c) Summarise follow-up time (eg, average and total amount)

Figure 2,
Tables 2-3

Outcome data

15

Report numbers of outcome events or summary measures over
time

Tables 2-3,
Appendix 6

Main results

16

(a) Give unadjusted estimates and, if applicable, confounderadjusted estimates and their precision (eg, 95% confidence
interval). Make clear which confounders were adjusted for and
why they were included

Tables 2-3,
Appendix 6

(b) Report category boundaries when continuous variables were
categorized

Tables 1-3,
Appendix 6

(c) If relevant, consider translating estimates of relative risk
into absolute risk for a meaningful time period

N/A

17

Report other analyses done—eg analyses of subgroups and
interactions, and sensitivity analyses

Tables 1-3,
Appendix 6

Key results

18

Summarise key results with reference to study objectives

Discussion

Limitations

19

Discuss limitations of the study, taking into account sources of
potential bias or imprecision. Discuss both direction and
magnitude of any potential bias

Discussion

Interpretation

20

Give a cautious overall interpretation of results considering
objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence

Discussion

Generalisability

21

Discuss the generalisability (external validity) of the study
results

Discussion

22

Give the source of funding and the role of the funders for the
present study and, if applicable, for the original study on which
the present article is based

Title page

Other analyses
Discussion

Other information
Funding
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Appendix H: List of OHIP and CIHI codes for dialysis status and comorbidity
Database

Type of code

Codes

OHIP

Feecodes

CIHI

ICD-9
ICD-10

"R849" "G323" "G336" "G325" "G326" "G860" "G862"
"G863" "G865" "G866" "R825" "R826" "R827" "R833"
"R840" "R851" "G330" "G331" "G332" "G861" "G864"
"R852" "G082" "G083" "G085" "G090" "G091" "G092"
"G093" "G094" "G095" "G096" "G294" "G295" "G333"
"H540" "H740"
"V451" "V560" "V568" "36104"
"T824" "Y602" "Y612" "Y622" "Y841" "Z49" "Z992"
"N180" "E1022" "E1023" "E1122" "E1123" "E1322"
"E1323" "E1422" "E1423"
"5127" "5195" "6698"
"7SC59QD" "1KY76" "1PZ21"

Dialysis

procedure codes
intervention
codes

Hypertension
OHIP
CIHI

diagnosis codes
ICD-9
ICD-10

"401" "402" "403" "404" "405"
"401" "402" "403" "404" "405"
"I10" "I11" "I12" "I13" "I15"

OHIP

diagnosis codes

CIHI

ICD-9

"140" "141" "142" "143" "144" "145" "146" "147"
"148" "149" "150" "151" "152" "153" "154" "155"
"156" "157" "158" "159" "160" "161" "162" "163"
"164" "165" "170" "171" "172" "173" "174" "175"
"179" "180" "181" "182" "183" "184" "185" "186"
"187" "188" "189" "190" "191" "192" "193" "194"
"195" "196" "197" "198" "199" "200" "201" "202"
"203" "204" "205" "206" "207" "208"
"V10" "140" "141" "142" "143" "144" "145" "146"
"147" "148" "149" "150" "151" "152" "153" "154"
"155" "156" "157" "158" "159" "160" "161" "162"
"163" "164" "165" "170" "171" "172" "173" "174"
"175" "176" "179" "180" "181" "182" "183" "184"
"185" "186" "187" "188" "189" "190" "191" "192"
"193" "194" "1950" "1951" "1952" "1953" "1954"
"1955" "1958" "196" "197" "198" "1990" "1991"
"2000" "2001" "2002" "2008" "2010" "2011" "2012"
"2014" "2015" "2016" "2017" "2019" "2020" "2026"
"2028" "2029" "203" "204" "205" "206" "207" "208"
"230" "231" "232" "233" "234"
"80003" "80006" "80013" "80023" "80033" "80043"
"80102" "80103" "80106" "80113" "80123" "80203"
"80213" "83123" "87202" "87203" "959" "965" "966"
"967" "968" "969" "970" "971" "980" "982" "984"
"985" "986" "987" "988" "989" "990" "991" "993"
"C00" "C01" "C02" "C03" "C04" "C05" "C06" "C07"
"C08" "C09" "C10" "C11" "C12" "C13" "C14" "C15"
"C16" "C17" "C18" "C19" "C20" "C21" "C22" "C23"
"C24" "C25" "C26" "C30" "C31" "C32" "C33" "C34"
"C37" "C38" "C39" "C40" "C41" "C43" "C44" "C45"
"C46" "C47" "C48" "C49" "C50" "C51" "C52" "C53"
"C54" "C55" "C56" "C57" "C58" "C60" "C61" "C62"
"C63" "C64" "C65" "C66" "C67" "C68" "C69" "C70"
"C71" "C72" "C73" "C74" "C75" "C76" "C77" "C78"
"C79" "C80" "C81" "C82" "C83" "C84" "C85" "C90"
"C91" "C92" "C93" "C94" "C95" "C96" "C97" "D00"
"D01" "D02" "D03" "D04" "D05" "D06" "D07" "D09"

Cancer

ICD-10

Cardiovascular disease
OHIP

feecodes
(procedure)

CIHI

ICD-9
ICD-10
procedural codes
intervention

"Z434" "R742" "R743" "N220" "R792" "R802" "R816"
"R817" "R783" "R784" "R785" "R814" "R787" "R780"
"R797" "R804"
"39" "40" "41" "42" "43" "44" "45"
"I"
"4802" "4803" "4809" "481" "5024" "5034" "5125"
"1IJ50" "1IJ76" "1KA76" "1KG76"
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codes

Anemia
CIHI

ICD-9
ICD-10

"285"
"D509"

Ischemic heart disease/coronary artery disease
ICD-9
ICD-10

"414"
"I120" "I121" "I122" "I123" "I124"
"I125"

Diabetes
OHIP
CIHI

fee codes
ICD-9
ICD-10

"K045" " K046" " K029" " K030" " Q040"
"250"
"E10" "E11" "E13" "E14"

diagnostic codes
ICD-9

"311"
"2962" "2963" "2966" "3000" "3002" "3003" "3004"
"309" "311"
“F063" "F064" "F204" "F313" "F314" "F315" "F32"
"F33" "F341" "F400" "F401" "F402" "F408" "F409"
"F410" "F411" "F412" "F413" "F418" "F419" "F420"
"F421" "F422" "F428" "F429" "F430" "F431" "F432"

Anxiety/depression
OHIP
CIHI

ICD-10

Heart failure
OHIP
CIHI

Fee codes
diagnostic codes
ICD-9
ICD-10
procedure codes
intervention
codes

"R701" "R702" "Z429"
"428"
"425" "5184" "514" "428"
"I099" "I420" "I425" "I426" "I427" "I428" "I429"
"I43" "I500" "I501" "I509" "I255" "J81"
"4961" "4962" "4963" "4964"
"IHP53" "IHP55" "1HZ53GRFR" "1HZ53LAFR" "1HZ53SYFR"

OHIP – Ontario Health Insurance Plan; CIHI – Canadian Institute for Health Information (same-day surgery and
discharge abstract database); ICD – International Statistical Classification of Diseases and Related Health Problems
medical classification (ICD-9 before 2002; IHD/CAD – ischemic heart disease/coronary artery disease
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Appendix I: Characterizing the living donor evaluation process
We captured all OHIP physician and laboratory billings for up to four years prior to
donation (1826 unique billing codes) and obtained the description for each billing code.
Based on these descriptions and prior validation studies, we grouped these codes into
procedures based on a priori judgement (Step I in Table below). We categorized
remaining billing codes (observed >5 times for privacy requirements) based on the
descriptions (Step II in Table below). We then assigned general billing codes to a
procedure based on the main speciality of the billing physician (obtained from the ICES
Physician Database, IPDB) (Step III in Table below). We then assigned remaining
general billing codes to a procedure based on other procedures performed on the same
day (Step IV in Table below). Next, we combined similar procedures into a single
category (Step V in Table below). Finally, we considered similar procedures performed
on the same day to belong to a single category if we believed the procedures were related
(i.e., we combined a billing code categorized as “pain management” on the same day as a
billing code categorized as “anesthesia” as “anesthesia”) (Step VI in Table below).
In order to identify the date of first contact (the date the donor started the evaluation), we
set up specific rules independent of the data to decide which procedures would be
considered part of the living donor evaluation process. For example, all nephrology
consults and nuclear medicine exams were considered part of the evaluation since a
healthy non-donor would be unlikely to have these billed if not part of the evaluation.
Any procedure performed within 14 days of donation was considered part of the preadmission visit and not a unique procedure in its own right (i.e., a nephrology consult
during this time is likely not the main nephrology consult). The only exception to this
rule is the surgical consult, which is allowed by some transplant programs to occur this
late in the evaluation process. We provide the full list of rules in Appendix J.
Step I – procedures defined a priori (n=1726)
Procedure
OHIP billing codes
Nephrectomy
Stress test
Urinalysis
Biochemistry

'S411',
'E694',
'G315',
'J607',
'L253',
'G481',
'L065',
'L112',

'S423',
'E753',
'G174',
'J608',
'L254',
'G006',
'L067',
'L093',

'S413',
'E766',
'G111',
'J807',
'L633',
'G007',
'L068',
'L634'

'S415',
'E767',
'G112',
'J808',
'L641',
'G008',
'L204',
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'S416',
'E768',
'G319',
'J809',
'G001',
'G009',
'L226',

'S420',
'E792',
'G582',
'J866',
'G002',
'G010'
'L004',

'S421',
'S412'
'G583',
'J609',
'G003',

'S436',
'G584',
'J666'
'G004',

'L005', 'L111',

Renal biopsy
Ultrasound
Nephrology consult

Urology consult
Echocardiography
Counselling
Surgery consultation
Glucose tolerance test
Immunohematology
Histocompatibility test
Chest x-ray
CT
MRI
Pyelogram
Cystoscopy
Cancer screen (pap)
Cancer screen (breast)
Cancer screen (PSA)
Cancer screen (FOBT)

'Z601', 'E820'
'J128', 'J135', 'J138', 'J162', 'J163', 'J428', 'J435', 'J438',
'J462', 'J463', 'J205', 'J505'
'A135', 'A136', 'A138', 'A435', 'C435', 'C135', 'C136', 'A133',
'A134', 'A131', 'C133', 'C134', 'C131', 'A161', 'A163', 'A164',
'A165', 'A166', 'A168', 'C132', 'C137', 'C139', 'C101', 'C138',
'G860', 'G323', 'G333', 'E083', 'H540'
'A355', 'A356', 'A935', 'A353', 'A354', 'C355', 'C356', 'C935',
'C353', 'C354'
'G560', 'G561', 'G562', 'G566', 'G567', 'G568', 'G570', 'G571',
'G572', 'G574', 'G575', 'G576', 'G577', 'G578', 'G581'
'K013', 'K014', 'K033', 'K040', 'K041'
'A095', 'A096', 'A935', 'A093', 'A094', 'C095', 'C096', 'C935',
'C093', 'C094', 'C033', 'C034', 'A033', 'A034', 'A036', 'C035', 'C036'
'G498', 'L104'
'L471', 'L482', 'L473', 'L490', 'L492', 'L493', 'L494', 'L495'
'L582', 'L581', 'L583', 'L580'
'X090', 'X091', 'X092'
'X231', 'X232', 'X233', 'X126', 'X409', 'X410'
'X451', 'X461'
'X129', 'X130', 'X138'
'Z606', 'Z607'
'G365', 'G394', 'E430', 'L812', 'L713'
'X184', 'X185', 'X186', 'X187', 'X172', 'X178','Z139','Z143'
'L354', 'L358'
'Q150A', 'Q005A', 'Q118A', 'Q119A', 'Q120A', 'Q121A', 'Q122A' 'Q123A',
'Q152A', 'Q043A', 'L181', 'G004', 'L179', 'Q152', 'Z535', 'Z536',
'Z555', 'Z580'
'A015', 'A016', 'C015', 'C016', 'A903'

Anaesthesiology
consult
1726 donors, 1826 unique billing codes, 215,363 rows
SUBTOTALS
Delete any feecodes that occur <6 times in the cohort
1726 donors, 777 unique billing codes, 211,942 rows
SUBTOTALS

Step II – categorize remaining billing codes not yet assigned after Step I above (n=1726)
Group A – billing codes that will be discarded later (not relevant to donation) but retained for the
present (may be needed to explain other codes; for example, a biochemistry test performed on the same
day as an emergency medicine visit is likely due to the emergency medicine visit, and not the donor
evaluation)
Procedure
OHIP codes
'G196','G197','G200','G202','G209','G212'
Allergies
'A008','E411','G367','G378','J157','J158','J159','J160','J164','J168',
Baby care

STD counselling
Biochemistry
Other CT
Other surgical
radiology

Emergency medicine
General eye care
Fracture/casting

'J457','J458','J459','J460','J464','L103','L819','L820','P003','P004',
'P005','P006','P007','P008','P014','P016','P018','P023','P025','P030',
'P041'
'K028'
'G871','G872','L718','L719'
'X400','X401','X402','X404','X407','X412','X415'
'X001','X004','X005','X007','X008','X016','X020','X025','X027','X028',
'X034','X035','X039','X045','X046','X048','X049','X050','X051','X052',
'X053','X054','X055','X056','X060','X063','X064','X065','X066','X067',
'X068','X069','X202','X203','X204','X205','X206','X207','X208','X210',
'X212','X215','X217','X218','X219','X220','X221','X224','X225','X226',
'X227','X228','X229','X230'
'K963','K996','Q090'
'A111','A238','E140','E950','G219','Z847'
'F004','F008','F027','F061','Z203','Z204','Z213'
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Diagnostic ultrasound
of face
Mandatory reporting
to Ministry of
Transportation
MRI (other)
Some paediatric code
Sleep study
Sports medicine or
physical medicine
Other/unknown

'J105','J108','J182','J183','J196','J200','J405','J482','J483','J496',
'J500'
'K035'

'X421','X425','X471','X475','X490','X492','X493','X495'
'A261','A263','A264','A265'
'J690','J889','J890','J895','J896'
'A917','D016','E494','E552','E584','G370','G371'
'H991','K037','K080','K683','M012','M060','N290','Q590','R110','R204',
'R205','R207','R302','R355','R416','R441','R495','R542','R687','G014',
'S120','S205','S247','S323','S738','S741','S745','S752','S754','S757',
'S772','S810','Z101','Z154','Z218','Z314','Z907'

Group B – lab tests referred to under the umbrella of “biochemistry”
Procedure
OHIP codes
'L303','L309','L310','L315','L318','L319','L322','L325','L328','L329',
Radioassay
Cholesterol
Microbiology
Immunology/virology
Hematology
General
Cytology

'L330','L331','L332','L334','L339','L340','L341','L345','L347','L606',
'L607','L608','L609'
'L055','L117','L243'
'L622','L625','L626','L627','L628','L630','L636','L639','L643','L650',
'L653','L654','L655','L665','L668','L679','L683'
'L500','L501','L535','L544','L550','L551','L552','L553','L555','L575',
'L610','L842'
'L393','L398','L419','L445','L451','L453','L462','L829'
'L018','L030','L031','L045','L046','L','L051','L053','L061','L066','L0
85','L107','L139','L146','L150','L157','L165','L169','L183','L191','L1
94','L208','L222','L223','L251','L252','L257','L266'
'L700','L711','L733','L800','L810'

Group C – other codes deemed relevant and either started a new procedure category or merged in with
Step I above
Procedure
OHIP codes
'A007'
Intermediate
assessment
'A013','A014','C012','C013','C014','C998','E001','E003','E004','E007',
Anesthesiology
Cardiac evaluation
Counselling
CT
Cholecystectomy
Some specialist
consult
Dermatology
Electrocardiogram
Diagnostic radiology
Endocrinology
Gastroenterology
consult
General consult
Hematology consult
Immunization
Infectious disease
consult

'E010','E011','E017','E020','E022','E023','E400','E401'
'A605','A608','G268','G269','G297','G483','G489','J611','J613','J667',
'J804','J811','J813','J814','J867','Z440','Z442'
'K002','K004','K005','K007','K016','K024','K025','K099','K190','K195',
'K197','K205'
'X405','X406','X417'
'E794','S287'
'A145'
'A023','A024','A025'
'E451','G310','G313','G579','G650','G651','G652','G658','G682','G683',
'G690','G692','G693'
'A331','A335','J021','J022','X036','X037','X038','X100','X101','X103',
'X104','X106','X111','X113','X125','X181','X182','X189','X194','X200'
'A154','A155','J817','J818','J820'
'A415','A418','C415','Z399','Z496','E702','J832','E705','E717','E719',
'E720','E740','E741','E746','E747','E749','Z499','Z527','Z543','Z570',
'Z571','Z787'
'A001','A003','A004','A005','C003','C004','C933','K131'
'A615','A618'
'A625','G538','G539','G590','G591','G842','G847','Q003','Q130'
'A465,','L868'
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Critical care
MRI
Musculoskeletal
consult
Nephrectomy
Nephrology consult
Neurology evaluation
Nuclear medicine
Obstetrics/gynaecolog
y
Ophthamology
Orthopedic
Otology/laryngology
Pain management
Pathology
Physical medicine
Plastic surgery
Pregnancy test
Psychiatry
Pulmonary function
Skin lesion
Respirology
Rheumatology
Sclerotherapy
Smoking cessation
General surgeon
consult
Ultrasound
Urology consult
Bone mineral density
test
Birth control surgery
Home visit
Travel reimbursement

'G391','G395','G400','G401','G521','G523','G557'
'X455','X465','X487','X499'
'J650','J651','J850','J851'
'E762','E769','G347','S435','S548'
'A160','C162','C165','C166'
'A185','A188','G414','G418','G544','A044','A045'
'J834','J835','J836','J838','J880','Y814','Y831'
'A203','A204','A205','A206','C202','C203','G334','G399','X147','Z553',
'Z583','Z720','Z730','Z731','Z770'
'A233','A234','A235','A253','G425','G432','G435','G436','G813','G818',
'G820','G853','G857','G858'
'A063','A064','A065','A066','C062'
'A243','A244','A245','G191','G403','G420','G440','G441','G442','G443',
'G451','G525','G526','G529','G530','G533','Z321'
'C215','G220','G222','G223','G224','G227','G228','G231','G235','G238',
'G246','G247','G264'
'A585','L720','L816','L817','L821','L840','L863','L864'
'A315','A318','G455','G456','G457','G466','G999','H312'
'A083','A084','A085'
'G005'
'A194','A195','C192','G478','K198','K199','K313','K623','Q020'
'E450','J301','J304','J306','J307','J310','J311','J313','J315','J318',
'J319','J322','J323','J327','J332','J333','J340','J860'
'R031','R051','Z156','Z162','Z169','Z170'
'A475','A478','Z296','Z299','Z327'
'A485'
'G536','G537'
'E079','K039','Q041','Q042'
'A035', 'A644','A645','C032'
'J149','J161','J165','J193','J198','J201','J202','J203','J206','J425',
'J493','J498','J501','J502'
'C352','G193','G475','G476','G900'
'X146','X153','X155'
'S626'
'A901','B994'
'K036'

Group D – cancer screening codes
Procedure
OHIP codes
'Q005','Q133','Q142'
Colorectal
Fecal occult blood test 'Q150'
'Q002','Q131','R111','X201','J427','J127'
Breast
'Q001','Q011','Q140'
Papanicolaou test

Step III – categorize remaining billing codes not yet assigned after Step II using the main specialty
associated with the usage of that code (n=1726)
OHIP codes
'E082'

'E078'

Procedure (using main specialty)
gastroenterology, urology, nephrology, respirology,
orthopaedic, general surgery consult, general consult, internal
medicine
rheumatology, cardiac evaluation, nephrology, respirology,
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'A473'
'A183','A184'
'H065','H101','H103','H123','H124','H
131','H133','H153','H154','H151'
'Z611','Z113','Z116','Z117'
'Z611'
'A888'
'A603','A604'
Any code

gastroenterology, internal medicine, neurology, hematology,
endocrinology
Respirology
Neurology
Emergency medicine
Dermatology
Ob/gyn, otolaryngology
General consult
Cardiac evaluation
Nephrectomy (if on donation date)

Step IV – generic billing codes that will be assigned using any procedure already defined on the
same day (i.e., a general code on the same day as a cardiac evaluation will be considered part of that
cardiac evaluation) (n=1726)
OHIP billing codes
'Q012','G379','E409','E542','E545','E595','A613','C002','C109','C123','C124
','C992','E005','Q016','C994','G118','G322','H103','H055','H123','H133','H1
34','H152','H153','H154','C122','H104','H132','Z153','J001','K070','A483','
E078','K055','K992','K991','K994','K995','K998','K999','Q013','Q200','Q033'
,'Z114','Z116','Z117','Z176','Z125','Z546','Z552','Z553','Z611',
'G700','G373','G372'
'C122','Z176','R868','E595','A888'

NOTE: the first part of this table was repeated in case there was >1 generic code on the same day

Procedure
Various

Unknown/other
–

Step V – combining similar procedures (n=1726)
Rule
Nephrectomy codes the day before donation was assigned the donation date
Surgeon consult + urology consult
Counselling + psychiatry
NOTE: The same procedures on the same day are combined (rows are merged) and the
total costs for the same procedure on the same day are summed
NOTE: Cancer screening tests are removed from dataset if they occurred >1 year before
any other test

Step VI – combining similar procedures if done on the same day (n=1403)
Procedure 1 (to be combined with [renamed as]
Procedure 2)
Pain management
CT (discard)
MRI (discard)
Dermatology
Diagnostic ultrasound of face

Procedure 2

Pulmonary function
Pulmonary function
Pulmonary function
Pulmonary function

Allergies (discard)
Respirology
Smoking cessation
Sleep study (discard)

Anesthesia
CT
MRI
Skin lesion
Ultrasound
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Procedure
Nephrectomy
Surgeon/
urology consult
Counselling/
psychiatry
–
–

Smoking cessation
Smoking cessation

General consult
Intermediate assessment

Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment

Gastroenterology
Cardiac evaluation
Pulmonary function
Ophthalmology
Obstetrics/gynaecology
Otology/laryngology
Sclerotherapy
Pathology
Sports medicine/physical medicine (discard)

Cytology
Anaesthesiology
Obstetrics/gynaecology
Plastic surgery
Plastic surgery
Plastic surgery
Diagnostic radiology

Obstetrics/gynaecology
Cystoscopy
Cancer screen (pap)
Skin lesion
Orthopaedic
Cancer screen (breast)
Ultrasound

Anaesthesiology
Orthopaedic
Physical medicine
Plastic surgery
Pain management

Sports medicine/physical medicine (discard)
Sports medicine/physical medicine (discard)
Sports medicine/physical medicine (discard)
Sports medicine/physical medicine (discard)
Sports medicine/physical medicine (discard)

Sleep study (discard)

Cardiac evaluation

Fecal occult blood test
Gastroenterology
Anaesthesiology
Cytology
Intermediate assessment

Cancer screen (colorectal)
Cancer screen (colorectal)
Cancer screen (colorectal)
Cancer screen (colorectal)
Cancer screen (colorectal)

Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology

Infectious disease consult
Cancer screen (pap)
Cancer screen (breast)
Cancer screen (colorectal)
Fecal occult blood test
Cytology
Dermatology
Gastroenterology
Obstetrics/gynaecology
Skin lesion

Respirology
General consult
Cytology
General consult
General consult
General consult

Otology/laryngology
Cancer screen (pap)
Cancer screen (pap)
Cancer screen (colorectal)
Cancer screen (breast)
Cancer screen (PSA)
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General consult
Anaesthesiology
Intermediate assessment

Birth control surgery (discard)
Birth control surgery (discard)
Birth control surgery (discard)

Diagnostic radiology
Diagnostic radiology
Diagnostic radiology
Diagnostic radiology
Diagnostic radiology
Diagnostic radiology
Diagnostic radiology
Diagnostic radiology
Diagnostic radiology
Diagnostic radiology

Cancer screen (breast)
Cancer screen (colorectal)
Renal biopsy
Ultrasound
Chest x-ray
Diagnostic ultrasound of face (discard)
Other surgical radiology (discard)
Sports medicine (discard)
Emergency medicine (discard)
Bone mineral density test

Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment
Intermediate assessment

Cardiac evaluation
Surgeon/urology consult
Nephrology consult
Counselling/psychiatry
General surgery consult
Neurology
Anaesthesiology
Orthopaedic
Obstetrics/gynaecology
Otology/laryngology
Home visit
Physical medicine
Pain management
Rheumatology
Respirology

Any procedure <14 days prior to donation (except
Surgeon/urology consult)
Any procedure (verified through quality checks)
Any procedure (verified through quality checks)
Any procedure (verified through quality checks)
Any procedure (verified through quality checks)
Any biochemistry procedure

Pre-admission
Fracture/casting
Cholecystectomy
General eye care (discard)
Some paediatric code (discard)
Biochemistry
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Appendix J: Steps to identify donor’s point of first contact
Rules to keep visit

Procedures where rules are applied

No rules (all are kept)
Last visit (i.e., most recent before nephrectomy)
No rules (all are kept)
4 months before nephrology consult or anytime
thereafter
±6 months of any nephrology consult or
surgeon/urology consult

Nephrology consults
Surgery/urology consult, preadmission
Nuclear medicine
Cardiac evaluation
- Lab tests (urinalysis, biochemistry test,
cytology, immunohematology)
- Diagnostic tests (CT, ultrasound,
echocardiography, ECG, MRI, chest x-ray,
stress test, pulmonary function, pyelogram)
- Consults (general consult, intermediate
assessment, counselling/psychiatry,
gastroenterology, surgery/urology consult,
renal biopsy, cystoscopy, endocrinology,
hematology, musculoskeletal, neurology,
pathology, plastic surgery, respirology,
rheumatology)
General surgeon consult

±6 months of any nephrology consult or
surgeon/urology consult AND associated with a
physician who previously billed a code related to
donation or a surgeon/urology consult
Within 30 days before a previously retained
procedure
Within 1 year of nephrectomy
Within 3 years of nephrectomy

Counselling/psychiatry, cardiac evaluation
Cancer screen (pap, breast)
Cancer screen (colorectal)

Rules to delete visit
No rules (all remaining are discarded)
If the first test is this procedure, this is deleted
since this was likely done for another reason (i.e.,
the evaluation should not start with a cancer screen,
a specialist consultation, etc) (repeated 8× until this
was no longer observed)
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All procedures not kept (as per the above rules)
Cancer screen (any)

Appendix K: Research Ethics Board approval for retrospective for retrospective
chart review
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Appendix L: Specific transitions used in scenario analysis
Transition time (days)
N
median (IQR)
mean (SD)
Transition times between major consults (nephrology, surgery, psychosocial) –
for Scenarios 3 and 4a
Nephrology
to surgery
315
23 (3, 66)
45.0 (56.9)
Counselling
to surgery
136
3 (0, 18)
13.8 (26.7)
Nephrology
to counselling
189
0 (0, 14)
14.6 (53.0)
Surgery
to nephrology
80
19 (7, 41)
45.6 (87.6)
Counselling
to nephrology
65
13 (6, 23)
38.2 (99.9)
Surgery
to counselling
36
12 (2, 22)
19.4 (26.8)
Transition times from various major medical consults (nephrology, surgery) to
a cardiology consult – for Scenario 5a
Nephrology
43
7 (0, 84)
66.7 (114)
Surgery
7
16 (3, 45)
69.4 (140)
Transition times from various procedures to a nuclear medicine exam – for
Scenario 6a,b
Biochemistry
147
21 (7, 41)
29.4 (28.9)
Computed tomography
102
7 (3, 13)
17.1 (73.8)
Chest x-ray
100
7 (2, 18)
14.8 (19.3)
Intermediate assessment
80
17 (8, 34)
42.7 (100)
Nephrology
65
20 (8, 29)
33.9 (61.5)
Stress test
46
0 (0, 0)
0.10 (0.70)
Electrocardiogram
43
12 (5, 36)
26.7 (48.9)
Ultrasound
41
0 (0, 6)
7.80 (20.3)
Cardiology consult
29
7 (6, 20)
29.5 (78.8)
Counselling
28
16 (5, 32)
23.9 (26.6)
Surgical consult
27
13 (1, 27)
16.0 (15.3)
General consult
26
20 (13, 40)
41.8 (60.5)
Pulmonary function test
25
0 (0, 0)
0.40 (1.70)
Echocardiography
20
7 (4, 11)
8.80 (8.60)
Cervical cancer screen
20
7 (4, 19)
14.3 (16.7)
Nuclear exam
13
22 (8, 49)
25.4 (22.1)
Colorectal cancer screen
11
18 (3, 130)
59.1 (71.5)
Cytology
10
33 (18, 41)
38.9 (29.2)
Breast cancer screen
9
8 (6, 11)
11.6 (10.2)
a
also used for scenarios 1-2
b
nuclear renogram not restricted to a test of total glomerular filtration rate or split
function
Mean and median estimates of transition times were tabulated for all donors who
donated a kidney after March 2004 (n=1256), using a list of procedures deemed
relevant to the evaluation process.
SD – standard deviation; IQR – 25th, 75th percentile
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Appendix M: Codes for exclusion of potential healthy non-donor controls for
matching
Database

Type of code

Codes

Dialysis
OHIP

Feecodes
ICD-9
ICD-10

CIHI
procedure codes
intervention
codes

"R849" "G323" "G336" "G325" "G326" "G860" "G862" "G863"
"G865" "G866" "R825" "R826" "R827" "R833" "R840" "R851"
"G330" "G331" "G332" "G861" "G864" "R852" "G082" "G083"
"G085" "G090" "G091" "G092" "G093" "G094" "G095" "G096"
"G294" "G295" "G333" "H540" "H740"
"V451" "V560" "V568" "36104"
"T824" "Y602" "Y612" "Y622" "Y841" "Z49" "Z992" "N180"
"E1022" "E1023" "E1122" "E1123" "E1322" "E1323" "E1422"
"E1423"
"5127" "5195" "6698"
"7SC59QD" "1KY76" "1PZ21"

Hypertension
OHIP
CIHI

diagnosis codes
ICD-9
ICD-10

"401" "402" "403" "404" "405"
"401" "402" "403" "404" "405"
"I10" "I11" "I12" "I13" "I15"

Cancer

OHIP

diagnosis codes

ICD-9

CIHI

ICD-10

"140" "141" "142" "143" "144" "145" "146" "147" "148"
"149" "150" "151" "152" "153" "154" "155" "156" "157"
"158" "159" "160" "161" "162" "163" "164" "165" "170"
"171" "172" "173" "174" "175" "179" "180" "181" "182"
"183" "184" "185" "186" "187" "188" "189" "190" "191"
"192" "193" "194" "195" "196" "197" "198" "199" "200"
"201" "202" "203" "204" "205" "206" "207" "208"
"V10" "140" "141" "142" "143" "144" "145" "146" "147"
"148" "149" "150" "151" "152" "153" "154" "155" "156"
"157" "158" "159" "160" "161" "162" "163" "164" "165"
"170" "171" "172" "173" "174" "175" "176" "179" "180"
"181" "182" "183" "184" "185" "186" "187" "188" "189"
"190" "191" "192" "193" "194" "1950" "1951" "1952"
"1953" "1954" "1955" "1958" "196" "197" "198" "1990"
"1991" "2000" "2001" "2002" "2008" "2010" "2011" "2012"
"2014" "2015" "2016" "2017" "2019" "2020" "2026" "2028"
"2029" "203" "204" "205" "206" "207" "208" "230" "231"
"232" "233" "234"
"80003" "80006" "80013" "80023" "80033" "80043" "80102"
"80103" "80106" "80113" "80123" "80203" "80213" "83123"
"87202" "87203" "959" "965" "966" "967" "968" "969"
"970" "971" "980" "982" "984" "985" "986" "987" "988"
"989" "990" "991" "993" "C00" "C01" "C02" "C03" "C04"
"C05" "C06" "C07" "C08" "C09" "C10" "C11" "C12" "C13"
"C14" "C15" "C16" "C17" "C18" "C19" "C20" "C21" "C22"
"C23" "C24" "C25" "C26" "C30" "C31" "C32" "C33" "C34"
"C37" "C38" "C39" "C40" "C41" "C43" "C44" "C45" "C46"
"C47" "C48" "C49" "C50" "C51" "C52" "C53" "C54" "C55"
"C56" "C57" "C58" "C60" "C61" "C62" "C63" "C64" "C65"
"C66" "C67" "C68" "C69" "C70" "C71" "C72" "C73" "C74"
"C75" "C76" "C77" "C78" "C79" "C80" "C81" "C82" "C83"
"C84" "C85" "C90" "C91" "C92" "C93" "C94" "C95" "C96"
"C97" "D00" "D01" "D02" "D03" "D04" "D05" "D06" "D07"
"D09"

Cardiovascular disease
OHIP

CIHI

feecodes
(procedure)
ICD-9
ICD-10
procedural codes
intervention
codes

"Z434" "R742" "R743" "N220" "R792" "R802" "R816" "R817"
"R783" "R784" "R785" "R814" "R787" "R780" "R797" "R804"
"39" "40" "41" "42" "43" "44" "45"
"I"
"4802" "4803" "4809" "481" "5024" "5034" "5125"
"1IJ50" "1IJ76" "1KA76" "1KG76"

Human immunodeficiency virus
OHIP

diagnosis codes

"042" "043" "044"
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CIHI

ICD-9
ICD-10

"042" "043" "044" "V08" "176"
"B24" "C46" "Z21",

Nephrectomy
OHIP

feecodes

CIHI

ICD-9
ICD-10
procedural codes
intervention
codes

"E762" "S435" "E769" "S434" "E771" "Z631" "G347" "G348"
"G412" "G408" "G409"
"V420" "99681"
"T861" "N165" "Z940"
"6743" "675"
"1PC85"

Renal biopsy
OHIP
CIHI

feecodes
procedural codes
intervention
codes

"Z601",
"6781" "6782"
"1PC87"

diagnosis codes
ICD-9
ICD-10

"274"
"274"
"M10"

Gout
OHIP
CIHI

Pulmonary disease
CIHI

ICD-9
ICD-10

"46" "47" "48" "49" "50" "51"
"J"

ICD-9
ICD-10

"57"
"K7"

Liver disease
CIHI

Systemic lupus erythematosus
CIHI

ICD-9
ICD-10

"7100"
"M32"

Rheumatoid arthritis
CIHI

ICD-9
ICD-10

"714"
"M05" "M06"

Genitourinary disease
CIHI

ICD-9
ICD-10

"58" "59" "60" "61" "62"
"N"

ICD-9

"303" "3050"
"E24" "E512" "F10" "G312" "G621" "G721" "I426" "K292"
"K70" "K860" "T510" "X45" "X65" "Y15" "Y573" "Z502"
"Z714" "Z721"

Alcoholism
CIHI

ICD-10

OHIP – Ontario Health Insurance Plan; CIHI – Canadian Institute for Health Information (same-day surgery and
discharge abstract database); ICD – International Statistical Classification of Diseases and Related Health Problems
medical classification (ICD-9 before 2002
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Appendix N: Healthcare utilization patterns of the most common procedures
determined from OHIP billing codes
Quantity utilized by living donors who started the evaluation as early as March 31,
2000 until 1-year follow-up post-donation, entire cohort

Evaluation period

Perioperative period

Follow-up period

N (%)

mean (SD)a

N

mean (SD)a

N

1256 (100%)

–

1240 (99%)

–

1223 (97%)

–

1256 (100%)
1256 (100%)
1210 (96%)
1177 (94%)
1163 (93%)

1.91 (1.74)
1.40 (1.00)
1.40 (0.70)
1.61 (0.98)
1.08 (0.30)

483 (40%)
842 (70%)
164 (14%)
88 (7%)
33 (3%)

4.17 (3.98)
2.80 (2.15)
2.24 (2.19)
1.69 (1.08)
2.76 (1.12)

935 (76%)
790 (65%)
119 (10%)
149 (12%)
50 (4%)

2.03 (1.70)
1.28 (0.76)
3.18 (2.71)
3.38 (2.72)
2.26 (1.10)

1038 (83%)
1061 (84%)
954 (76%)
890 (71%)
875 (70%)
805 (64%)

3.32 (2.20)
3.34 (2.18)
2.55 (2.53)
3.44 (3.36)
1.42 (0.79)
1.12 (0.37)

118 (10%)
228 (19%)
103 (9%)
434 (36%)
91 (8%)
0 (0%)

5.11 (6.96)
1.67 (1.43)
1.67 (0.96)
1.37 (0.67)
2.47 (1.70)
–

921 (75%)
967 (79%)
640 (52%)
817 (67%)
242 (20%)
<6 (<1%)

11.7 (11.3)
3.51 (2.82)
2.47 (2.18)
3.25 (2.93)
4.28 (2.83)
–

General consult
Echocardiogram
Cardiology evaluation
Stress test
Counseling/psychiatry
Cancer screen (pap)

646 (51%)
578 (46%)
527 (42%)
498 (40%)
486 (39%)
401 (32%)

2.19 (2.09)
1.09 (0.31)
1.89 (1.43)
1.11 (0.33)
2.42 (4.81)
1.64 (0.64)

159 (13%)
<6 (<1%)
47 (4%)
<6 (<1%)
60 (5%)
<6 (<1%)

1.20 (0.43)
–
1.53 (1.69)
–
1.23 (0.62)
–

524 (43%)
14 (1%)
186 (15%)
13 (1%)
193 (16%)
235 (19%)

1.94 (1.70)
4.36 (1.08)
1.81 (1.33)
3.54 (2.96)
3.39 (6.97)
2.62 (1.18)

Immunohematology test
Cancer screen (breast)
Pulmonary function test
Cancer screen (colorectal)
General surgery consult
Cystoscopy

397 (32%)
243 (19%)
224 (18%)
207 (16%)
111 (9%)
78 (6%)

1.07 (0.27)
1.23 (0.52)
1.09 (0.38)
1.51 (0.93)
1.22 (0.68)
1.03 (0.16)

0 (0%)
<6 (<1%)
<6 (<1%)
<6 (<1%)
52 (4%)
<6 (<1%)

–
–
–
–
2.02 (1.32)
–

15 (1%)
118 (10%)
32 (3%)
57 (5%)
55 (4%)
10 (1%)

2.73 (1.49)
2.57 (1.60)
6.66 (6.18)
1.18 (0.54)
1.67 (1.50)
1.10 (0.32)

67 (5%)
67 (5%)
54 (4%)
39 (3%)
31 (2%)
30 (2%)

1.15 (0.40)
1.28 (0.57)
1.02 (0.14)
1.05 (0.22)
1.03 (0.18)
1.57 (1.04)

<6 (<1%)
29 (2%)
0 (0%)
<6 (<1%)
0 (0%)
<6 (<1%)

–
1.21 (0.49)
–
–
–
–

29 (2%)
69 (6%)
0 (0%)
57 (5%)
0 (0%)
<6 (<1%)

2.62 (2.27)
3.96 (2.36)
–
2.05 (0.93)
–
–

Procedure
Number of

donorsb

Nephrology consult
Surgery/urology consult
Chest x-ray
Electrocardiogram
Computed tomography
Biochemistry (bloodwork)
Cytology
Urinalysis
Intermediate assessment
Ultrasound
Nuclear medicine

Magnetic resonance
Gastroenterology consult
Renal biopsy
Pathology consult
Pyelogram
Hematology consult

mean (SD)a

Neurology consult
27 (2%)
1.37 (0.84)
<6 (<1%)
–
15 (1%)
1.60 (1.55)
Plastic surgery consult
26 (2%)
2.15 (1.32)
<6 (<1%)
–
20 (2%)
2.40 (1.93)
Respirology consult
21 (2%)
1.57 (0.93)
<6 (<1%)
–
35 (3%)
1.60 (1.26)
Endocrinology consult
13 (1%)
1.08 (0.28)
0 (0%)
0 (–)
<6 (<1%)
–
Musculoskeletal consult
10 (1%)
1.10 (0.32)
0 (0%)
0 (–)
<6 (<1%)
–
Rheumatology consult
8 (1%)
1.38 (0.52)
0 (0%)
0 (–)
<6 (<1%)
–
costs presented only for more common procedures (present in >10% of donors)
a mean (standard deviation, SD) number of procedures per donor, restricted to those who had the procedure during the specified
period of coverage.
b restricted to donors with an OHIP billing code in the specified period
c estimated (not measured) number of hours spend with a donor
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Appendix O: Healthcare utilization patterns
Evaluation period
Common consultations: Several donors had more than one nephrology [mean 1.93 (SD
1.74)] and surgery [mean 1.40 (SD 1.00)] consultation. Other common consultations
included intermediate assessments (a detailed donor examination performed by a
physician in a family practice or pediatric services), which were utilized by 71% of
donors during the evaluation period, general consultations (51%), cardiology
consultations (42%), a psychosocial assessment (39%), and a general surgery
consultation (9%).
Preliminary and diagnostic tests: Chest x-ray, electrocardiography and computed
tomography (CT) exams were used by at least 93% of donors. With respect to laboratory
tests, cytology, biochemistry and urinalysis was used by 76-83% of donors. A nuclear
medicine exam was used by 64% of donors. CT and nuclear renograms were repeated
infrequently: mean 1.08 (SD 0.30) and 1.12 (SD 0.37) exams per donor.
Other diagnostic tests and consultations: Cancer screening was used by 32% of donors
for a pap smear, 19% for a breast exam, and 16% for a colorectal exam. Other
procedures, including echocardiograms (46%), stress tests (40%), pulmonary function
tests (18%), cystoscopy (6%), magnetic resonance (MR) exams (5%), renal biopsy (4%),
and pyelography (2%), were also considered important parts of the donor evaluation and
were infrequently used (mean 1.02-1.15 per donor). Other consultations, including
gastroenterology (5%), pathology (3%), neurology (2%), hematology (2%), plastic
surgery (2%), respirology (2%), endocrinology (1%), musculoskeletal (1%), and
rheumatology (1%) were also retained since they may be necessary components of the
evaluation (e.g., incidental findings, clearance from the perspective of pre-existing
conditions).
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Post-donation follow-up period
During the follow-up period, some healthcare procedures were utilized by most donors,
including nephrology consultation (76%), surgery consultation (65%), blood and urine
tests (52-79%), and intermediate assessments (67%). For small subgroups of donors, the
frequency of certain healthcare procedures more than doubled after donation. For
example, a mean 3.18 chest x-rays were conducted for 10% of donors during follow-up
period compared with a mean 1.40 images among 96% of donors during the evaluation
period. Similar observations were found for electrocardiograms, CT scans, renal
ultrasound, echocardiograms, stress tests, immunohematological tests, breast cancer
screening, pulmonary function tests, MR scans, and gasteroenterology consults.
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Appendix P: Average cost of common procedures calculated from billing codes in
Apr 1 2010 – Mar 31 2014

Procedure**
Number of donors
donation

Cost per unit for selected procedures
(2017 Canadian dollars)*
N Median (IQR)
Mean (SD)
589 –
–
511 $2,167 ($1,663-$2,839)
$2,168 ($835)

Nephrology consult
Surgery/urology consult
Chest x-ray
Electrocardiogram
Computed tomography

739
642
541
649
436

$165 ($83-$170)
$87 ($85-$161)
$36 ($34-$36)
$18 ($12-$18)
$149 ($126-$197)

$137 ($60)
$102 ($47)
$35 ($4)
$20 ($21)
$172 ($57)

Biochemistry test
(bloodwork)
Cytology
Urinalysis
Intermediate assessment
Ultrasound
Nuclear medicine

1069
1139
748
593
348
392

$25 ($12-$76)
$8 ($8-$8)
$3 ($3-$4)
$38 ($37-$40)
$89 ($84-$149)
$253 ($203-$272)

$51 ($53)
$8 ($4)
$3 ($1)
$39 ($10)
$120 ($58)
$220 ($95)

General consult
Echocardiogram
Cardiology evaluation
Stress test
Counseling/psychiatry
Cancer screen (pap)

261
214
304
198
262
212

$25 ($23-$32)
$254 ($244-$278)
$41 ($10-$88)
$112 ($107-$115)
$85 ($67-$205)
$20 ($20-$49)

$38 ($29)
$247 ($53)
$72 ($82)
$158 ($138)
$128 ($69)
$42 ($40)

Immunohematology test
Cancer screen (breast)
Pulmonary function test
Cancer screen (colorectal)
General surgery consult
Cystoscopy

146
86
70
73
43
27

$11 ($11-$11)
$71 ($67-$77)
$4 ($4-$4)
$44 ($14-$285)
$98 ($95-$101)
$77 ($75-$78)

$13 ($4)
$76 ($29)
$33 ($64)
$150 ($178)
$94 ($19)
$84 ($28)

Magnetic resonance
Gastroenterology consult
Renal biopsy
Pathology consult
Pyelogram
Hematology consult

28
36
21
7
<6
13

$274 ($246-$329)
$169 ($133-$208)
$156 ($152-$156)
$83 ($71-$138)
–
$165 ($162-$168)

$267 ($82)
$187 ($110)
$155 ($6)
$100 ($33)
–
$140 ($53)

Neurology consult
13 $186 ($79-$193)
$144 ($64)
Plastic surgery consult
15 $29 ($28-$86)
$44 ($26)
Respirology consult
13 $165 ($85-$166)
$141 ($75)
–
Endocrinology consult
<6 –
–
Musculoskeletal consult
<6 –
Rheumatology consult
9 $126 ($37-$168)
$115 ($62)
costs presented only for more common procedures (present in >10% of donors),
estimated from costs accrued from April 1, 2010 through March 31, 2014
IQR – interquartile range; SD – standard deviation
*costs calculated as of 2010 and later to account for any changes in cost over time
**the cost for a given procedure was calculated by summing the costs of all relevant
Ontario Health Insurance Plan billings performed on the same day (see Appendix I).
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12 Curriculum Vitae
Steven Habbous, MSc, PhD(c)
Toronto Ontario
Software expertise
- Microsoft Office
- SAS
- STATA
- TreeAge Pro
-R
Methodological expertise
- Cohort studies
- Case-control studies
- Randomized clinical trials
- Delphi survey
- Health economic evaluation
- Cost-effectiveness analysis
- Critical appraisal
Statistical expertise
- Linear and logistic regression
- Generalised linear models
- Regression of skewed data
- Multiple imputation
- Principal component analysis
- Survival analysis (censored data)
- Systematic review
- Meta analysis
- Multilevel (hierarchical) modeling
- Data envelopment analysis
Personal interests
- Sports (top 3: hockey, badminton,
table tennis)
- Reading (top 3: The Count of
Monte Cristo, Les Misérables,
Captain Blood)

MISSION STATEMENT
I believe that health is more important than wealth.
Society should strive to promote health equity through
preventive medicine, improving the built environment,
changing societal norms, and treating illness. This is
everyone’s responsibility and I will do my part to produce
the greatest impact I can.

EDUCATION
2014-2018

University of Western Ontario

PhD – Epidemiology and Biostatistics
Experiences:
-

Analytic epidemiology
Biostatistics
Clinical epidemiology
Health economics
Population health surveillance
University Teaching and Learning (certificate stream)
Dean’s PhD Stipend for Graduate Research award in
2014 (maximum $25,000/year)
- Canadian Institutes for Health Research doctoral award
– Frederick Banting and Charles Best Canada Graduate
Scholarships ($35,000 over 3 years: May 2015 – April
2018)

2007-2010

University of Toronto at St. George

MSc – Institute of Medical Science
Experiences:
-

Cardiovascular research
Biomaterials and biomedical engineering
Ethics of experimentation on animals
Molecular biology
Cytological and histological imaging
Ontario Graduate Scholarship (OGS) scholarship
awarded in 2008 ($15,000)

2003-2007

University of Toronto at Scarborough

Honors BSc – Specialist in Cell & Molecular Biology
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PROFESSIONAL AND LEADERSHIP EXPERIENCE

2018-

Cancer Care Ontario
Functional Lead – Quality, Measurement, and Evaluation
-

2014-2018

Conduct current state analyses on how cancer patients are diagnosed and
treated, with focus on regional and socioeconomic variability
Develop algorithms to determine the date of suspicion of breast cancer
Optimize methods to measure various cancer outcomes, including disease
recurrence using administrative data
Coach analysts on how to analyze, interpret, and report data

University of Western Ontario
Clinical researcher – Institute for Clinical Evaluative Sciences (ICES)
-

-

2010-2018

Tasked with understanding the efficiency of the living kidney donor
evaluation process
Performed qualitative and quantitative research to understand the barriers and
facilitators of an efficient evaluation; supervised junior researchers on
projects; and engaged various stakeholders including patients, providers, and
decision-makers.
Prepared 10 manuscripts for publication and identified potential solutions to
improve healthcare delivery.
Member of the Canadian National Transplant Research Program

University of Toronto & Western University
Teaching assistant
-

-

2010-2016

Taught seminars and labs for first-year and third-year undergraduate courses
(30-50 students).
Instructed students and created course material for health economics, a
graduate-level course for 3-10 students. Taught students how to use the
TreeAge program to conduct cost-effectiveness analyses.
Provided ongoing support after the course was completed to students
interested in pursuing publication of their economic evaluation.

Princess Margaret Cancer Centre
Clinical research data coordinator
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-

-

2000-2016

Tasked with better understand the epidemiology of human papillomavirus in
head and neck cancer.
Established a large head and neck cancer database, planned and executed a
multi-centred Canada-wide study, collaborated with experts across
disciplines, and mentored junior researchers.
Advanced 14 reports for publication (8 as lead or co-lead author). The most
recent publication (Habbous et al., CMAJ 2017) received substantial media
(television, radio, online) attention due to its high-impact and potential to
influence public health policy, including CTV, CBC, Global News Calgary
and Toronto, the Canadian Press, and the Canadian Dental Association
among others.

City of Toronto – Parks, Forestry and Recreation
Aquatic supervisor, trainer, instructor, and lifeguard
-

-

-

2007-2010

Managed recreational and instructional swimming programs with the City of
Toronto; facilitated the Toronto Sport Leadership Program, a program
targeting at-risk youth in Toronto.
Ensured facilities are up to standard, staff are certified and qualified to work,
and liaised with Community Recreation Programmers on issues related to
staff, public relations, and facility management.
Delivered high-quality service to patrons and served as a role model for
children and adolescents. Helped adolescents prepare resumes and apply for
jobs with the City of Toronto and the YMCA through the Toronto Sport
Leadership Program.

Hospital for Sick Children
Basic science researcher
-

-

Challenged with elucidating part of the molecular mechanism behind
ischemic and pharmacologic preconditioning
Performed a series of molecular and biochemical assays to track the
movement of a specific protein through the rabbit heart after oxygen
starvation or drug treatment
Characterised the spatiotemporal movement of this protein before and after
the ischemic or pharmacologic stimuli
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